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Abstract 
 
 
Anti-tuberculosis drug-induced liver injury is a rare but serious adverse drug reaction. 
This study aimed to identity specific genes conferring susceptibility to this serious 
adverse drug reaction, especially in relation to isoniazid treatment and to study the 
underlying mechanism for toxicity.  
 
Anti-tuberculosis drug-induced liver injury cases (n=26) and community controls 
(n=90) from Europe and South Asia were genotyped for polymorphisms in NAT2, GST 
genes, CYP2E1, PXR and SOD2. NAT2 slow acetylators were more susceptible to liver 
injury (OR=4.60; 95% CI=1.47-14.44). The GSTM1 null genotype was more common 
in cases than controls (OR=2.91; 95% CI=1.14-7.43). Risk of liver injury was 
significantly increased in subjects with combined NAT2 slow acetylator and GSTM1 
null genotype (OR=3.71; 95% CI=1.48-9.31). No significant effects were seen for the 
other genotypes studied except that a GSTA4 haplotype was slightly more common in 
liver injury cases.  
 
The contribution of NAT2 genotype to isoniazid toxicity was examined using an in vitro 
overexpression approach. Stable expression of either NAT2*4 or NAT*5 constructs in 
HepG2 cells had small effects on reduced glutathione to oxidised glutathione ratio and 
apoptosis. These changes were consistent with higher NAT2 activity increasing 
isoniazid toxicity. In addition, overexpression and siRNA knockdown approaches 
showed protective roles for GSTA1 and A4 against isoniazid toxicity.  
 
The relevance of combinations of anti-tuberculosis drugs to overall toxicity was 
investigated by studies in human hepatocytes and LS180 cells. In the LS180 cells, 
rifampicin coadministation with isoniazid resulted in a small but significant decrease in 
both isoniazid and pyrazinamide toxicity. Studies on the isoniazid-rifampicin 
combination in human hepatocytes gave inconsistent findings but a decrease in cell 
toxicity due to isoniazid by pretreatment with rifampicin was seen in some donors. 
Increased expression of the carboxyesterase gene CES2 was seen in LS180 cells and in 
some hepatocytes and could represent a protective effect. 
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1.  Introduction 
1.1 Adverse drug reactions  
 
According to WHO, adverse drug reactions (ADRs) are defined as ‘a response to a 
medicine which is noxious and unintended, and which occurs at doses normally used in 
man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function’ (WHO, 2002). ADRs are a significant cause of hospital 
admission, often lead to considerable morbidity and mortality and remain a challenging 
clinical issue faced by the healthcare professionals (Farcas and Bojita, 2009). A meta-
analysis of 39 prospective studies reported by Lazarou et al. suggested that the total 
incidence of ADRs was 6.7% with an overall fatality rate of 0.32% of hospitalised 
patients and found that ADRs are listed as one of the top ten causes of death in the 
United States (Lazarou et al., 1998). A recent Swedish study has also implicated ADRs 
to be the seventh most common cause of death with an estimation of 6.4% for the 
incidence of fatalities in hospital caused by ADRs (Wester et al., 2008). In the UK, at 
least 1 in 7 hospital in-patient experienced an ADR, resulting in prolonged 
hospitalisation and considerable financial burden to National Health Service (NHS) 
(Davies et al., 2009). Warfarin, fibrinolytics, unfractionated heparin, loop diuretics and 
allopurinol were found to be the most frequently implicated drugs causing ADRs in the 
large-scale prospective study (Davies et al., 2009). That study estimated that ADRs cost 
the NHS around £637 million annually, or approximately £5000 per hospital bed per 
year. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely 
prescribed drugs for their anti-inflammatory, anti-pyretic, anti-thrombotic and analgesic 
properties and causing serious gastrointestinal ADRs including bleeding and ulceration 
(Helin-Salmivaara et al., 2007). ADRs Over half of the ADRs are definitely or 
potentially avoidable, and strategies are needed to minimize the risk of preventable 
ADRs. Although medication errors can occasionally occur, not all ADRs are 
attributable to medication errors and therefore identification of risk factors contributing 
to ADRs is essential to reduce the event of preventable ADRs. Factor predisposing 
patients to ADRs are presented in Table 1.1. Patient with concomitant diseases such as 
renal, cardiac and hepatic impairment are at greater risk for developing an ADR. 
Incidence of ADR is increased in aged patients and patients receiving multiple 
medication or polypharmacy (Davies et al., 2009). Drug-drug interactions are also an 
important contributor to approximately 15% of ADRs involving altered bioavailability, 
distribution and clearance of certain drugs (Passarelli et al., 2005). Over the past few 
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decades, the association of genetic polymorphisms in drug metabolising enzymes with 
various ADRs have been extensively studied. Recent progress in pharmacogenetics 
research suggests that patients with specific genetic characteristics may be prone to 
specific ADRs and personalized drug therapy with pharmacogenetics can therefore lead 
to safer, more effective drugs and reduce ADRs. The detailed information of the current 
research progress on genetic polymorphisms in drug-metabolising enzymes and drug 
transporters is described in section 1.5. The evaluation of predisposing factors of ADRs 
may not fully prevent the occurrence of ADRs, but it can reduce the incidence and 
severity of ADRs, reduce the overall cost of healthcare and improve patient outcomes. 
The practice of pharmacovigilance by regulatory agencies, pharmaceutical companies, 
and individual health care providers is important in monitoring for ADRs. 
Pharmacovigilance is a science relating to the detection, assessment, understanding, and 
prevention of adverse effects, particularly long-term and short-term side effects of 
medicines (WHO, 2004). The involvement of all healthcare providers in 
pharmacovigilance practice and the participation of patients in ADRs reporting are vital 
to minimize the risk of ADRs as much as possible.  
 
ADRs can be classified into Type A and B drug reactions (Patel et al., 2007). Type A 
reactions are predictable, dose related and account for the majority of ADRs. These 
common dose related ADRs are due to an increased in the effective concentration of the 
drug or its metabolite, resulting in either on-target or off-target toxic side effects. Unlike 
Type A, Type B ADRs are unpredictable, not dose related and do not resemble the 
known pharmacologic profile of the causative agent. Type B reactions are also referred 
to as idiosyncratic drug reactions and often involve a small subset of treated patients. 
Premarketing trials generally fail to identify potentially serious ADRs of this type due to 
their very low incidence and ADRs are usually observed only when the drugs are 
marketed for a period of time and given to large patient populations. Thus idiosyncratic 
ADRs are a major problem to the healthcare professionals, pharmaceutical industry and 
drug regulatory agencies such as the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA). They are the leading cause for drugs withdrawn 
from the market or receiving a black box warning. This often results in the 
abandonment of potentially effective drugs. Statin-induced myopathy, drug-induced 
long QT and drug-induced liver injury (DILI) are the major idiosyncratic ADRs. DILI, 
in particular, is a leading cause of acute liver failure and is described in more detail in 
section 1.2. 
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             Table 1.1 Risk factors that contribute to the development of ADRs* 
 
Risk factors for ADRs 
Pharmacodynamics  
         Variation in drug response resulting from altered receptor sensitivity  
Pharmacokinetics  
 Changes in drug absorption, distribution, metabolism and excretion 
Presence of underlying or concurrent disease 
 Renal, cardiac and hepatic impairment 
Drug-drug interactions 
 Concomitant administration of other drugs 
Physiologic conditions 
 Age, pregnancy, obesity 
Diet and lifestyle 
 Smoking, alcohol intake 
Genetic polymorphisms 
 Variation in drug response traits 
Adherence to regimen prescribed 
 Poor adherence to prescribed medication especially elderly patients who 
require continuous polypharmacy 
 Medication errors 
 Errors in medication prescribing, dispensing or use 
    
 
    *
 Table adapted from Farcas et al: Adverse drug reactions in clinical Practice: A 
causality assessment of a case of drug-induced pancreatitis (Farcas and Bojita, 
2009) 
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1.2 Drug-induced liver injury  
 
The liver is commonly affected by drugs because of its role as the central organ in drug 
metabolism and detoxification. Drug-induced liver injury (DILI) is the most common 
ADRs and accounts for more than 50% of acute liver failure cases (Ostapowicz et al., 
2002). DILI or hepatotoxicity can be defined as liver injury caused by drugs used either 
in medical practice or herbal medicines resulting in persistent significant elevations in 
liver enzyme levels, abnormalities in liver test or liver dysfunction. Medications such as 
antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics are the most 
commonly prescribed drugs associated with DILI (Ibanez et al., 2002). Commonly used 
medications that have exhibited hepatotoxic effects are listed in Table 1.2. The effect of 
DILI leads to a large range of pathological conditions including chronic hepatocellular 
hepatitis, cholestasis, cirrhosis, steatosis, sinusoidal and hepatic artery or vein damage 
(Larrey, 2000). The idiosyncratic nature of such adverse drug reactions has drawn most 
attention because they are unpredictable and often occur unexpectedly (Boelsterli, 
2003). Although DILI is infrequent, up to 10% of cases may develop acute liver failure 
(Kaplowitz, 2005) and it has been shown that 75% of cases of acute liver failure linked 
to DILI led to liver transplantation or death (Ostapowicz et al., 2002). This significant 
patient morbidity and mortality has caused DILI to be the key reason for drug 
withdrawals from the pharmaceutical market (Temple and Himmel, 2002). An 
examination of the Physician’s Desk Reference (PDR) for all new chemical entities 
approved by the FDA within the past 25 years (1975-1999) by Lasser et al. had revealed 
that approximately 10% of a total of 548 new chemical entities acquired a new black 
box warning or were withdrawn from the market (Lasser et al., 2002). Four (25%) out 
of 16 drugs withdrawn from the market were associated with DILI. Unrecognised 
serious ADRs were usually emerged after FDA approval and the safety of the new 
drugs can only be established with complete certainty until the drugs are marketed for 
many years.  Examples of drugs that have been received black box warnings for 
hepatotoxicity include bosentan, trovafloxacin, tolcapone, felbamate and isoniazid, 
while drugs withdrawn from the market because of idiosyncratic hepatotoxicity include 
nefazodone, rofecoxib, troglitazone and bromfenac.  
 
DILI due to idiosyncratic reactions involves individual susceptibility related to 
environmental and/or genetic factors that remain poorly understood. Routine animal 
toxicology fails to identify the risk of subsequent problems in drug development as 
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idiosyncratic reactions are not reproduced in experimental animals and appear only after 
a latency period of weeks to years (Lee, 2003). Drug-induced idiosyncratic 
hepatotoxicity remains a major challenge for clinicians, the pharmaceutical industry and 
regulatory agencies including the Food and Drug Administration (FDA) because of the 
limited knowledge regarding its mechanism, identification of susceptible individuals 
and pre-clinical test systems. Clinical diagnosis and prediction of DILI remains 
complex due to confounding factors such as pre-existing liver disease, multiple drug 
usage and lack of reliable screening methods or diagnostic standards. Further 
advancement and better understanding of idiosyncratic drug hepatotoxicity is important 
to provide practical solutions instead of limiting the use of drugs associated with DILI 
through withdrawals from the pharmaceutical market. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
7 
 
                      Table 1.2 Commonly-used drugs associated with DILI 
 
Indication/drug action Drug 
Hepatocellular injury  
Analgesic Paracetamol 
NSAIDs Diclofenac, ibuprofen, naproxen 
Antibiotics Isoniazid, Pyrazinamide, minocycline, nitrofurantoin, 
trovafloxacin 
Antifungal Ketoconazole 
Immunosuppressants Azathioprine, cyclophosphamide 
Anti-arrhythmia Amiodarone 
Anticonvulsant Carbamazepine, phenytoin, felbamate, valproic acid 
Pulmonary hypertension Bosentan 
Cholesterol-lowering Niacin 
Gout Allopurinol 
Antithyroid Propylthiouracil 
Anaesthetic Halothane 
Immunomodulator Leflunomide 
Acne Isotretinoin 
Anti-androgen Flutamide 
Alcoholism Disulphiram 
Muscle relaxant Dantrolene 
Diabetes Acarbose 
Antipsychotic Nefazodone 
Alzheimer’s disease Tacrine 
Asthma Zafirlukast, Zileutin 
Parkinson’s disease Tolcapone 
CNS stimulant Pemoline 
Cholestatic  injury  
NSAIDs Sulindac 
Antibiotics Rifampicin, ciprofloxacin, erythromycin, flucloxacillin, 
amoxicillin-clavulanic acid 
Antifungal Terbinafine 
Antipsychotic Phenothiazines, chlorpromazine 
Depression Tricyclic antidepressants 
Hypertension Angiotensin-converting enzyme inhibitors 
 
*
 Table adapted from Kaplowitz (2005): Idiosyncratic drug hepatotoxicity (Kaplowitz, 
2005)  
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1.2.1 The epidemiology of DILI 
 
The epidemiology of DILI is poorly understood owing to the lack of prospective studies 
on its incidence (Bjornsson, 2010).  The frequency of DILI among users of most drugs 
is extremely rare with the estimation of an occurrence rate from 1 in 10,000 to 1 in 
100,000 or even lower in other drugs (Larrey, 2002). Most clinical drug trials recruit 
less than 10,000 patients, indicating that DILI is often not detected during clinical trial 
stages and it has been mostly discovered in the post-marketing phase. The highly 
variable and inconsistent findings in a small number of retrospective studies reflect the 
lack of internationally standards for its diagnosis, under-reporting and incomplete 
reporting of DILI events which lead to bias in the data collected (Bjornsson, 2010). 
Several retrospective studies have reported the incidences rate of DILI to be between 
1.27 and 7.4 cases per 100,000 inhabitants, which is probably an underestimation 
(Hussaini et al., 2007; De Valle et al., 2006; Meier et al., 2005; de Abajo et al., 2004; 
Ibanez et al., 2002). Meier et al. have observed the incidence of DILI to be 1.4% with 
approximately 1 in 100 patients developing DILI during the course of hospitalisation 
(Meier et al., 2005) though most of the cases in this survey appeared to have suffered 
mild DILI with elevated levels of liver enzymes only just above the upper limit of 
normal. In retrospective studies from the UK, the reported crude incidence rate of DILI 
and drug-induced jaundice were 2.4 and 1.27 per 100,000 inhabitants per year 
respectively (Hussaini et al., 2007; de Abajo et al., 2004). In a recent study from 
Sweden, a crude incidence rate of 2.3 per 100,000 inhabitants was reported and DILI 
cases constituted 6.6% of patients in an out-patient hepatology clinic (De Valle et al., 
2006). So far, only one population-based prospective study has been carried out in 
France but this is generally considered the best estimation so far of the true incidence of 
DILI (Sgro et al., 2002). The reported incidence rate of DILI was 13.9 per 100,000 
inhabitants which would be 16 times greater than is being officially spontaneously 
acknowledged (Sgro et al., 2002). Determining DILI remains a major challenge in 
clinical practice because of the lack of reliable markers. Clinical scales such as the 
Councils for International Organisation of Medical Sciences/ Roussel Uclaf Causality 
Assessment Method (CIOMS/RUCAM) is considered the best method for assessing 
causality in DILI (Lucena et al., 2008b) and the details of this scoring system is 
discussed in section 1.3.1. 
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1.2.2 Types of DILI 
 
DILI covers a wide variety of clinical and pathological expressions of liver damage 
(Zimmerman, 1981). Liver injury can result from direct damage to hepatocytes leading 
to hepatocellular necrosis and may interfere with bile flow by damaging the bile ducts 
or vascular structures (Lee, 2003). Total bilirubin (TBIL), alkaline phosphatase (ALP), 
alanine transaminase (ALT) and aspartate transaminase (AST) are the useful 
biochemical markers in the evaluation and detection of DILI. DILI can be characterised 
as hepatocellular, cholestatic, or mixed type injury (Lee, 2003). Although 
hepatocellular, cholestatic and mixed reactions are the general terms used to classified 
DILI, the other form of DILI phenotypes include granulomas, fibrosis, steatohepatitis, 
cirrhosis, vascular and neoplastic lesions (Verma and Kaplowitz, 2009). Hepatocellular 
hepatotoxicity is predominantly associated with the elevation of ALT whereas 
cholestatic injury is linked to an increase in ALP level, conjugated bilirubin, and γ-
glutamyl transpeptidase (Holt and Ju, 2006). Mixed pattern or cholestatic hepatitis is 
manifested when both ALT and ALP are elevated. Even though biochemical markers 
are good predictors for the patterns of liver injury, observation of histological 
abnormality, clinical picture and the cell type involved are more accurate in 
characterisation of liver injury (Abboud and Kaplowitz, 2007).  
 
1.2.2.1 Hepatocellular injury 
 
Hepatocellular injury has been defined as an increase in serum transaminase with an 
ALT/ALP ratio greater than 5 (Benichou, 1990). Although manifestation of 
hepatocellular injury includes hepatocyte necrosis with or without steatosis, patients 
may present as asymptomatic or experience fatigue, right upper quadrant pain, jaundice 
or acute liver failure (Verma and Kaplowitz, 2009). Halothane, a widely used 
anaesthetic has been reported to cause serious hepatocellular injury and fatal jaundice 
with a high mortality rate (40 %) (Bjornsson and Olsson, 2005). Other common drugs 
associated with hepatocellular injury are disulfiram, isoniazid, nitrofurantoin, halothane, 
azathioprine, flutamide, omeprazole and ibuprofen (Bjornsson and Olsson, 2005). 
Reactive drug metabolites generated during the process of drug biotransformation have 
been postulated to be the important cause for hepatocellular injury. The interaction 
between these reactive metabolites and cellular macromolecules such as proteins, lipids, 
and nucleic acids will lead to protein dysfunction, lipid peroxidation, DNA damage, 
oxidative stress and cellular dysfunction (Holt and Ju, 2006). The accumulated 
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oxidative stress, loss of ionic gradients and altered cellular calcium homeostasis may 
result in the dysfunction of mitochondria and lead to the pathogenesis of necrotic and 
apoptotic cell death (Holt and Ju, 2006). Damage to hepatocytes may trigger activation 
and inflammatory responses of innate immune cells and result in the initiation of 
immunological reactions (Kaplowitz, 2005). The mechanism of immune-mediated DILI 
is further described in section 1.4. 
 
1.2.2.2 Cholestatic injury 
 
By contrast to hepatocellular injury, cholestatic injury is defined as the elevation of 
ALP or an increase in ALT/ALP ratio of less than 2. Cholestatic injury is manifested 
primarily by jaundice and pruritus, resulted from impairment of bile flow and retention 
of bile salts and bilirubin. Cholestatic injury due to progressive destruction of small bile 
ducts may also lead to vanishing bile duct syndrome (Reau and Jensen, 2008). Though 
it can be bland without any parenchymal inflammation or may show slight hepatocyte 
injury and mild portal inflammation, rare cases of cholestatic injury may progress to 
ductopenia and primary biliary cirrhosis (Reau and Jensen, 2008). Examples of drugs 
associated with cholestatic injury are rifampicin, estradiol, nafcillin, flucloxacillin, co-
amoxiclav, chlorpromazine, erythromycin and trimethoprim-sulfamethoxazole (Lee, 
2003). Cholestasic injury appears to be less serious than hepatocellular patterns of 
injury but a high mortality rate ranging from 5-14.3% has been reported in recent 
studies (Chalasani et al., 2008; Andrade et al., 2006; Bjornsson and Olsson, 2005). In 
patients with cholestatic injury, the liver test abnormalities often resolved over the 
course of several months longer compared to the hepatocellular type injury (Andrade et 
al., 2002; Andrade et al., 2001). The prolonged cholestatic injury could be due to the 
slower regeneration capacity of bile duct cells than the hepatocytes (Abboud and 
Kaplowitz, 2007). 
 
1.2.2.3 Mixed pattern of liver injury 
 
The mixed form of DILI is characterised by the combination of both hepatocellular and 
cholestatic injury. It is defined as the elevation of both ALT and ALP with an ALT/ALP 
ratio between 2 and 5. This pattern of liver injury has been associated with the lowest 
mortality rate (approximately 2%), comparing to hepatocellular and cholestatic type of 
DILI (Chalasani et al., 2008; Andrade et al., 2006; Bjornsson and Olsson, 2005). Drugs 
known to cause hepatocellular or cholestatic liver injury including flucloxacillin, 
erythromycin, diclofenac, amoxicillin-clavulanate and carbamazepine may also give rise 
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to this form of DILI in some patients (Bjornsson and Olsson, 2005). Though it is mainly 
drugs that are known to induce cholestatic injury that are most often implicated in 
mixed pattern DILI (Larrey, 2000), some drugs found to induce a hepatocellular pattern 
of damage may sometimes be associated with mixed injury (Andrade et al., 2004).  
 
1.3 Causality assessment in DILI 
 
The diagnosis of DILI and prediction of DILI occurrence remain challenging as DILI is 
a diagnosis of exclusion and the lack of an objective, valid and widely available 
screening method makes the causality assessment of DILI difficult. Identification of 
elements in the medical history, clinical presentation, laboratory results, as well as 
subsequent course is important in assigning causality in DILI. The assessment criteria 
such as the onset of DILI, course of the reaction, clinical features, risk factors for the 
reaction, the exclusion of other causes of liver damage, and previous information on the 
hepatotoxicity of the implicated agent were proposed to improve causality assessment. 
Information regarding the rechallenge of the administered drug could confirm the role 
of a drug in the development of DILI. A positive rechallenge is manifested by 
significant doubling of the ALT (hepatocellular injury) and ALP (cholestatic injury) 
values (Zimmerman, 1999). Nevertheless, it may not be feasible in some cases as false 
negative response to rechallenge may be seen in certain drugs such as isoniazid and 
some causative agents can evoke serious and potentially lethal hypersensitivity 
reactions upon rechallenge (Papay et al., 2009). Rechallenge is usually performed only 
if no other alternative medication available and the potential benefits of re-introducing 
the drug outweigh the potential risks to the patient (Lee, 2003). Evaluation of liver 
biopsy is essential for assigning causality in DILI although it is often not available. 
However, the timing in assessing histological features of DILI and also characterisation 
of the role of liver biopsy in improving the diagnosis and management of DILI are to be 
defined clearly (Fontana et al., 2010). The use of in vitro laboratory tests include the 
lymphocyte-stimulation or transformation test have been proposed to aid the diagnosis 
of immune-mediated drug reactions, particularly in patients exposed to more than one 
drug (Maria and Victorino, 1998). Though the studies of this test have been promising, 
standardisation, test sensitivity and reproducibility are needed in order to fully realise its 
potential benefits in the identification of causative drugs. Recently, several reports 
suggest that use of the CIOMS assessment method (see section 1.3.1) with some 
modification is the most appropriate approach for assessing DILI causality (Aithal, 
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2011; Takikawa et al., 2003; Lucena et al., 2001). This approach has the advantage that 
it is suitable for use by non-expert assessors (Aithal, 2011). However, there are also 
alternative recent recommendations requiring assessment of each case by expert 
hepatologists (Fontana et al., 2010) and these are considered in Section 1.3.2 below.  
 
1.3.1 International Organisation of Medical Sciences (CIOMS) scale/ 
RUCAM 
 
The first method developed at international consensus meetings for drug causality 
assessment in DILI was the International Organisation of Medical Sciences (CIOMS) 
method which is also referred to as the Roussel Uclaf Causality Assessment Method 
(RUCAM) (Danan and Benichou, 1993). It was established by an international panel of 
experts who aimed to develop a standardised scoring system for the diagnosis and 
determination of the severity of DILI. The parameters required for RUCAM scale were 
based on six components:   
 Time to onset and  clinical course of the reactions  
 Risk factors (age, alcohol consumption, pregnancy) 
 Assessing the role of concomitant therapies  
 Screening for non-drug related causes 
 Previous information on hepatotoxicity of the drug 
 Validation of the reaction by positive rechallenge or in vitro assay 
  
According to RUCAM, hepatocellular injury pattern is characterised by an increase in 
ALT >2 x ULN (upper limit of normal) or R ≥ 5, where R is the ratio of serum activity 
of ALT to ALP. Cholestatic type is defined by ALP >2 x ULN or R ≤ 2, whereas mixed 
injury pattern is defined by ALT >2 x ULN and 2 < R <5.  The RUCAM scale provides 
a scoring system with the sum of points varied from -3 to +3 for each component. Based 
on the final scores ranges from -8 to +14, the degree of association between the 
causative agent and ADRs was translated as highly probable (score > 8), probable 
(score 6-8), possible (score 3-5), unlikely (score 1-2) and excluded (score ≤ 0). 
Validation of the RUCAM using patients who had been positively rechallenged was 
originally assessed by (Benichou et al., 1993) The system had shown to be reliable with 
high levels of sensitivity (86%) and specificity (89%) in assessing causality for DILI 
prior to rechallenge or when concomitant drugs were included (Benichou et al., 1993). 
The RUCAM has the advantage of providing a subjective and definite diagnosis of DILI 
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with minimal required questions and also with newly marketed drugs or old drugs 
associated with unrecognised DILI previously (Andrade et al., 2007). Nevertheless, the 
RUCAM scale has its limitations, which include the complexity of its scoring system 
and the arbitrary weighting of factors such as age, alcohol consumption and pregnancy 
(Andrade et al., 2007). It was recently validated by three experts in the Drug-induced 
Liver Injury Network (DILIN) study and was found to be of mediocre reliability in 
assessing DILI events (Rochon et al., 2008). Though RUCAM appears to be superior to 
other causality assessment systems and proved useful to identify the event of ADRs, 
modifications are needed to improve its efficiency, reliability and reproducibility in 
DILI causality assessment. Detailed recommendations on how this can be achieved have 
now been assembled as part of a phenotype standardisation project for DILI (Aithal, 
2011). 
 
1.3.2      DILIN expert opinion  
 
An attempt to standardise expert opinion for assessing causality was initiated by the 
Drug-Induced Liver Injury Network (DILIN) by reviewing a prospective registry of 
patients with DILI with the aims to develop and evaluate causality assessment 
instruments for used prescription and non-prescription drugs, as well as herbal products 
(Fontana et al., 2009). This methodology relies on the clinical judgment of three 
experienced hepatologists who were given clinical, laboratory and imaging data to 
assign a causality score independently ranging from 1 to 5 to minimise individual 
biases. Score 1 is assigned as definite when the percentage likelihood of causality used 
was ≥95%, and followed by score 2 (highly likely; 75-94% likelihood), score 3 
(probable; 50-74% likelihood), score 4 (possible; 25-49% likelihood) and score 5 
(unlikely; <25). The DILIN’s expert opinion method has its strengths by providing a 
prospective evaluation of patients who met the minimal laboratory or histological 
criteria within 6 months of DILI onset. A long term follow up was also included to 
identify any other etiology in causing DILI and whether rechallenge occurred. Though 
expert opinion has been considered as the gold standard for diagnosis of DILI, it is 
limited by its lack of generalizability and the weighted kappa score for assessment of 
the level of agreement between all three hepatologists was low (0.23-0.38) (Fontana et 
al., 2010). Thus, continuous efforts to produce an authoritative, unbiased, reliable and 
user-friendly causality assessment instrument are needed to improve the diagnosis, 
management and prevention of DILI.  
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1.4 Mechanism of DILI 
1.4.1 Overview of DILI mechanism  
 
Though the liver is involved in detoxification of many drugs, drugs and their reactive 
metabolites can also potentially cause toxicity to the liver in various ways based on their 
mechanism of action. The exact mechanism of DILI remains largely unknown, but 
currently there have been at least six mechanisms involving hepatocytes proposed for 
liver injury (Lee, 2003) (Figure 1.1). Drugs and their reactive metabolites that interrupt 
the bile salt transport proteins such as basolateral bile salt efflux pump (BSEP), encoded 
by ABCB11 at the canalicular membrane, may disrupt bile excretion, allowing toxic 
bile acids to accumulate and causing injury to hepatocytes (Trauner et al., 1998). 
Biotransformation by CYP enzymes may lead to covalent binding of drugs to 
intracellular proteins, causing disruption of calcium homeostasis that results in the 
disassembly of actin fibrils at the cell surface, cell rupture and lysis (Kaplowitz, 2002). 
Formation of adducts through binding of drug metabolites to cellular proteins, DNA or 
other cellular molecules could result in hepatic cellular dysfunction that then initiates 
both adaptive and innate immune responses. Drug-protein adducts may migrate to the 
cell surface and induce adaptive immune responses that causes liver damage by direct 
cytotoxic T cell or antibody-mediated cytotoxic responses (Robin et al., 1997). 
Hepatocyte stress could trigger the inflammatory responses of the innate immune 
system by the activation of Kupffer cells (KC), natural killer (NK) cells and natural 
killer T (NKT) cells. Hepatocyte exposure to cytokines produced in immune-mediated 
injury may initiate apoptosis through ligand-receptor interactions of TNF-α and Fas 
ligand (FasL) that triggers a cascade of caspases activation leading to loss of viability 
(Reed, 2001). Another mechanism for liver injury involves drug induced mitochondrial 
damage by disrupting fatty acid oxidation and energy production (Pessayre et al., 1999).  
Hepatocellular and cholestatic/mixed patterns liver injury can be classified as immune- 
and non-immune-mediated reactions (Abboud and Kaplowitz, 2007). An immune-
mediated reaction is characterised by the presence of clinical signs of drug 
hypersensitivity such as fever, rash, eosinophilia, formation of autoantibodies and the 
rapid onset on rechallenge. Conversely, non-immune-mediated reactions, also known as 
metabolic idiosyncratic reactions are characterised by the absence of such signs 
(Abboud and Kaplowitz, 2007; Zimmerman, 1999).  
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Figure 1.1 The six mechanisms of DILI 
  
Drugs and its metabolites may affect the hepatocytes in six ways. (A) Drugs may interact 
with the bile salt transport proteins at the canalicular membrane hence, disrupting bile 
excretion and causing injury to hepatocytes as toxic bile acid accumulates. (B) 
Biotransformation of drugs cause disruption of calcium homeostasis that results in the 
disassembly of actin fibrils at the cell surface leading to cell lysis. (C) Drug-protein adduct 
formation may initiate the innate immune responses by activating the Kupffer cells (KC), 
natural killer (NK) cells and natural killer T (NKT) cells; or (D) induce the adaptive 
immune response causing liver damage by direct cytotoxic T cell (Tc) and antibody-
mediated cytotoxic response. (E) Immune-mediated injury may initiate apoptosis through 
ligand-receptor interactions of TNF-α and FasL that triggers a cascade of caspases 
activation leading to the loss of viability. (F) Drugs may disable respiratory chain enzymes 
or mitochondrial DNA causing oxidative stress that lead to severe adverse effects in liver 
cells (Image adapted from Lee, 2003 (Lee, 2003)). 
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1.4.2 Immunological idiosyncratic reactions 
1.4.2.1  The hapten hypothesis 
 
Many DILI reactions appear to be immune-mediated rather than due to metabolic 
idiosyncracy (Uetrecht 2007). Though several hypotheses for DILI mechanisms have 
been proposed in the past, the hapten hypothesis is still considered as a dominant 
mechanistic hypothesis. The hapten hypothesis involves a chemically reactive drug or 
reactive metabolite acting as a hapten that covalently binds to cellular protein, DNA or 
other cellular molecule and lead to an adaptive immune response. It was first observed 
by Landsteiner et al. that immune reactions could not be triggered by small molecules 
unless they were chemically reactive and bound to protein (Landsteiner and Jacobs, 
1935). Many drugs can be converted into a chemically reactive metabolite by drug 
metabolising enzymes such as the cytochrome P450 enzymes to form the hapten. For 
instance, halothane is oxidized by cytochrome P450 to trifluoroacetyl chloride (TFA), 
an electrophilic reactive intermediate which may bind covalently to hepatocyte 
macromolecules and phospholipids to form TFA-protein adducts (Eliasson et al., 1998). 
These TFA-protein adducts may be recognised as foreign by the immune system, 
resulting in the generation of autoantibodies (Eliasson and Kenna, 1996). It has been 
demonstrated that several different autoantibodies and TFA-protein adducts can be 
detected in the serum of patients with halothane-induced hepatitis (Spracklin et al., 
1997). In addition, TFA can also bind to the CYP enzyme responsible for the generation 
of these electrophilic reactive intermediate and thus elevate the immunological reaction. 
It has been reported that a high levels of autoantibodies against TFA-modified CYP2E1 
was identified in human and rats treated with halothane, indicating that the 
autoantibodies recognizing this autoantigen may evoke an immune response and play an 
important role in the pathogenesis of halothane hepatitis (Spracklin et al., 1997).  
 
1.4.2.2 Danger hypothesis 
 
The danger hypothesis of Matzinger proposes that an additional “danger signal” is 
required for the development of an immune-related idiosyncratic drug reaction as 
haptenized proteins alone might not be sufficient to trigger an immune reaction 
(Matzinger, 1994). Absence of a danger signal even though drug- and/or metabolite-
specific antibodies were detected in some cases would be associated with immunologic 
tolerance (Uetrecht, 2008). This tolerance prevents the body from initiating an immune 
response when the foreign antigens/hapten poses no threat or danger to the individual. 
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Thus, a second-stimulatory trigger, the danger signal is required alongside the 
presentation of the hapten to the APC for the development of a full immune response. 
Danger signals which include cytokines may be released as a result of oxidative stress 
and/or cellular damage.  
 
1.4.2.3 Activation of the adaptive immune response 
 
Formation of adducts through binding of drug metabolites to cellular proteins, DNA or 
other cellular molecules results in hepatic cellular dysfunction that may initiate both 
adaptive and innate immune responses. Drug-protein adducts may migrate to the cell 
surface and induce adaptive immune responses that cause liver damage by direct 
cytotoxic T cell or antibody-mediated cytotoxic responses (Robin et al., 1997). Major 
histocompatability complex (MHC) class II proteins present on the surface of antigen 
presenting cells (APC) along with the release of co-stimulatory signals allow 
recognition by helper T cells, leading to a T cell response to the antigen. The cytotoxic 
T cells are then targeted against hepatocytes that express the protein adducts or with 
MHC class I present on the cell surface and this leads to the subsequent development of 
DILI (Kaplowitz, 2005). Activation of B cells by helper T cells causes production of 
antibody to protein adducts, promoting antibody-dependent hepatotoxicity.  
 
1.4.2.4 Stimulation of innate immune response 
 
Hepatocyte stress and/or cell damage could release the danger signals that trigger the 
inflammatory responses of the innate immune system by the activation of Kupffer cells 
(KC), natural killer (NK) cells and natural killer T (NKT) cells. These cells produce 
proinflammatory mediators including cytokines, chemokines and reactive oxygen 
species (ROS) that contribute to the progression of DILI. Inflammatory cytokines such 
as tumour necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), Fas or Fas ligand 
(FasL) and interleukin-1 beta (IL-1β) have been shown to be directly involved in 
causing tissue damage in the liver (Ishida et al., 2002; Blazka et al., 1996; Blazka et al., 
1995). On the other hand, activated innate immune cells also release interleukin-10 (IL-
10), interleukin-6 (IL-6) and other cytokines which play a hepatoprotective role of 
counteracting inflammatory responses and stimulating liver regeneration (Masubuchi et 
al., 2003; Bourdi et al., 2002; Ju et al., 2002). It has been shown that IL-10 and IL-6 null 
mice are more susceptible to paracetamol toxicity, suggesting the protective role of IL-
10 and IL-6 against paracetamol-induced liver injury (Masubuchi et al., 2003; Bourdi et 
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al., 2002). Therefore, the balance of hepatotoxic and hepatoprotective mediators 
produced by activation of innate immune cells will determine an individual’s 
susceptibility to DILI.  
 
1.4.2.5 Autoimmunity 
 
Drug-induced autoimmunity is associated with the apparent lack of immune reactions 
observed in immune-mediated hepatitis and often misclassified as metabolic or 
nonimmune-mediated DILI (Uetrecht, 2008). Two drugs, nitrofurantoin and 
minocycline were reported to be the main causes of drug-induced autoimmune hepatitis 
(Bjornsson et al., 2010). The autoimmune reactions resulting in production of 
autoantibodies against self-antigens/haptenised proteins and the antigens are still present 
even after the causative drug is stopped. However, autoimmune DILI usually, although 
not always, resolves rapidly after administration of the offending drug has stopped. 
Therefore the continued administration of the responsible drug is required in an event of 
autoimmune DILI, possibly to provide the additional danger signal necessary to 
stimulate an immune response (Uetrecht, 2008). When the drug is removed, the 
autoimmune T cells are consequently made anergic. Thus, the lack of a rapid onset on 
rechallenge seen in drug-induced autoimmunity could be due to the induction and 
maintenance of immune tolerance involving the autoimmune T cells. Many immune-
mediated DILI cases could have been misclassified and autoimmunity is still remained a 
special problem when causality in DILI is being assessed. 
  
 
1.4.3 Metabolic idiosyncratic reactions 
1.4.3.1 Toxic metabolites 
  
Metabolic idiosyncrasy is also referred as non-immune idiosyncratic reactions may be 
caused by aberrant drug metabolism or clearance, leading to the accumulation of toxic 
metabolites and causing toxicity to hepatocytes. For this reason, genetic variation 
affecting drug-metabolizing enzymes has been suggested to be a risk factor for DILI. 
The inter-individual differences in the ability to metabolize or detoxify certain drugs 
could increase susceptibility to DILI due to toxic metabolites accumulation. 
Polymorphisms in genes encoding drug metabolizing enzymes such as cytochromes 
P450 (CYP450), glutathione S-transferases (GST) and N-acetyltransferase 2 (NAT2), 
together with others encoding proteins such as superoxide dismutase 2 (SOD2) and 
  
 
19 
cytokines have been proposed to be associated with metabolic idiosyncrasy (Verma and 
Kaplowitz, 2009). Though P450-mediated metabolism usually biotransforms drugs into 
water-soluble metabolites which are easier to eliminate, in some cases it causes the 
activation of a drug to a hepatotoxic metabolite and increases drug toxicity. In the case 
of isoniazid, polymorphisms in metabolic enzymes such as NAT2 and CYP2E1 have 
been shown to be associated with isoniazid-induced liver injury due to the increased 
level of toxic metabolites of isoniazid. However, significance of NAT2 and CYP2E1 
polymorphisms and their susceptibility to isoniazid-induced liver injury remains unclear 
and has not been confirmed in all studies, suggesting that additional factors may be 
required to explain the idiosyncratic nature of liver toxicity caused by isoniazid 
(Uetrecht, 2008). Isoniazid-induced hepatotoxicity is discussed further in section 1.6. It 
is also possible that metabolic idiosyncrasy may be due to environmental or nutritional 
factors rather than genetic factors (Xu et al., 2005). 
 
1.4.3.2 Disruption of intracellular calcium homeostasis  
 
Drug and their reactive metabolites may cause hepatotoxicity which is usually 
predictable and dose-dependent. Paracetamol is a classic example of a known intrinsic 
or predictable hepatotoxin, however paracetamol overdoses can produce the reactive 
metabolite N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione 
resulting in an excessive quantity of reactive metabolites. The resultant unconjugated 
reactive metabolites may bind covalently to cellular proteins and DNA, causing 
disruption of calcium homeostasis. Disruption of intracellular calcium homeostasis 
leads to the disassembly of actin fibrils at the cell surface of the hepatocyte which 
results in cell rupture and lysis (Kaplowitz, 2002).  
 
1.4.3.3 Mitochondrial damage  
 
Another mechanism for liver injury involves drug induced mitochondrial damage by 
disrupting fatty acid oxidation and energy production. Extensive formation of reactive 
metabolites that disable respiratory chain enzymes or mitochondrial DNA results in 
oxidative stress, defined as the exposure of the cell to extreme amount of oxidants 
commonly known as reactive oxygen species (ROS). ROS such as superoxide, 
hydrogen peroxide and hydroxyl radicals have been implicated in liver injury. When 
hepatocytes are exposed to excess ROS or there is lack of ROS elimination by 
antioxidants, oxidative stress occurs and can trigger the mitochondrial permeability 
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transition pore to open. The pore opening leads to an influx of protons from the 
intermembrane space into the mitochondrial matrix, culminating in mitochondrial 
depolarisation, major ATP depletion and cell necrosis (Boelsterli and Lim, 2007). Pore 
opening may also result in the entry of water into the mitochondrial matrix, causing the 
rupture of the outer membrane and release proapoptotic substances such as cytochrome 
c, which activate caspases and induce apoptosis (Haouzi et al., 2000). It has been 
suggested that progressive mitochondrial damage may produce a danger signal and 
initiate an innate and/or adaptive immune response (Uetrecht, 2008).  
 
1.5 Pharmacogenomics in DILI 
1.5.1 Xenobiotic metabolism 
 
Genetic factors determining susceptibility to drug-induced hepatotoxicity have recently 
gained much attention as the important risk factor for DILI. Genetic associations related 
to DILI are generally drug specific. Most of the susceptibility genes may relate to a 
range of different pathways, including those encoding drug-specific metabolising 
enzymes and drug transporters, immune reactions, mitochondrial function and apoptosis 
(Kaplowitz, 2005). The rarity of DILI and the wide range of drugs have contributed to 
the difficulty of recruiting a desired number of affected individuals for statistical power. 
However, some replicated associations for DILI susceptibility with particular genes due 
to specific drugs have been detected by using genome-wide association studies (GWAS) 
and candidate gene association studies (Daly, 2010).  
Biotransformation of drugs usually involves several steps, including Phase I reactions 
including reduction, oxidation or hydrolysis, followed by Phase II metabolism which 
includes acetylation, methylation, conjugation to glucuronide, sulphate or glutathione 
that will produce hydrophilic products to be exported into plasma or bile and 
subsequently excreted by the kidney or the gastrointestinal tract. Inter-individual and 
inter-ethnic differences in gene encoding the drug metabolising enzymes result in 
variability to drug response. It may cause abolished, reduced, altered or increased 
enzyme activity and can either cause susceptibility or protection to DILI dependent 
upon whether the drug or its metabolite causes the adverse drug reactions.  
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1.5.2 Phase I metabolising enzymes  
 
Human cytochrome P450 (CYP450) superfamily of phase I metabolising enzymes are 
often responsible for many idiosyncratic hepatotoxicity due to the formation of reactive 
metabolites of the drug. CYP450 enzymes are present primarily in drug-eliminating 
organs, including the liver, kidney and intestinal tract. So far, over 57 CYP450 genes 
have been identified. Within the same family, all CYP proteins share at least 40% 
sequence identity in their amino acid sequence and those within the same subfamily 
sharing greater than 55% identity (Nelson et al., 1996). Families CYP1, CYP2, and 
CYP3 are those most commonly involed in the metabolic cleareance of the most 
xenobiotics/drugs and these genes are highly polymorphic resulting in interindividual 
variation in the rate of enzyme activity. There is some limited data suggesting 
associations between CYP polymorphisms and susceptibility to some forms of DILI. 
The main association reported is between INH-induced DILI and certain CYP2E1 allelic 
variants. CYP2E1 plays a major role in the metabolic activation of paracetamol, 
chlorzoxazone, and ethanol and it has been linked to paracetamol-induced DILI in 
humans though data on this is quite limited (Sinclair et al., 1998). The CYP2E1*5 allele 
is common CYP2E1 variant with polymorphisms in the 5’-flanking region which have 
been reported to cause an increase in the expression of the enzyme (Watanabe et al., 
1994; Hayashi et al., 1991) and it has been linked to associated with an increased risk of 
developing hepatotoxicity due to anti-tuberculosis drugs including INH, though not all 
studies show this. Genetic polymorphism of CYP2E1 and the risk of anti-tuberculosis 
medication are discussed further in section 1.7.   
Another P450 named CYP3A4, may also have a more indirect involvement in some 
forms of DILI. It is believed that CYP3A4 interindividual variability is mainly due to 
CYP3A4 enzyme induction and inhibition rather than variations in the gene (Burk et al., 
2004). CYP3A4 is regulated by pregnane X receptor (PXR). It has been shown that 
CYP3A4 contributes to the formation of reactive metabolites in troglitazone and 
flucoxacillin, though there is currently no evidence for the involvement of the reactive 
metabolite in the troglitazone or flucoxacillin induced hepatotoxicity (Masubuchi, 2006; 
Lakehal et al., 2001). However, in a recent study, an upstream polymorphism affecting 
levels of PXR expression was found to be associated with flucoxacillin-induced liver 
injury (Andrews et al., 2010). DILI cases due to this drug were more likely to have the 
allele associated with low PXR expression which may be associated with lower 
CYP3A4 expression.  
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1.5.3 Phase II metabolising enzymes  
 
Phase II reactions consist of glucuronidation, acetylation, methylation, sulphation, and 
glutathione conjugation. Associations between genetic polymorphisms of Phase II 
metabolising enzymes with DILI have been studied extensively. Polymorphism in the 
genes encoding arylamine N-acetyltransferase 2 (NAT2), glutathione transferases 
(GSTs) and UDP-glucuronosyltransferases (UGTs) have been reported to increase 
susceptibility to adverse drug reactions. 
 
1.5.3.1 UDP-glucuronosyltransferases (UGTs) 
 
The human UDP-glucuronyl transferase (UGT) superfamily has been classified into the 
UGT1A, 2A and 2B subfamilies which catalyse reactions of conjugation with 
glucuronic acid. UGTs are found in many of the major organs including the liver and 
responsible for the elimination of drugs and other xenobiotics and endogenous 
compounds such as bile acids, bilirubin hydroxyl-steroids and thyroid hormones 
(Kaivosaari et al., 2011). UGT1A1 is the most abundant UGT isoform in the liver and 
individuals who carry the UGT1A1*28 mutant allele can be more susceptible to 
irinotecan toxicity due to impaired UGT1A activity (Iyer et al., 2002). An association 
between UGT1A6-A528G polymorphism with tolcapone-induced hepatotoxicity was 
found by Acuna et al., where the G allele was associated with decreased enzyme 
activity resulting in compromised drug clearance and drug toxicity (Acuna et al., 2002). 
Diclofenac-induced liver injury has also been associated to glucuronidation mechanism 
pathway, resulting in the production of reactive metabolite, diclofenac acyl glucuronide. 
The reactive diclofenac acyl glucuronide is capable of covalent modification of cellular 
proteins and resulting in immune-mediated destruction of hepatocytes (Kretz-Rommel 
and Boelsterli, 1995). The UGT2B7 has been implicated in the diclofenac-induced DILI 
and the variant UGT2B7*2 allele is associated with increased enzyme activity which in 
turn may result in the increased production of the toxic diclofenac acylglucuronide 
(Daly et al., 2007). 
 
1.5.3.2 Arylamine N-acetyltransferase 2 (NAT2) 
 
The human arylamine N-acetyltransferase 2 (NAT2) is involved in the acetylation of 
numerous xenobiotics and ary-lamine or hydrazine-containing drugs such as isoniazid 
(INH), sulfamethoxazole, hydralazine, dapsone and procainamide. Blum and colleagues 
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have first provided evidence that the gene encoding NAT2 is polymorphic through 
‘INH inactivation’, thus causing interindividual variation in the NAT2 acetylation 
capacity and resulting in rapid or slow acetylator phenotypes (Blum et al., 1990). 
NAT1, on the other hand, is monomorphic and shows no variability in the N-acetylation 
of certain arylamine drugs such as p-aminosalicylic acid. Vatsis and colleagues were 
then confirmed that NAT2 corresponds to INH acetylator phenotypes  (Vatsis et al., 
1991). Determination of NAT2 genotype and phenotype has been proposed to predict 
hepatotoxicity in patients with tuberculosis receiving INH or concomitant treatment of 
INH with other anti-tuberculosis medication such as rifampicin, pyrazinamide and 
ethambutol. It has been suggested that slow acetylators/poor metabolisers are prone to 
adverse drug reactions due to accumulation of toxic metabolites or low detoxification of 
drugs and/or their toxic metabolites. The role of NAT2 in DILI caused by anti-
tuberculosis medication is described in detail in section 1.7.  
 
1.5.3.3 Glutathione S-transferases 
 
The glutathione S-transferase enzymes (GSTs) play a major role against endogenous 
oxidative stress, as well as in the detoxification of exogenous potential toxins including 
toxic chemicals, carcinogens and drugs. They protect cells for direct toxicity by their 
detoxification effects through the conjugation of glutathione with harmful electrophiles 
generated during oxidative stress and lipid peroxidation. The mammalian cytosolic 
GSTs have been classified into eight classes including alpha, kappa, mu, omega, pi, 
sigma, theta and zeta (Pearson, 2005). Studies to date have been limited to the common 
deletion polymorphisms in the genes encoding the GSTM1 and GSTT1 resulting in the 
absence of enzyme. The presence of combined alleles GSTM1 and GSTT1 deficiencies 
has been associated with raised liver enzymes and increases susceptibility to DILI 
regardless of the type of causative agents (Lucena et al., 2008a). A more detailed role of 
GSTs in DILI caused by anti-tuberculosis medication is described in section 1.7.  
 
1.5.4 Drug transporters 
 
Member of the ATP binding cassette (ABC) transporter family such as P-glycoprotein 
(P-gp) and multidrug resistance-associated protein (MRP) play a vital role in the 
disposition of drugs in the body by providing a formidable barrier against drug 
penetration (Xu et al., 2005). Drugs and their metabolites can be effluxed from the 
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hepatocyte via these ABC transporters into the bile (Figure 1.2). Along with P-gp 
(MDR1; ABCB1), the bile salt efflux protein (BSEP; ABCB11) is a major bile acid 
efflux pump. The human MRP subfamily consists of at least nine members. MRP2, also 
known as ABCC2 is present on the canalicular membrane and involved in drug 
excretion into bile, especially of glucuronidated metabolites. Different from MRP2, 
MRP1 and MRP3 are found on the basolateral membrane of polarised cells which efflux 
drugs and metabolites into the bloodstream leading to increased excretion into the urine. 
Polymorphisms in some transporter genes have been shown to affect susceptibility to 
DILI caused by either specific drugs or a mix of drugs. A polymorphism in exon 13 of 
BSEP which has been linked with apparent decreased of hepatic BSEP expression was 
found to have an association with drug-induced cholestasis caused by various drugs 
(Lang et al., 2007). The C-24T MRP2 polymorphism which has previously been 
associated with decreased functional expression of the transporter was shown to be 
associated with diclofenac-induced liver injury (Daly et al., 2007). Choi and colleagues 
have further studied a few variants in MRP2 and found that a haplotype containing the 
C-24T variant was associated with hepatocellular type liver injury, and haplotype 
containing the -1774delG polymorphism was found with increased frequency in 
cholestatic and mixed liver injury caused by various causative drugs, specifically herbal 
remedies. The same study also looked at the functional significance of these variants 
including -1774delG, G-1549A and C-24T polymorphisms, and results revealed that 
these genetic variations in the promoter region of MRP2 are associated with decreased 
promoter activity leading to the development of liver injury (Choi et al., 2007).  
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Figure 1.2 Transport proteins for drugs and endogenous substances in 
basolateral and apical membranes of hepatocytes. 
  
Human hepatocyte uptake transporters in the basolateral (sinusoidal) membrane 
include the sodium/taurochplate co-transporting peptide (NTCP), organic anion 
transporting polypeptide (OATP), organic anion transporter (OAT) and organic 
cation transporter (OCT). Efflux pumps include several multidrug resistance proteins 
(MRP3, MRP4 and MRP6) are localised to the basolateral membrane and 
effluxchemicals. Apical (canalicular) efflux pumps of the hepatocyte comprise P-gp; 
bile-salt export pump (BSEP); breast cancer resistance protein (BCRP); and MRP2. 
In addition, multidrug and toxin extrusion protein 1 (MATE1) is located in the apical 
hepatocyte membrane for excretion of organic cations in the liver (Image adapted 
from Giacomini et al., 2010 (Giacomini et al., 2010)). 
 
BILE 
OAT, OCT, OATP, NTCP 
MRP3 
MRP4 
MRP6 BCRP 
BSEP 
P-gp 
MATE1 MRP2 
BLOOD 
HEPATOCYTE 
  
 
26 
1.5.5 Oxidative stress  
 
Reactive oxygen species (ROS) such as hydrogen peroxide, superoxide and hydroxyl 
radical are generated as a result of energy production from mitochondria, as well as 
detoxification reactions carried out by the CYP450 system. When the production of 
ROS exceeds the body’s natural antioxidant defence mechanisms, oxidative stress 
occurs. Oxidative stress in liver can be induced by drugs and their reactive metabolites, 
ethanol and inflammatory stress, causing cell death and leading to the pathogenesis of 
liver injury. Genetic polymorphisms in ROS detoxification enzymes can contribute to 
individual susceptibility to DILI. These enzymes participate in a number of different 
reactions. Superoxide dismutases (SOD) convert superoxide to hydrogen peroxide 
whereas glutathione peroxidases (GPX) convert hydrogen peroxide to water in 
glutathione-dependent reactions. A polymorphism in mitochondrial enzyme manganese-
dependent superoxide dismutase (SOD2), a major scavenger of mitochondrial 
superoxide is associated with DILI. This T to C allele substitution in exon 2 of the 
SOD2 which results in a valine to alanine change (SOD2 Val16Ala) in the leader 
sequence involved in import of the enzyme into mitochondria, was subsequently related 
to increased susceptibility to DILI caused by a combination of hepatotoxic drugs 
(Huang et al., 2007). Recently, Lucena and colleagues have found an association of 
SOD2 Val16Ala polymorphism with the risk of developing DILI, particularly in 
patients with cholestatic/mixed hepatotoxicity (Lucena et al., 2010). In addition to 
SOD2, the group also studied the glutathione peroxidase I (GPXI) polymorphism, a 
proline to leucine substitution (GPX1 Pro200Leu) which has previously been associated 
with reduced enzyme activity (Hamanishi et al., 2004). Patients homozygous for GPX1 
Leu allele were shown to be associated with a 5.1–fold increased risk for developing 
cholestatic type liver injury (Lucena et al., 2010). Another mitochondrial enzyme, DNA 
polymerase gamma (POLG) may also be relevant to risk of DILI. Rare mutations lead 
to decreased activity which may result in impaired ability to deal with oxidative stress. 
Patients exhibiting rare mutations in POLG were more likely to develop DILI caused by 
sodium valproate (VPA) (Stewart et al., 2010; McFarland et al., 2008). 
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1.5.6 Immune related genes  
1.5.6.1 Human leukocytes antigen (HLA) 
 
Genetic polymorphisms of the human leukocyte antigens (HLA) have been strongly 
associated with drug-induced hepatotoxicity, indicating the presence of an immune-
mediated reaction (Daly, 2010). The HLA is the name of the human major 
histocompatibility complex (MHC) and can be classified into HLA class I and HLA 
class II whose gene products are predominantly involved in antigen presentation on the 
surface of cells. Genes of the HLA class I are grouped into A, B or C and the class II 
genes are grouped into DR, DP or DQ. All these genes are located in the MHC region of 
chromosome 6 in a region where there is strong linkage disequilibrium extending over a 
long distance. 
 
A GWAS has revealed that the class I HLA-B*5701 is strongly associated to 
flucloxacillin-induced liver injury with a significant odds ratio of approximately 80 
when DILI cases were compared to flucloxacillin-tolerant controls (Daly et al., 2009). 
Abacavir-induced hypersensitivity reactions are found to be very significantly 
associated with the HLA-B*5701 in another study (Mallal et al., 2002) though these 
reactions don’t normally involve the liver and the reason why the flucloxacillin and 
abacavir reactions show a similar genetic association remains unclear. The HLA class II 
allele DRB1*1501 has been previously associated with co-amoxiclav induced liver 
injury in two small cohort studies (O'Donohue et al., 2000; Hautekeete et al., 1999). 
Recently the association between DRB1*1501 and DILI due to co-amoxiclav was 
replicated, suggesting that DRB1*1501 allele may play a particularly important role in 
co-amoxiclav induced hepatotoxicity (Donaldson et al., 2010). Very recently, a GWAS 
on co-amoxiclav DILI has found that in addition to the DRB1*1501 association, a HLA 
class I gene A*0201 is also a risk factor for DILI (Lucena et al., 2011). It has also been 
suggested that ximelagatran-induced hepatotoxicity is related to immune-mediated DILI 
as it is found to be associated with a HLA class II haplotype DRB1*0701-DQA1*0201 
(Kindmark et al., 2008). A further HLA association has recently found to be associated 
with DILI caused by selective NSAID COX-2 inhibitor lumiracoxib (Singer et al., 
2010). The GWAS study has identified a strong association to a common HLA 
haplotype DRB1*1501-DQB1*0602-DRB5*0101-DQA1*0102 which may indicate a 
role of HLA class II alleles as a markers for NSAID-induced liver injury (Singer et al., 
2010). A high incidence of ticlopidine-induced severe cholestatic hepatotoxicity was 
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observed in Japanese patients with HLA-A*3303, suggesting a role of HLA 
polymorphisms in ticlopidine-induced hepatotoxicity (Hirata et al., 2008). Sharma and 
colleagues have shown that patients with specific HLA alleles (the absence of HLA-
DQA1*0102 or the presence of HLA-DQB1*0201 alleles were at increased risk of 
hepatotoxicity due to anti-tuberculosis medication (Sharma et al., 2002). However, in a 
genome-wide association study involving 28 European DILI cases linked to INH, no 
evidence for a HLA association was found (Urban et al., 2011). All these published 
studies have demonstrated associations between certain HLA genotypes with their 
relevant causative agents, thus suggesting that the immune mechanism in these specific 
examples of DILI could be caused by drug-specific factors rather than by the types of 
liver injury (Daly, 2010).  
 
1.5.6.2 Cytokine genes 
 
Associations between genetic polymorphisms in genes encoding cytokine-related 
proteins and susceptibility to DILI have been reported. Aithal and colleagues observed 
polymorphisms in IL-4 (C-590TA) and IL-10 (C-627A) resulting in low IL-10 and high 
IL-4 gene transcription were associated with diclofenac-induced hepatotoxicity (Aithal 
et al., 2004). Apart from IL-4 and IL-10, genetic polymorphisms of IL-6 (-597A, -572G, 
-174G and variable nucleotide tandem repeat-D alleles) were found to be associated 
with DILI caused by tacrine, an anticholinesterase inhibitor used for the treatment of 
Alzheimer’s disease (Carr et al., 2007). Although some associations of cytokine 
polymorphisms have been associated with DILI, the associations are not as strong as 
that seen in HLA alleles, thus suggesting a minor role of cytokines in contributing to 
DILI.    
 
1.6 Anti-tuberculosis drugs-induced liver injury 
1.6.1 The burden of tuberculosis (TB) 
 
Tuberculosis (TB) is a deadly infectious disease caused by Mycobacterium tuberculosis 
(M. tuberculosis) and a major cause of disease burden worldwide. This disease is 
contracted through the exposure to M. tuberculosis in microscopic droplets expelled 
into the air from an infected person by coughing, speaking or sneezing. According to 
the World Health Organisation (WHO), over one-third of the world’s population is 
currently infected with M. tuberculosis (WHO, 2010b) but not everyone who is infected 
develops the disease as asymptomatic latent TB infection is most common. However, 
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untreated latent infections will eventually progress to active TB. In 2009, the estimates 
of the global burden of disease caused by TB are as follows: 14 million latent TB cases 
(a prevalence rate of 203 cases per 100,000 population), 9.4 million active TB cases (an 
incidence rate of 139 cases per 100,000 population), 1.3 million deaths among human 
immunodeficiency virus (HIV) -negative people and 0.38 million deaths among HIV-
positive people (WHO, 2010a). In the UK, a total of 8497 active TB cases were reported 
in 2006, a rate of 14.0 cases per 100,000 population (HPA, 2007). Increased risk factors 
for contracting TB have been identified as age, sex, HIV infection, smoking and family 
history of TB infection (Lienhardt et al., 2003). The disease is more common in 
countries with poverty, malnutrition and crowding as the risk of exposure to M. 
tuberculosis, consequently risk of infection is increased (Accorsi et al., 2005). 
According to the latest WHO annual report, most cases were in the South-East Asia 
(35%), African (30%) and western Pacific regions (20%) (WHO, 2010a). HIV-positive 
individuals who infected with M. tuberculosis are more susceptible to develop active 
TB due to their weak immune system. In Africa, HIV is the single most important factor 
contributing to the increase in the incidence of TB and accounted for approximately 
80% of these cases (WHO, 2010a). It has also been noted that healthcare workers have 
higher risk of exposure and latent infection (Kayanja et al., 2005).  
 
1.6.2 Anti-TB drugs (ATD) 
 
First-line anti-TB drugs used for disease treatment and latent TB infection (LTBI) are 
isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), ethambutol and streptomycin 
(Figure 1.3). For the past 15 years, the gold-standard treatment for TB involves six 
months of daily treatment with RMP and INH, supplemented with PZA and either 
ethambutol or streptomycin in the initial two months (six-month, four-drug regimen) 
(HPA, 2007). The initial four-drug regimen is designed to diminish the bacterial 
population as rapidly as possible and also to prevent emergence of drug- and multidrug-
resistant TB strains. The recommended daily oral dosages for the treatment of TB by the 
British National Formulary are 300mg for INH, 450-600mg for RMP, 1.5-2g for PZA 
and 15mg/kg for ethambutol (Table 1.3). Ethambutol is bacteriostatic against actively 
growing mycobacteriae by disrupting cell wall synthesis and is included in a treatment 
regimen when INH resistance is suspected. Streptomycin, a bactericidal aminoglycoside 
given at a dose of 15 mg/kg daily, is rarely used in the UK except for the initial phase of 
TB treatment if resistance to INH has been established. INH, also known as isonicotinyl 
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hydrazine, is cheap and highly effective, and commonly combined with RMP in treating 
TB. RMP belongs to the rifamycin group of antibiotics produced by Streptomyces 
mediterranei and covers a broad spectrum of antibacterial, antiviral and antineoplastic 
activity. It acts by binding to DNA-dependent RNA polymerase in bacterial cells, thus 
inhibiting transcription and subsequent translation of proteins. PZA is an effective TB 
drug that helps shorten the treatment regimen from 9 months to 6 months when used in 
combination with RMP and INH. It is a prodrug that needs to undergo metabolic 
activation catalysed by bacterial pyrazinamidase into its active derivative pyrazinoic 
acid for activity against M. tuberculosis (Konno et al., 1967). The emergence of drug-
resistant TB is mainly caused by human errors, including inconsistent or incomplete 
treatment, wrong treatment regimens prescribed by doctors and health workers, and also 
unknown or unreliable source of quality drugs (WHO, 2010b). Multidrug-resistant TB 
(MDR-TB), a particularly dangerous form of drug-resistant TB is caused by 
mycobacterial strains resistant to the two most potent first-line anti-TB drugs, especially 
INH and RMP. Though MDR-TB is generally curable by extensive chemotherapy with 
second-line anti-TB drugs that takes up to two years, the treatments are more costly and 
cause more severe ADRs than the first-line drugs. These second-line agents include 
amikacin, capreomycin, cycloserine, azithromycin, clarithromycin and moxifloxacin.   
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Figure 1.3 Schematic diagrams of molecular structures of isoniazid, 
rifampicin, pyrazinamide, streptomycin and ethambutol (Kumari and Ram, 
2004). 
Isoniazid 
Pyrazinamide 
Rifampicin 
Streptomycin 
Ethambutol 
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Table 1.3 Recommended doses of first-line anti-tuberculosis drugs for adults  
 
Drugs    Dose and range                         
(mg/kg body weight) 
    Maximum dose 
Isoniazid               
+ 
  5 (4-6) mg/kg daily 300 
Rifampicin              
+ 
10 (8-12) mg/kg daily 600 
Pyrazinamide  
together with  
25 (20-30) mg/kg daily 2000 
Ethambutol          
or 
15 (15-20) mg/kg daily – 
Streptomycin 15 (12-18) mg/kg daily – 
 
 
1.6.3 Metabolism of anti-TB drugs (ATD) 
1.6.3.1 Isoniazid (INH) 
 
INH is primarily cleared through acetylation by N-acetyltransferase 2 (NAT2) in the 
liver, resulting in acetylisonazid which is then hydrolysed to isonicotinic acid and 
monoacetylhydrazine (MAH) (Figure 1.4). INH also undergoes hydrolysis catalysed by 
isoniazid hydrolase and forms hydrazine, which is then metabolised to MAH by NAT2. 
MAH can be acetylated to diacetylhydrazine which is non-toxic, or oxidised by 
cytochrome P4502E1 (CYP2E1) into hepatotoxic intermediates (Ryan et al., 1985). 
Acetylhydrazine can be hydrolysed to hydrazine which may further induce CYP2E1, 
increasing the production of toxic metabolites. Hydrazine, MAH and isonicotinic acid 
are potentially hepatotoxic metabolites of INH and accumulation of these reactive 
metabolites in patients may cause serious adverse drug reactions. The enzyme 
responsible for INH hydrolysis has still not been well characterised. It is usually 
described as an amidase but in a recent report (Tafazoli et al., 2008), it was found that 
hydrazine formation from INH in rat hepatocytes could be inhibited by treatment with 
bis-p-nitrophenylphosphate, which was originally described as a carboxylesterase 
inhibitor (Buch et al., 1969). There is increasing evidence that the hydrolysis of INH is 
catalyzed by a carboxylesterase but the precise isoform responsible is still unclear 
(Yamada et al., 2009). In human liver, two carboxylesterase isoforms CES1A1 and 
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CES2 are expressed at detectable levels and show different substrate specificities (Yang 
et al., 2009). 
 
1.6.3.2 Rifampicin (RMP) 
 
The metabolic pathways for RMP are deacetylation and non-enzymatic hydrolysis 
(Venkatesan, 1989). In the liver, RMP is deacetylated to 25-desacetylrifampicin, a 
major metabolite that possesses potent bactericidal activity against M. tuberculosis. 
RMP is also hydrolysed to form 3-formylrifampicin SV and 3-formyldesacetyl 
rifampicin. It is known as a very potent inducer of drug metabolism, including its own 
metabolism. This is due to it being a potent agonist for the nuclear pregnane X receptor 
(PXR) which upregulates expression of a number of enzymes important in drug 
 
Figure 1.4 Isoniazid metabolic pathways  
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metabolism. It promotes the upregulation of phase I CYP450 enzymes, particularly 
CYP3A4 which catalyse the metabolism of 50-60% of clinically prescribed drugs 
(Kolars et al., 1994; Shimada et al., 1994). In addition to CYP3A4, RMP has shown to 
induce drug transporters such as multidrug resistance 1 (MDR1), mediated through PXR 
activation (Rae et al., 2001). It promotes the clearance of potentially toxic xenobiotics 
or their reactive metabolites from the liver and intestine, and has also been shown to 
interplay with CYP3A4 in RMP inducing drug-drug interactions (Cummins et al., 
2003). Studies have indicated that RMP administration may induce the production of 
hepatotoxic hydrazine metabolites by accelerating the INH hydrolase activity in the 
non-acetylating hydrolysis metabolic pathway particularly in individual with slow 
acetylator phenotype (Fukino et al., 2008; Askgaard et al., 1995; Sarma et al., 1986).  
 
1.6.3.3 Pyrazinamide (PZA) 
 
PZA is an effective sterilising drug and subjected to metabolism by hepatic microsomal 
deamidase and xanthine oxidase (XO) (Yamamoto et al., 1989). PZA, a prodrug is 
hydrolysed to the active metabolite pyrazinoic acid by a liver microsomal deamidase 
(Figure 1.5). This reaction can also be performed by the mycobacterial enzyme 
pyrazinamidase. Pyrazinoic acid is further hydroxylated to 5-hydroxypyrazinoic acid by 
XO. PZA is also directly oxidised to 5-hydroxypyrazinamide by XO. As with INH 
conversion to hydrazine (section 1.6.3.1), the microsomal deamidase involved in 
pyrazinamide hydrolysis is probably a carboxylesterase but the isoform responsible has 
not been identified. These three PZA metabolites are mainly excreted in urine (Lacroix 
et al., 1989; Weiner and Tinker, 1972). Pyrazinoic acid may be converted to pyrazinuric 
acid through a minor pathway by its conjugation with glycine.  
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1.6.4 Anti-TB drugs-induced liver injury (ATD-DILI) 
 
The three key drugs for this treatment, RMP, INH and PZA are potential causes of 
hepatotoxicity and may lead to serious adverse effects including hepatitis, cutaneous 
reactions, gastrointestinal intolerance, haematological reactions and renal failure (Forget 
and Menzies, 2006). The frequency of anti-TB drugs hepatotoxicity increases greatly 
when they are used simultaneously (van Hest et al., 2004). It has been reported that the 
frequency of overt clinical hepatitis caused by INH and RMP coadministration was 
2.6%, but only 1.1% with rifampicin alone and 1.6% with INH alone (Steele et al., 
1991). ATD-DILI varies widely in severity, ranging from asymptomatic elevation of 
liver transaminases to acute liver failure (Kumar et al., 2010; Reuben et al., 2010). 
 
Figure 1.5 Pyrazinamide metabolic pathways (Tostmann et al., 2010). 
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Factors that increase the risk of anti-TB drug-induced hepatotoxicity include HIV 
infection, chronic viral hepatitis B and C infections, old age, malnutrition and 
alcoholism (Tostmann et al., 2008; Dworkin et al., 2005; Fernandez-Villar et al., 2004; 
Ungo et al., 1998; Krishnaswamy et al., 1991).  
 
In 1969, INH received a black box warning from the US Food and Drug Administration 
due to its association with high incidence of adverse drug reactions, particularly 
hepatocyte injury (Black et al., 1975). Various metabolites of INH have been suggested 
as hepatotoxic, including hydrazine, monoacetyl hydrazine (MAH), acetylisoniazid and 
isonicotinic acid (Mitchell et al., 1976). Administration of acetylhydrazine or 
acetylisoniazid in rats leads to the production of reactive alkylating species and covalent 
binding to liver proteins, causing hepatocyte injury (Timbrell et al., 1980). NAT2, the 
major known enzyme involved in the metabolic pathway of INH and metabolites is 
suggested to play an important role in INH-induced hepatotoxicity, particularly the 
NAT2 slow acetylator genotypes/phenotypes. A more detailed of the association 
between NAT2 genetic polymorphisms and ATD-DILI is found in section 1.7.  
RMP has also been reported to affect metabolism of other drugs by inducing CYPs and 
UGT activities (Burk et al., 2004; Schuetz et al., 1996), which may complicate the 
analyses of ATD-DILI due to potential overlapping toxicities and drug-drug interactions 
following the concomitant administration of RMP and some first-line ATD. It has also 
been suggested that RMP may increase hepatotoxicity by inducing CYP3A4 metabolic 
activity in combination treatment with INH (Li et al., 1997). It is also shown to enhance 
idiosyncratic hepatocellular reactions by inducing formation of hydrazine from INH 
particularly in NAT2 slow acetylators (Sarma et al., 1986). Several studies have shown 
that serious liver injury by RMP alone is rare but this apparent low rate of 
hepatotoxicity awaits confirmation in larger prospective studies (Page et al., 2006; 
Menzies et al., 2004).  
 
PZA may exhibit both dose-dependent and idiosyncratic hepatotoxicity. The incidence 
of PZA-induced liver injury has been reported to be higher when supplemented with 
other first-line anti-TB drugs (Chang et al., 2007; Yee et al., 2003; Parthasarathy et al., 
1986; Association, 1981). A retrospective cohort study involving 3,007 patients has 
shown that the risk of hepatotoxicity for PZA-containing regimens relative to standard 
regimens that do not contain PZA was 2.6, suggesting that incorporation of PZA to INH 
and RMP increases the risk of DILI. In a separate study, seven out of 12 patients (58%) 
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treated for latent TB with ethambutol and PZA developed transaminase elevation of 
more than four times the upper limit of normal (Younossian et al., 2005). Because 
ethambutol alone is not hepatotoxic, PZA was likely to be the offending agent. The two 
months regimen of RMP and PZA for latent infection has reported serious 
hepatotoxicity and therefore it is no longer recommended to patients (CDC, 2003).  
RMP may occasionally cause interference with bilirubin excretion by inhibiting the 
major bile salt exporter pump, resulting in transient hyperbilirubinaemia (Byrne et al., 
2002). It is probably that co-administration of RMP affects the activities of drug 
transporters of some first-line ATD (INH, PZA and ethambutol) and leads to a more 
severe ATD-DILI.  
 
Hepatotoxicity has also been reported in simultaneous administration of the anti-TB 
drugs with other hepatotoxic drugs including paracetamol, methotrexate, sulfasalazine, 
carbamazepine and allopurinol (Vanhoof et al., 2003; Berkowitz et al., 1998; Crippin, 
1993; Lacroix et al., 1988). For example, increased paracetamol metabolism as a 
consequence of CYP induction by INH causes the formation of toxic metabolites, 
depletion of GSH stores and subsequent hepatotoxicity (Crippin, 1993). Accumulation 
of pyrazinoic acid induced by allopurinol will decrease its clearance and cause toxicity 
in the liver (Lacroix et al., 1988). Anti-TB DILI occurs with high frequency and 
severity in patients demonstrating hepatoxicity risk factors (Fernandez-Villar et al., 
2004) and complications could be reduced by monitoring patients at risk through 
frequent laboratory testing of liver function. 
 
1.7 Candidate genes for ATD-DILI 
 
Metabolism of ATD is a very complex process, involving both activation and 
detoxification processes catalysed by a variety of enzymes. Genetic polymorphisms in 
the genes that encode ATD-metabolising enzymes have been hypothesised to contribute 
to the development of ATD-DILI. Genetic variants in these genes can result in 
differences in protein expression and catalytic activity, thus resulting in individuals, 
groups or population variability in the efficacy and toxicity of ATD. Reactive toxic 
metabolites generated by ATD-metabolising enzymes may cause more hepatotoxicity 
than the parent drug itself and could be converted to immunogens by covalently binding 
to endogenous proteins to initiate an immune response. Thus, identification and analysis 
of single nucleotide polymorphisms (SNPs) in the ATD-metabolising enzymes can 
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potentially unveil the underlying genetic mechanism of ATD-DILI. The relationship 
between particular genes and susceptibility to ATD-DILI has been identified and some 
of these reported associations such as NAT2, CYP2E1 and GSTM1 have now been 
replicated. 
 
1.7.1 N-acetyltransferase 2 (NAT2)  
 
Polymorphism in NAT2 gene causes different biotransformation rates of substrate drugs 
and individual INH N-acetylation capacity is used to classify rapid or slow acetylators 
phenotypes (Blum et al., 1991). Besides INH, other substrates such as sulfamethazine, 
sulfonamides, procainamide, hydralazine, dapsone, and caffeine were used to determine 
the NAT2 acetylator phenotype (Blum et al., 1991). The NAT2 phenotype variation is 
due to SNPs in the 870bp NAT2 protein coding sequence. Rapid acetylators are 
homozygous or heterozygous for wild-type allele (NAT2*4) while slow acetylators are 
homozygous for mutant alleles (NAT2*5, NAT2*6 and NAT2*7) associated with amino 
acid substitutions which appear to abolish enzyme activity. The frequency of slow 
acetylators varies widely among different ethnic groups, ranging from 90% in North 
Africans, 50% in Caucasians and South Asians and 10% in East Asians (Daly, 2003). A 
number of studies have examined the association between INH-induced DILI and NAT2 
acetylator status. It was initially suggested that rapid acetylator individuals were more 
susceptible to hepatic injury because they generate more acetyl isoniazid, which further 
metabolise to the toxic intermediate, MAH (Yamamoto et al., 1986; Mitchell et al., 
1975). However, both rapid and slow acetylators were observed to excrete similar 
proportions of MAH, suggesting that rapid acetylators also convert MAH into non-toxic 
diacetyl hydrazine more rapidly and decrease MAH hepatotoxin accumulation (Ellard et 
al., 1978). Another NAT2 phenotyping study has shown that the slow acetylator 
phenotype lacking functional NAT2 catalytic activity is associated with an increased 
risk of INH-induced DILI (Dickinson et al., 1981). Several confirmation studies 
involving genotyping analyses (Table 1.4) have been performed during the past decade, 
indicating that slow acetylator instead of rapid acetylator status predisposes to ATD-
DILI. Among these, five studies on East Asian populations (Japan, Korea and Taiwan) 
which have a lower prevalence of NAT2 slow acetylator genotypes (approximately 
10%) have reported a significant increased frequencies of ATD-DILI in slow acetylators 
(Lee et al., 2010; Kim et al., 2009; Cho et al., 2007; Huang et al., 2002; Ohno et al., 
2000). Another three studies based in Brazil, Turkey and Northern India where a higher 
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prevalence of the slow acetylation genotypes is found have also confirmed the findings 
in Asia (Bose et al., 2011; Bozok Cetintas et al., 2008; Possuelo et al., 2008). 
Nonetheless, no association of risk with acetylator status was observed in two studies 
based in Europe and Canada with mixed ethnicity (Yamada et al., 2009; Vuilleumier et 
al., 2006). Recently a polymorphism in the NAT2 promoter region (-9796T>A) was 
found to be associated with decreased expression of NAT2 with individuals carrying the 
variant -9796 A allele were predisposed to ATD-DILI (Kim et al., 2009). Generally, the 
role for NAT2 in susceptibility to ATD-DILI is evident and has been highlighted in 
majority of published studies, however its overall impact on DILI severity is not well 
understood and requires further investigation.  
 
Table 1.4 Previous published genotyping studies of NAT2 acetylator status and 
their association with ATD-DILI 
 
Ethnicity Number 
of cases 
Increased risk of 
DILI 
Odds ratio Reference 
Japanese 14 slow acetylator 4.0 (1.9-6.1) and 28 
(26-30) 
(Ohno et al., 
2000) 
Taiwanese 33 slow acetylator 3.66 (1.58-8.49); 
P=0.003 
(Huang et al., 
2002) 
Korean 18 slow acetylator 5.4 (1.8–16.6); 
P=0.005; 
(Cho et al., 2007) 
Turkish 30 slow acetylator 8.8 (3.3-23.9); 
P<0.0001 
(Bozok Cetintas 
et al., 2008) 
Brazilian 14 slow acetylator 5.4 (1.57 – 19.4); 
P=0.003 
(Possuelo et al., 
2008) 
Korean 67 slow acetylator 2.33 (1.45-3.78) for 
NAT2*6 possession 
(Kim et al., 
2009) 
Taiwanese 45 slow acetylator 3.15 (1.47-6.48); 
P=0.0026 
(Lee et al., 2010) 
Northern 
India 
 slow acetylator 2.99 (1.4-6.2);  
P=0.0045 
(Bose et al., 
2011) 
Mixed 34 No association Not significant (Vuilleumier et 
al., 2006) 
Mixed 23 No association Not significant (Yamada et al., 
2009) 
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1.7.2 CYP2E1 
 
CYP2E1 is constituently expressed primarily in the human liver and involved in the 
metabolic activation of many toxicants including paracetamol and ethanol. Several 
polymorphic sites in the CYP2E1 at the 5’-regulatory or intron as well as in exon 
regions have been identified. To date, 13 different CYP2E1 alleles have been described 
from the Human Cytochrome P450 Allele Nomenclature Committee 
(http://www.cypalleles.ki.se/cyp2e1.htm). In the 5’-flanking region, a tandem repeat 
polymorphism namely CYP2E1*1D is associated with greater CYP2E1 transcriptional 
activity and has been shown to promote metabolic activity in patients with chronic 
alcoholism and obesity (Nomura et al., 2003; McCarver et al., 1998). Three 
nonsynonymous polymorphisms have been identified but only one allele namely 
CYP2E1*2 (Arg to His substitution) is associated with decreased enzyme synthesis and 
catalytic activity (Hu et al., 1997). This variant allele occurs at a low frequency (2.6%) 
and has only been identified in Chinese population but not other ethnic groups (Hu et 
al., 1997). CYP2E1*5 and CYP2E1*6 polymorphisms in the 5’-flanking region are the 
most studied variants. The CYP2E1*5B allele is identified by loss of a RsaI restriction 
site and designated c2 whereas the wild-type allele with the restriction site is designated 
c1. The CYP2E1*6 allele is identified by a DraI restriction fragment length 
polymorphism (RFLP). A common allele CYP2E1*5A is designated when both the RsaI 
variant and DraI variant are present, as is usually the case.  The RsaI polymorphism has 
been evaluated in association with DILI due to anti-tuberculosis drugs including INH. 
CYP2E1 is involved in the metabolism of INH, catalyses oxidation of MAH and forms 
hepatotoxic intermediates (Ryan et al., 1985). Huang and colleagues have reported that 
the wild-type CYP2E1 c1/c1 genotype shows higher CYP2E1 activity and therefore 
may lead to increased production of hepatotoxins (Huang et al., 2003). They have 
further demonstrated an increased risk of ATD-DILI from 3.94 for NAT2 rapid 
acetylators with CYP2E1 c1/c1 genotype to 7.43 for slow acetylators with the CYP2E1 
c1/c1 genotype (Huang et al., 2003). Another two independent studies based in China 
(Wang et al., 2010) and Taiwan (Lee et al., 2010) have also reported a significant 
association between ATD-DILI and the CYP2E1 c1/c1 genotype. Bose and colleagues 
have recently found an association between the mutant C allele of CYP2E1 DraI 
polymorphism (CYP2E1*5A and *6 alleles) with the risk of ATD-DILI (Bose et al., 
2011). Combined analysis of acetylator status and variants for the CYP2E1 DraI 
polymorphism was further performed and it was shown that slow acetylators and 
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carriers of the variant allele were predisposed to develop ATD-DILI (Bose et al., 2011).  
However, controversial results have been reported in some studies with no association 
found between CYP2E1 and susceptibility to ATD-DILI in Koreans (Kim et al., 2009; 
Cho et al., 2007) and in the British Columbian population of Canada (Yamada et al., 
2009). 
  
1.7.3 Glutathione S-transferase enzymes (GSTs)  
 
Oxidative stress has been suggested as the important factor that accelerates the 
progression of ATD-DILI.  Increased oxidative stress and raised levels of reactive 
oxygen species (ROS) due to generation of reactive ATD metabolites are closely 
associated with decreased glutathione levels. The glutathione S-transferase enzymes 
(GST) may play a major role against liver injury by its detoxification effects through the 
conjugation of glutathione with harmful electrophiles generated during oxidative stress 
and lipid peroxidation. However there is limited information about genetic 
polymorphism of these detoxification enzymes and their association with DILI as 
previous published studies appear to be restricted to GSTM1 and GSTT1. GSTM1 and 
GSTT1 deficiencies, caused by a homozygous deletion of the gene (null genotype) are 
common. Though the prevalence of GSTM1 and GSTT1 null genotypes varies between 
different ethnic groups, it was reported that the frequency of GSTM1null genotype 
ranges from 13.1% to 54.5% in Caucasians, from 41.7% to 55.5% in Asians, 46.7% in 
African-Americans, and 26.9% in Africans (Mo et al., 2009). For the GSTT1null 
genotype, the reported prevalence rates were 11.1-28.6% in Caucasians, 41.9-52% in 
Asians, 26.7% in African-Americans, and 36.6% in Africans (Mo et al., 2009). 
Individuals with homozygous null mutations of these genes have no enzymatic activity 
for the particular enzyme and therefore are likely to be more susceptible to carcinogens 
and drug-related toxicities. The presence of combined alleles GSTM1 and GSTT1 
deficiencies has been associated with raised liver enzymes and increases susceptibility 
to tacrine-induced hepatotoxicity in Alzheimer's disease patients (Simon et al., 2000). 
Lucena and colleagues have shown an 8.8-fold increased risk of developing NSAID-
induced hepatotoxicity in carriers of double GSTM1 and GSTT1 deletion (Lucena et al., 
2008a). They have also reported the individuals of double GSTM1/GSTT1 null 
genotypes had an overall of 2.7-fold increased risk of developing DILI regardless of the 
type of causative agents, indicating the possible role of both GSTT1/GSTM1 null 
genotypes as the non drug-specific biomarkers of DILI susceptibility (Lucena et al., 
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2008a). Individuals homozygous null for both GSTM1 and GSTT1 have also been 
associated with an increased risk of DILI relating to troglitazone, co-amoxiclav and 
carbamazepine (Lucena et al., 2008a; Ueda et al., 2007; Watanabe et al., 2003). It has 
been shown that homozygosity for the GSTM1 or GSTT1 null allele was associated with 
ATD-DILI in three independent studies. Two studies based in India and Taiwan 
reported an association with the GSTM1 null genotype but no association was found 
between cases and controls for GSTT1 null genotype (Huang et al., 2007; Roy et al., 
2001), whereas another study involving the Caucasian population showed an a higher 
frequency of GSTT1 null genotype in cases compared with controls but no difference 
was found for GSTM1 null genotype (Leiro et al., 2008). In addition, the gene encoding 
the manganese superoxide dismutase (MnSOD) which is known as SOD2, an anti-
oxidative stress gene important in detoxifying mitochondrial ROS was also found to be 
associated with increased susceptibility to DILI, especially to ATD-DILI (Huang et al., 
2007).  
 
1.8 Aims of the study  
 
The primary aim of this study was to identify specific genes conferring susceptibility to 
hepatotoxicity due to anti-tuberculosis drugs (ATD). To identify novel genetic 
associations, polymorphisms in genes involved in relevant ATD metabolic pathways 
were evaluated by a case-control study approach. The examined predictors of ATD-
DILI were chosen based on previously published studies or biological relevance and 
include NAT2, CYP2E1, GSTM1, GSTT1 and SOD2, as well as PXR, GSTA1, GSTA4 
and NAT1 which may be potential genetic predictors for ATD associated hepatotoxicity. 
The functional significance of NAT2 acetylation phenotypes will also be examined 
using an in vitro overexpression approach to characterise NAT2 acetylation phenotypes 
and their relevance to the development of isoniazid-induced hepatotoxicity. In addition, 
the protective role of glutathione S-transferase (GSTs) and their association with 
isoniazid-induced DILI will be assessed by using in vitro overexpression and siRNA 
knockdown approaches.  
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Chapter 2. General Materials and Methods 
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2 General Materials and Methods 
2.1 General Laboratory Practice 
 
All experiments were performed to university standards for safe working with 
chemicals substances in laboratories, which comply with the Control of Substances 
Hazardous to Health Regulations 2002 (COSHH, 2002). Routinely used chemicals of 
analytical and molecular biology grade were obtained from the named suppliers as listed 
(Table 2.1). Water for all experiments was purified by a Nanopure water purification 
system (Thermo Scientific). Where necessary, sterilisation of water, biological and 
chemical reagents, plastics, glassware and other equipment was achieved by autoclaving 
at 120°C, 15 pounds per inch (PSI) pressure for 20 min. In addition solutions for tissue 
culture work were filter-sterilised using 0.2 mm filters (Millipore). For PCR work and 
primer dilution pre-purchased sterile water was used (Fresenius Kabi Limited). For all 
RNA work, diethyl pyrocarbonate (DEPC) treated, nuclease free water (Fisher 
Scientific) was used in the preparation of solutions. 
 
2.2 Chemical Reagents 
 
Unless otherwise stated, all routine chemical reagents were purchased from Sigma-
Aldrich. 
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  Table 2.1 List of suppliers and addresses 
 
Supplier Address 
Bioline London, UK 
Bio-Rad Hemel Hempstead, UK 
Eurofin MWG Operon London, UK 
Fermentas York, UK 
Fisher Scientific Loughborough, UK 
GE Healthcare Little Chalfont, UK 
Greiner Bio-ONe Stonehouse, UK 
Gibco-Invitrogen Paisley, UK 
Macherey-Nagel (MN) Surrey, UK 
Merck Biosciences Nottingham, UK 
Milipore  Watford, UK 
Molecular Devices Winnersh, UK 
New England Biolabs (NEB) Hitchin, UK 
PAA Laboratories GMBH Austria 
PE Applied Biosystems Warrington, UK 
Promega Southampton, UK 
QIAGEN Crawley, UK 
Sarstedt Leicester, UK 
Scientific Laboratory Supplies Newcastle, UK 
Sigma Aldrich Gillingham, UK 
Stuart Scientific Essex, UK 
Thermo Scientific Barnstead, UK 
VH Bio Gateshead, UK 
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2.3 Mammalian Cell culture 
2.3.1  General Materials 
 
Unless stated otherwise, all disposable tissue culture plastic ware was from Greiner Bio-
One and cell culture reagents from PAA Laboratories. 
 
2.3.2 Routine Passage 
 
Cell culture was performed under aseptic conditions in a Class II laminar flow 
microbiological safety cabinet. LS180 colon cancer cells, HepG2 hepatoblastoma cells, 
Huh7.5 hepatocellular carcinoma and Caco-2 colon cancer cells were cultured as 
adherent monolayers in T75 flask at 37˚C, 5% CO2 in humidified air. Routine culture 
was performed in complete growth medium (GM). LS180, HepG2 and Caco-2 cells 
were cultured in Eagle’s Minimum Essential Medium (EMEM) and Huh7.5 cells were 
cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM). Both Media 
were supplemented with 10% foetal calf serum (FCS), Penicillin-Streptomycin (0.1 
mg/ml), 2 mM L-glutamine and 0.1 mM non essential amino acid (NEAA). Cells 
exposed to drugs were cultured in drug-containing maintenance media (MM) 
supplemented with 2% FCS, Penicillin-Streptomycin (0.1 mg/ml) and 2 mM L-
glutamine. All media were stored at 4˚C and warmed to 37˚C prior to use. 
 
2.3.3 Cell line maintenance 
 
Cultures displaying 70-80% confluence were passaged within 3-5 days. Medium was 
aspirated, the cell monolayer rinsed with sterile 1x Dulbecco’s phosphate buffered 
saline (PBS) (PAA Laboratories) followed by 0.25% trypsin-EDTA 
(ethylenediaminetetraacetic acid) (Gibco-Invitrogen). After removing trypsin-EDTA, 
the monolayer was then incubated at 37˚C for 5 min until the cells dissociated. 
Detached cells were resuspended in GM, and passaged at a ratio of 1:3-6. 
 
2.3.4 Cell line storage 
 
Cell stocks were accumulated early and frozen at -80˚C allowing experiments to be 
performed using stores of low passage number cells. Logarithmically growing cell 
cultures were pelleted then resuspended in freezing medium composed of FCS 
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supplemented with 10% dimethylsulphoxide (DMSO). 1 ml aliquots of 5 X 10
6
 were 
frozen in 1.8 ml cryogenic vials (Corning). To revive the cells, frozen stocks were 
rapidly thawed at 37˚C, resuspended in GM and centrifuged at 1000 rpm for 5 min. The 
supernatant was discarded, the cell pellet was resuspended in GM, and plated in tissue 
culture flasks.  
 
2.3.5 Microscopy and cell counting 
 
Cell pellets were resuspended in complete medium and 10 µl of single cell suspension 
was then transferred to a haemocytometer counting chamber. The number of cells 
overlying the ruled grid was counted using low power magnification (x10) on an 
inverted microscope (Olympus) and the number of cells per ml was calculated. The 
suspension was then appropriately diluted, and the correct cell number seeded out for 
each experiment.  
 
2.3.6 Cell lines 
 
The LS180 colon cancer cell line, purchased from the European Collection of Cell 
Cultures (ECACC) (Porton Down, UK), was derived from a 58 year old female 
Caucasian with Dukes type B adenocarcinoma of the colon. Caco-2, HepG2 and Huh7.5 
cell lines were given by Professor Geoffrey Toms. Caco-2 is derived from a human 
colon adenocarcinoma, while HepG2 and Huh7.5 are derived from human 
hepatoblastoma and hepatocellular carcinoma respectively. 
 
2.4 Genomic DNA preparation and analysis 
2.4.1  DNA extraction 
 
Cells were pelleted by centrifugation (Sigma 3-16PK centrifuge) at 3000 g for 10 min at 
4ºC and resuspended with 2 ml of nuclear lysis buffer (400 mM tris-HCl pH 8.0, 60 mM 
EDTA, 150 mM sodium chloride and 1% (w/v) sodium dodecyl sulphate). The mixture 
was then transferred into a 15 ml polypropylene centrifuge tube and 0.5 ml of 5 M 
sodium perchlorate was added. The samples were then rotary mixed at room 
temperature for 15 min (Stuart Scientific) and incubated at 65ºC for 30 min. The 
samples were combined with 2.5 ml chloroform and rotary mixed for 10 min at room 
temperature to form a homogenous emulsion before centrifugation at 3000 g for 10 min 
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at 4ºC. The top aqueous layer containing DNA was removed and dispersed into a new 
15 ml polypropylene centrifuge tube. Ethanol (5 ml) was added and mixed by rapid 
inversion of the tube several times. The precipitated DNA was spooled using a sterile 
disposable plastic loop and allowed to air-dried for 10 min at room temperature. The 
DNA was then dissolved overnight at 60ºC in 200 µl 5 mM tris -HCl, pH 8.0 in a sterile 
1.5 ml screw-cap microcentrifuge tube.  
 
2.4.2  Determinants of DNA yield and purity 
 
The amount and purity of the DNA samples were examined by Nanodrop 
spectrophotometer ND-1000 (Thermo Scientific). An absorbance unit of 1 at 260 nm is 
equivalent to 50 µg/ml double stranded DNA. The absorbance at 260 and 280 nm is 
used to assess the purity of DNA and a 260/280 nm ratio of 1.8 – 2.0 indicates pure 
DNA. A secondary measure of DNA purity can be assessed by measuring the 
absorbance at 260 and 230 nm. The 260/230 nm ratio of 1.8-2.2 indicates pure DNA. If 
the ratio is appreciably lower, it may indicate the presence of protein, phenol or other 
contaminants. 
 
2.4.3 DNA sample storage 
 
The quantified DNA samples were diluted to 50 ng/µl and aliquoted into 1.5 ml sterile 
screw-cap microfuge tubes. Working stocks were kept at 4ºC and the remaining 
aliquotes were stored at -80ºC. 
 
2.4.4 Polymerase Chain Reaction (PCR) 
2.4.4.1 Primers  
 
Primer sets were designed using PerlPrimer v1.1.3 software, unless otherwise stated. 
Nucleotide blast search (NCBI, www.ncbi.nlm.nih.gov/blast) was performed to ensure 
sequence specificity. Primers were purchased from Eurofin MWG Operon in a 
lyophilized state. All primers were dissolved in sterile water to a stock concentration of 
200 µM and stored at -20ºC. 
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2.4.4.2 PCR procedure 
 
The PCR reaction was carried out in 25 µl solution consisting of 0.25 µM specific 
primer (Eurofin MWG Operon), 0.1 mM dNTPs (VH Bio), 0.1 µg of genomic DNA as 
template, and 0.625U Taq polymerase (NEB) in 50 mM potassium chloride, 10 mM 
tris-HCl pH 9.0, 0.1% (v/v) triton X-100, 1.5 mM MgCl2. The PCR program consisted 
of initial denaturation at 95ºC for 5 min and 35 cycles of denaturation at 94ºC for 1 min, 
annealing at a specified temperature for 1 min, extension at 72ºC for 1 min, and a final 
extension at 72ºC for 7 min. Amplifications were performed in an Applied Biosystems 
2720 Therma Cycler (PE Applied Biosystems). PCR products were visualized by 
ethidium bromide staining on 2% agarose gel (see section 2.6).  
  
2.4.5 Electrophoresis and visualisation of DNA fragments 
2.4.5.1 Agarose gel electrophoresis  
 
Two percent agarose gels were made using DNase and RNase free agarose powder 
(Bioline) in 1x tris-borate-EDTA (TBE) buffer (0.09 M tris-base, 0.09 M boric acid and 
2 mM EDTA), containing ethidium bromide (0.5 µg/ml ). One micro litre of 6 X gel 
loading buffer (0.25 % bromophenol blue, 0.25 % xylene cyanol, 30% glycerol) was 
mixed with 5 µl DNA sample and applied to the gel. The DNA fragment sizes were 
estimated by comparison to a 100 bp DNA ladder (NEB). Electrophoresis was 
performed at constant voltage of 80V for 30-45 min in 1 X TBE buffer.  
 
2.4.5.2 Polyacrylamide gel electrophoresis (PAGE)  
 
Polyacrylamide gel solution (10%) containing 30% acrylamide-bis arylamide 29:1 
(Fisher Scientific) in 1X TBE buffer, 0.4 mg/ml ammonium persulphate (APS) and 
0.1% TEMED was prepared. The gel was cast between two 200 mm x 200 mm glass 
plates separated by 0.8 mm spacers and allowed to polymerize at room temperature for 
30 min. Three micro litres of 6 X gel loading was mixed with 15 µl of DNA samples 
and applied to the gel. The DNA fragment sizes were estimated by comparison to a 
100bp DNA ladder (NEB). Electrophoresis was performed at constant voltage of 150V 
for 4-6 h in 1 X TBE buffer and the gels were stained for 30 min in 0.5 µg/ml ethidium 
bromide in 1 X TBE buffer. Gels were then destained for 10 min in distilled water 
before viewing. 
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2.4.5.3 Gel visualisation  
 
Visualization of the DNA fragments was done using the Flour-S MultiImager system 
(Bio-Rad Laboratories) and Quantity One analysis software (Bio-Rad Laboratories). 
 
2.4.6 DNA purification and sequencing 
 
PCR products and plasmid DNA were eletrophoresed in 1% agarose gel along with a 
100 bp DNA ladder. DNA fragments were then excised from the agarose gel and 
purified using the QIAquick gel extraction kit (QIAGEN) according to the 
manufacturer’s protocol. Both purified PCR products (5 ng/µl) and plasmid DNA (100 
ng/µl) were transferred into 1.5 ml microfuge tubes in a minimum volume of 15 µl. 
Primers used for PCR products sequencing were diluted to 2 ng/µl and transferred into 
1.5 ml microfuge tubes in a minimum volume of 15 µl. Both purified PCR products and 
plasmid DNA together with their specific primers used for sequencing were sent to 
Eurofin MWG. DNA sequencing was performed by Eurofin MWG and the sequences 
were then compared using BLAST alignment tool.  
 
2.5 Recombinant cell line construction  
2.5.1 Insertion of PCR product into plasmid vector 
 
PCR product was purified and ligated into a pTARGET mammalian expression vector 
(Promega) according to the manufacturer’s instructions. The pTARGET vector contains 
a 3’ terminal thymidine at both ends which improve the efficiency of ligation with the 
A-tailing of PCR product into the vector.  Figure 2.1 shows the map of the pTARGET 
vector. Briefly, a 10 µl reaction mixture was set up with 10 ng mammalian expression 
vector pTARGET (Promega), 5 µl of ligation buffer (2x), 1 µl T4 DNA ligase (1U), and 
3 µl of 300 ng of insert DNA fragment. The ligation reaction mixture was incubated at 
4°C for 16 h prior to transformation.  
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The pTARGET mammalian expression vector contains a 3’ terminal thymidine at 
both ends which improve the efficiency of ligation with the A-tailing of PCR 
product into the plasmid.  The vector contains a modified version of coding 
sequence of the α-peptide of β-galactosidase, allowing blue/white recombinant 
screening. The vector carries the human cytomegalovirus (CMV) immediate-
early enhancer/promoter region to promote constitutive expressions of cloned 
DNA inserts in mammalian cells. This vector also contains the neomycin 
phosphotransferase gene, a selectable marker for mammalian cells. Expression 
of the neomycin phosphotransferase gene in the pTARGET vector confers 
resistance to the antibiotic G-418 and allows the selection of stably transfected 
cells.  
Figure 2.1 Map of the pTARGET mammalian expression vector 
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2.5.2 Transformation 
 
Competent Escherichia coli (E. coli) JM109 cells (50 µl) were mixed with 2 µl of 
ligation reaction mixture in a sterile 15 ml polypropylene tube and transformed by 
placing on ice for 20 min. The E. coli cells were heat shocked by incubating the reaction 
tube in a water bath at 42°C for 1 min. After heat shock, the tube was immediately 
transferred to ice and incubated for 2 min. SOC medium (950 µl) (10 mM NaCl, 2.5 
mM KCl, 10 mM MgSO4, 10 mM MgCl2, 20 mM glucose, 0.5% yeast extract and 2 % 
tryptone)  was added into the cells. The tube was then incubated in an orbital incubator 
at 150rpm at 37°C for 1.5 h. Subsequently, E. coli cells (100 µl) were plated onto a 
1.5% Luria-Bertani (LB) agar plate containing 100 µg/ml ampicillin, 20 mg of 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside, and 200 mg/ml of isopropyl-β-D-
thiogalactopyranoside (IPTG). The plate was incubated overnight at 37°C.  
 
2.5.3 Isolating recombinant plasmid DNA 
 
The pTARGET vector contains a modified version of coding sequence of the α-peptide 
of β-galactosidase, allowing blue/white recombinant screening. The transformants 
(white colonies) were inoculated individually using a sterile pipette tip and transferred 
into LB broth (5 ml) containing 100µg/ml ampicillin. Transformants were allowed to 
grow for 16 h at 37°C and harvested by centrifugation at 1500rpm at 4°C for 10 min. 
Plasmids were then extracted using the QIAGEN mini-prep plasmid extraction kit. The 
presence of the recombinant construct was confirmed by digesting the plasmid DNA (3 
µl) with EcoRI restriction enzyme. Plasmids containing the desired insert were further 
confirmed by sequencing in both forward and reverse strands (see section 2.4.6). 
 
2.5.4 Transfection and generation of stable cell lines 
 
Exponentially growing cells were seeded at a density of 3x10
5
 cells per ml using 2 ml of 
antibiotic-free culture medium into 6-well plates. After 24 h, cells were transiently 
transfected using GeneJuice transfection reagent (Novagen, Merck Biosciences). 
Briefly, GeneJuice (3 µl) was premixed with 250 µl of EMEM (serum-free, non-
antibiotics) in a sterile 15 ml polyethylene tube and incubated for 5 min at room 
temperature. Plasmid DNA (1 µg) was then added into the mixture and incubated 
further at room temperature for 10 min. The complex mixture was then added into the 
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cells and incubated for 24 h. At 24 h after transient transfection, cells were transferred 
into 100 mm culture dish and stable cell lines were generated by selection with 500 
µg/ml G-418 antibiotic (Sigma) for 2-5 weeks. The pTARGET vector contains the 
neomycin phosphotransferase gene, which confers resistance to G-418. Death of cells 
not expressing neomycin phosphotransferase was detected after 10-14 days following 
addition of G-418. The medium were changed every 2-3 days until the drug-resistant 
clones appear. The cell clones were observed after PBS washing and the larger single 
cell clones were separated with sterile tip, cultured in 500 µg/ml G-418 selective culture 
medium for another 2 weeks. The stable transfected cell lines were obtained after 
passage by 2-3 generations and maintained in 250 µg/ml G-418 selective culture 
medium. 
 
2.6 RNA isolation and analysis 
2.6.1 RNA isolation and quantification 
 
Monolayer cell cultures were washed twice with ice-cold PBS, scraped off into PBS and 
pelleted by centrifugation for 5 min at 1000 rpm. Total RNA was extracted using 
NucleoSpin RNA II extraction kit (Macherey-Nagel, MN) according to the 
manufacturer’s instructions. RNA concentrations were then quantified using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific).  
 
2.6.2 Synthesis of cDNA 
 
One microgram of RNA was reverse transcribed in 1 X RT buffer + 2.5 U/µl reverse 
transcriptase (NEB), 5 mM deoxynucleotide (dNTP) mixture (Fermentas), 20 ng/µl 
random hexamers (QIAGEN), and 1 U/µl RNase inhibitor (NEB). RNA with random 
hexamers were incubated at 65˚C for 10 min and immediately put on ice. Reverse 
transcription was carried out at 42˚C for 30 min, 50˚C  for 30 min, 70˚C  for  10 min, 
then incubated at 4˚C. The cDNA was then stored at -20˚C prior to analysis. 
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2.6.3 Semiquantitative reverse transcription-PCR (Semiquantitative 
RT-PCR) 
 
Amplification of cDNA was performed using PCR (see section 2.4.4). The PCR 
conditions for the target gene were 35 cycles at 95ºC for 15 s, annealing at a specified 
temperature for 30 s, and 72ºC for 45 s except for Beta-actin (β-actin) and 
Glyceraldehyde-3-phosphate (GAPDH). β-actin and GAPDH are housekeeping genes 
which used as internal control to evaluate the gene expression analysis. The PCR 
conditions for β-actin and GAPDH were 30 cycles at 95ºC for 15 s, 52ºC for 30 s, and 
72ºC for 45 s. PCR products were then visualized by ethidium bromide staining on a 2% 
agarose gel. The primer sequences and PCR conditions used for semiquantitative RT-
PCR analysis are summarized in Table 2.2.  
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                                                                      Table 2.2 Semiquantitative RT-PCR primer sequences and conditions 
 
Gene name Short name Primer sequences Expected 
size 
Annealing 
Temperature 
Glyceraldehyde-3-phosphate GAPDH 5’-GACAACTTTGGTATCGTGGAAGGA-3’    
5’-ACCAGGAAATGAGCTTGAC-3’ 
445 bp 52ºC 
Beta-actin β-actin 5’-GTTGCCAATAGTGATGACCT-3’                
5’-GACCTGACAGACTACCTCA-3’ 
207 bp 52ºC 
N-acetyltransferase 2 NAT2 5’-ACGTCTCCAACATCTTCATTTATAACC-3’ 
5’-TCAACCTCTTCCTCAGTGAGAGTTTTA-3’ 
161 bp 51ºC 
Glutathione S-transferase alpha 4 GSTA4 5’-CAAGTTGCAGGATGGTAACC-3’               
5’-ACATGTCAATCAGGGTTCTC-3’ 
158 bp 53ºC 
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2.6.4 Quantitative real-time PCR (Quantitative RT-PCR)  
 
Real-time PCR is the continuous collection of fluorescent signal from polymerase chain 
reactions over a range of cycles. Quantitative real-time PCR, on the other hand, allows 
the conversion of the fluorescent signals from each PCR reaction into a numerical value 
for each sample (Dorak, 2006). It is based on the detection of the fluorescence signals 
produced by a reporter molecule which increases, as each cycle of the PCR 
amplification proceeds. By monitoring and recording the intensity of the fluorescence 
emission during each PCR cycle, it is possible to identify the exponential phase of the 
PCR reaction and from this to determine the initial amount of target template (Dorak, 
2006). The amount of target template present corresponds to the level of fluorescence. 
Thus, the higher the starting copy number of the target template, the fewer the 
amplification cycles needed before a significant increase in fluorescence is observed. 
During the initial cycles of PCR, the background signal prior to the significant 
accumulation of the target amplicon is used to determine the baseline fluorescence 
across the entire reaction. When the target amplification is sufficiently above the 
baseline value and within the exponential part of the amplification curve, a fixed 
fluorescence threshold is set. The threshold cycle (Ct) reveals the cycle number at which 
the fluorescence emission crosses the fixed threshold. It reflects the statistically 
significant point above the baseline during a reaction at which a sufficient number of 
amplicons have accumulated. Thus, the higher the initial amount of target template, the 
faster accumulated PCR product is detected, and the lower the Ct value.  
 
The commonly used fluorescent reporter molecules include intercalating fluorescent 
dyes such as SYBR Green I and sequence specific probes. Sequence specific probes, 
such as TaqMan probes are oligonucleotides longer than the primers (20-30 bases long) 
that contain a fluorescent reporter (FAM- and VIC-labelled) and a quencher (usually 
TAMRA or a non-fluorescent quencher) at their 5’ and 3’ ends, respectively (Figure 
2.2). A passive reference dye such as 6-carboxyl-x-rhodamine (ROX) is primarily used 
to normalise for non-PCR-related fluctuations in fluorescence signal. When the probe 
binds to an internal region of a PCR product, the 5’exonuclease activity of the DNA 
polymerase cleaves the reporter dye from the probe. This separates the reporter dye 
from quencher dye, ends the activity of the quencher and thus allows the fluorescence 
emitted by the reporter. The increased in the reporter fluorescence signal is correlated to 
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the amount of the PCR product generated in each reaction. The resulting fluorescence is 
only detectable if the cleavage occurs when the probe hybridizes to its target sequences. 
Therefore the detected fluorescence is specific amplification and little optimization is 
required for a well-designed TaqMan probe. However, compared to SYBR Green, 
TaqMan probes are relatively expensive and a different probe has to be synthesized for 
each specific target.  
 
SYBR Green I dye is an intercalating agent that binds to all double-stranded DNA or 
PCR products. During DNA denaturation, SYBR Green I dye is released and the 
fluorescence signal is drastically reduced. When PCR amplification is complete, SYBR 
Green I dye binds to the double stranded products, resulting in an increase in 
fluorescence (Figure 2.2). The advantage of using SYBR Green I dye is the relative 
simplicity of this assay system where no probes are required, thus reduces assay setup 
and running cost. However, the primary disadvantage is that it may generate false 
positive signals by binding to any double-stranded DNA including primer dimers, 
contaminating DNA, and PCR product from mis-annealed primer. Extensive 
optimization is therefore required for assay setup. Figure 2.3 shows a typical 
amplification plot on NAT2 expression obtained during this project. Melting point or 
dissociation curve analysis can be generated following a reaction to verify whether only 
one product is being amplified. As shown in Figure 2.4a, once the final PCR 
amplification cycle is completed, a maximum amount of SYBR Green I is bound to 
double-stranded DNA and a high level of fluorescence signals is generated. However, 
DNA product melts or dissociates with increasing temperature (>80ºC), releasing SYBR 
Green and decreasing the fluorescent signal. The melting point is defined as the 
inflection point of the melting curve which is shown as a peak in the derivative melt 
curve plot (Figure 2.4b). A single peak indicates a single product whereas multiple 
peaks indicate the presence of non-specific priming including primer dimers and 
genomic DNA contamination. The predicted size of single peak can be verified by 
agarose gel electrophoresis. 
 
The expression level of a target gene can be measured by relative quantitative in relation 
to the level of a control gene. An ideal control generally demonstrates gene expression 
that is highly abundant and relatively constant across tissues and cell types. By using an 
invariant control, quantitation of an mRNA target can be normalised for differences in 
  
 
58 
the amount of total RNA added to each reaction. Commonly used internal control genes 
such as Glyceraldehyde-3-phosphate (GAPDH), β-actin and 18S ribosomal RNA (18S 
rRNA) are constitutively expressed housekeeping proteins, however, they may not 
always the most ideal or appropriate candidates for normalisation in RT-PCR. For 
instance, GAPDH expression may be upregulated in proliferating cells, and β-actin is a 
better active reference for these cells instead of GAPDH (Suzuki et al., 2000). GAPDH 
is also not recommended for cancer studies due to its high expression in aggressive 
cancer cells (Goidin et al., 2001). Additional caution should be taken when 18S rRNA is 
used as an control especially if the expression level of the target gene is low (Dorak, 
2006). The strategy of using a combination of multiple controls as normaliser may be 
useful for relative expression studies by quantitative RT-PCR. More details and a 
typical calculation are shown in section 4.3.2.1. A Taqman probe-based RT-PCR assay 
(allelic discrimination assay) can also use to perform genotyping studies with any 
possible SNP by using two allele-specific probes. Use of a Taqman SNP genotyping 
assay is described in detail in section 3.2.7.  
 
The SYBR green-based RT-PCR assay used in our present study is SYBR Green I 
JumpStart Taq ReadyMix, obtained from Sigma-Aldrich. The hot-start mediated Taq 
polymerase (JumpStart Taq) enhances the efficiency and increases the specificity and 
yields of the desired sequence by eliminating polymerase activity at temperatures below 
70ºC. Briefly, quantitative RT-PCR was performed utilizing 0.2 µl cDNA per reaction 
in triplicate in a 13 µl volume on a ABI Prism 7000 Sequence Detection System. PCR 
amplification conditions were as follows: 50ºC, 2 min, followed by 95ºC, 10 min, then 
40 cycles at 95ºC, 15 s; and 40 cycles at 60ºC, 1 min. Amplification of GADPH or β-
actin was performed using the same conditions as the genes being tested but in separate 
tubes. A “no template” control for each gene was performed, replacing cDNA with 
water. Data analysis was performed using SDS 2.2 software (PE Applied Biosystems). 
At the end of the PCR, dissociation curves were generated and analysed to identify the 
possibility of non-specific PCR products. Standard curves were assessed by r
2
 value, 
with a minimum of 0.98 required for successful PCR analysis. Quantitation of the target 
cDNAs in all samples was normalized to GAPDH or β-actin (GAPDH; Cttarget – CtGAPDH 
= ∆Ct), and the effects of each compound on the target cDNA was expressed relative to 
the amount in the vehicle control sample (∆Ctcompound - ∆Ctvehicle = ∆∆Ct). Relative fold 
changes in target gene expression were determined by taking 2 to the power of the ∆∆Ct 
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value (2
-∆∆Ct
) as per the user bulletin (PE Applied Biosystems) (Livak and Schmittgen, 
2001). The primer sequences used for Q-RTPCR analysis are summarized in Table 2.3.  
 
 
 
 
 
1. Polymerization: A fluorescent reporter ® dye and a 
quencher (Q) are attached to the 5’ and 3’ ends of a 
TaqMan ® probe, respectively
1. Reaction setup: The SYBR ® Green I Dye fluoresces 
when bound to double-stranded DNA.
2. Strand displacement: When the probe is intact, the 
reporter dye emission is quenched.
2. Denaturation: When the DNA is denatured, the 
SYBR ® Green I Dye probe is released and the 
fluorescence is drastically reduced.
3. Cleavage: During each extension cycle, the DNA 
polymerase cleaves the reporter dye from the probe.
3. Polymerization: During extension, primer anneal 
and PCR product is generated.
4. Polymerization completed: Once separated from 
the quencher, the reporter dye emits its 
characteristic fluorescence.
4. Polymerization completed: When polymerization is 
complete, SYBR ® Green I Dye binds to the 
double-stranded product, resulting in a net increase 
in fluorescence detected by the assay system.
TaqMan ® Probe-based Assay Chemistry SYBR ® Green I Dye Assay Chemistry
 
 
Figure 2.2 Comparison of Taqman®- and SYBR®-Green based detection (Image 
obtained from Applied Biosystems website (http://www.appliedbiosystems.com)  
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Figure shows the amplification plots of target gene (NAT2) and control (GAPDH) in 
non-transfected, RAR- and SAR stably transfected HepG2 cells. NAT2 expressions in 
RAR- and SAR-stably transfected cells are higher than the non-transfected cells as a 
much lower Ct values (20-21) was detected in those cells compares to the non-
transfected cells (Ct values ≈ 30). The Ct values for GAPDH are quite consistent in 
all three types of cells with Ct values around 17.  
Figure 2.3 Representative amplification plot quantitative RT-PCR using SYBR 
Green I detection dye 
Non-transfected HepG2
RAR-stably transfected HepG2
SAR-stably transfected HepG2
GAPDH
NAT2
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Figure 2.4 Melting curve (a) and derivative melting curve (b) analyses 
for the reactions shown in Figure 2.3 
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Table 2.3 Quantitative RT-PCR primer sequences 
 
Gene name Short name Primer sequences 
Glyceraldehyde-3-phosphate GAPDH  5’-GGGTGTGAACCATGAGAAGTATGA-3’                  
5’-CATGAGTCCTTCCACGATACCAA -3’ 
Beta-actin β-actin 5’-GTTGCCAATAGTGATGACCT-3’                               
5’-GACCTGACAGACTACCTCA-3’ 
Cytochrome P450 3A4 CYP3A4 5’-TGTCCTACCATAAGGGCTTTTGTA-3’                     
5’-TTCACTAGCACTGTTTTGATCATG-3’ 
Carboxylesterase 2 CES2 5’-AACCTGTCTGCCTGTGACCAAGT-3’                                 
5’-ACATCAGCAGCGTTAACATTTTCTG-3’ 
Cytochrome P450 2E1 CYP2E1 5’-ACCTGCCCCATGAAGCAACC-3’                              
5’-GAAACAACTCCATGCGAGCC-3’ 
N-acetyltransferase 2 NAT2 5’-ACGTCTCCAACATCTTCATTTATAACC-3’             
5’-TCAACCTCTTCCTCAGTGAGAGTTTTA-3’ 
Glutathione S-transferase alpha 4 GSTA4 5’-CCGGATGGAGTCCGTGAGATGG-3’                              
5’-CCATGGGCACTTGTTGGAACAGC-3’ 
Glutathione S-transferase alpha 1 GSTA1 5’-AAGGAGAGAGCCCTGATTGATATGT-3’                
5’-GTCTTGTCCATGGCTCTTTAAGACT-3’ 
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2.7 Protein analysis 
2.7.1 Protein extraction and quantification 
 
Protein was extracted from harvested cells using RIPA buffer (Fisher Scientific) 
containing 25 mM tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS and a protease inhibitor cocktail (Sigma). Cell lysates were 
homogenised using a syringe and quantified using BioRad DC Protein Assay.  A 
standard dilution of Bovine Serum Albumin (BSA) (Bio-Rad) was prepared ranging 
from 0.125 – 4 mg/ml in RIPA buffer. Absorbance was read at 750nm using 
Spectramax M5e and protein concentrations were calculated using the Softmax Pro5.2 
software.  
 
2.7.2 SDS polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Protein preparations were analysed by SDS-polyacrylamide gel electrophoresis (PAGE) 
according to Laemmli et. al. (Laemmli, 1970). Polyacrylamide gels were cast and run 
using Mini PROTEAN II equipment (Bio-Rad). A 12% SDS-polyacrylamide resolving 
gel was cast under a 4% stacking gel. The resolving gel contained 16 ml acrylamide/bis 
solution, 20 ml resolving gel buffer (0.75 M tris-HCl, pH 8.8 and 0.2% (w/v) SDS), 400 
µl APS, 160 µl TEMED  and 4 ml H2O. The stacking gel contained 2 ml arylamide/bis 
solution with 5 ml stacking gel buffer (0.25 M tris-HCl, pH 6.8 and 0.2% (w/v) SDS), 
100 µl APS, 40 µl TEMED  and 3 ml H2O. The resolving gel was first cast between two 
200 mm x 200 mm glass plates and the gel surface was overlayed with 2-butanol to 
avoid any formation of air bubbles. The resolving gel was allowed to polymerize at 
room temperature for 30 min and rinsed with water after polymerisation. Subsequently 
the stacking gel solution was added on top of the resolving gel and a comb was placed 
between the gel plates. The stacking gel was then allowed to polymerize for 30 min 
before removing the comb. Fifty micrograms of protein was mixed with SDS sample 
loading buffer (5 M urea, 2.5% SDS, 0.5 M tris-HCl pH 6.8, 3.5% β-mercaptoethanol 
and 0.02% bromophenol blue) in the ratio of 1:1 and heated at 95°C for 5 min. Protein 
samples and molecular weight marker (PageRuler Prestained Protein Ladder, 
Fermentas) were applied to a SDS-PAGE gel and separated at 175V for 2 h in running 
buffer (25 mM tris-HCl pH 8.3, 192 mM glycine and 0.1% SDS). Proteins were then 
transferred onto a nitrocellulose membrane (Amersham Hybond-C, GE Healthcare) in 
transfer buffer (25 mM tris base, 0.15 M glycine, 10% methanol) at 60V for 2 h. After 
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transfer, proteins were visualised by staining the nitrocellulose membrane with Ponceau 
S solution and scanned before immunoblotting to ensure equal loading. Membranes 
were then rinsed with PBS to remove remaining Ponceau S stain. 
 
2.7.3 Western Blotting 
 
The nitrocellulose membrane containing transferred proteins was blocked for non-
specific binding with 10% milk in 1x phosphate buffered saline (PBS, pH 7.4) (120 mM 
NaCl, 9 mM Na2HPO4, 3.7 mM NaH2PO4 and 2.7 mM KCl) for 1 h at room 
temperature on a shaker. Primary antibodies were diluted in 1% milk made in PBS 
according to their optimised concentration and added onto the membrane for an 
overnight incubation at 4°C on a shaker. Membranes were washed three times in PBS 
for 10 min before incubated in appropriate horseradish peroxidase (HRP) labelled 
secondary antibodies for 1 h at room temperature on a shaker. After incubation, the 
membranes were washed three times in PBS for 10 min and the proteins were detected 
using chemiluminescence system by Amersham ECL
 
Western Blotting Detection 
Reagents (GE Healthcare). The membrane was then exposed on Amersham Hyperfilm 
(GE Healthcare) and developed manually through a 1 min rinse each in GBx developing 
and fixing solution. Membranes were then stripped by incubation at room temperature 
with gentle shaking for 10 min in 100% acetonitrile. The acetonitrile was removed from 
the membrane before their incubation at 56 ˚C in 150 ml stripping buffer for 30 min 
with gentle rocking. Membranes were then washed four times for 15 min in PBS on 
shaker and six times for 15 min in deionised water. They were either dried at room 
temperature and store between sheets of whatmann paper at -20 ˚C or used immediately 
for immunostaining. The list of antibodies used was shown in Table 2.4. 
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                          Table 2.4 Antibodies used for Western blotting 
 
Primary antibodies Source Company Dilution 
Anti-GAPDH polyclonal Rabbit Sigma 1:1000 
Anti-β-actin polyclonal Rabbit Sigma 1:1000 
Anti-NAT2 polyclonal Mouse Abnova 1:500 
Anti-GSTA4 polyclonal Mouse Abnova 1:1000 
Anti-GSTA1 monoclonal Mouse Abnova 1:1000 
Secondary antibodies    
HRP-labelled anti-mouse Goat DAKO 1:3000 
HRP-labelled anti-rabbit Goat DAKO 1 :3000  
 
 
 
 
 
2.7.4 Quantitation of protein bands 
 
Quantitation of the protein bands was done by using ImageJ software (Wayne Rasband, 
INH). A scanned image of the immunoblot was saved as a TIFF file and the intensity of 
the protein bands were quantified according the procedure detailed. 
(http://rsb.info.nih.gov/ij/).  
 
 
2.8 Assessment of cell viability  
 
A cell viability test was performed using the 3-(4,5-dimethypthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay in a 6-well plate. Cells were seeded 
overnight at a density of 1x10
6
 cells per ml and exposed to drug treatment for 
designated period of time. On the day of assay, medium was removed, cells were 
washed with PBS, and 900 µl of fresh medium together with 100 µl MTT solution in 
PBS (5mg/ml) was added into each well at 37ºC for 3 h. The media containing MTT 
solution was removed and 100µl of isopropanol containing 0.04 M HCl was added to 
each well. The plates were shaken to solubilise the blue formazan produced for 30 min 
at 4ºC and absorbance was measured at a wavelength of 570nm with background 
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subtraction at 690nm in a plate reader. Assays were performed in duplicate from three 
independent experiments. Data of the MTT assays were analyzed using two-way 
analysis of variance (ANOVA) to identify specific differences between selected groups. 
In all cases, P<0.05 was required for significance to identify specific differences. The 
fifty-percent effective concentration (EC50), representing the concentration
 
of drug 
causing 50% cell death compared with control cells, was determined by non-linear 
regression using GraphPad Prism 5.0 (California, USA).  
 
2.9 Determination of intracellular glutathione content 
 
The amount of reduced glutathione (GSH) and oxidized glutathione (GSSG) in 
mammalian cells were determined using the enzymatic recycling method adapted to 
microplate reader according to Baker et al. (Baker et al., 1990). The total intracellular 
GSH was determined by the colorimetric reaction of 5,5’-dithiobis(2-nitrobenzoic acid) 
(DTNB) with GSH to form the coloured product 5-thio-2-nitrobenzoic acid (TNB). 
GSSG is then reduced by glutathione reductase (GR) to form GSH, using the reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor. The rate of 
formation of TNB, which is proportional to the total GSH content (GSH + GSSG), was 
measured spectrophotometrically at 405nm. Briefly, cells were seeded overnight on a 6-
well plate at a density of 1x10
6
 cells/ml and subjected to drug treatment for designated 
time period in duplicate. A positive control was included in the assay by treating the 
cells with 0.5 mM diethyl maleate (DEM) which reduce GSH levels when compared to 
the media control (no drug treatment).  Cells were then washed with room temperature 
PBS and lysed by scraping them in 100 µl ice-cold 5% 5-sulfosalicylic acid (SSA). 
Lysed cells were transferred to 0.5 ml microfuge tubes, incubated for 10 min on ice and 
centrifuged at 8000 x g for 5 min. To assay for total GSH, cell lysates were first diluted 
1:2 with 5% SSA, and further diluted to 1:2 with 400 mM sodium carbonate, then 
further diluted 1:8 with phosphate-EDTA dilution buffer (100 mM sodium phosphate, 1 
mM EDTA, pH 7.4) (total dilution of 1:32). Standards containing from 0-8µM of GSSG 
were prepared by diluting the 5% SSA-diluted GSSG stock (16 µM) with 200 mM 
sodium carbonate and 2.5% SSA. The samples and standards were kept on ice until 
being loaded in the 96-wells microtiter plate. To measure the GSSG, the GSH in the 
samples was treated with 2-vinylpyridine (2VP) to conjugate GSH before assay of 
residual GSSG (Griffith, 1980). Equal volume of the optimized concentration of 2VP, 
200 mM final, was added into the samples and the samples were further diluted 1:2 with 
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400 mM sodium carbonate (total dilution 1:4). GSSG assay samples were incubated at 
room temperature for an hour to allow the conjugation of GSH with 2VP.  The 
microtitre plate was prepared by pipetting 20 µl of standards, 2VP-treated and untreated 
samples and blank per well. Subsequently, 180 µl of freshly prepared assay reaction 
mixture containing 0.4 mM NADPH, 0.3 mM DTNB, and 1.9 units/ml of GR in 
phosphate-EDTA dilution buffer was added into the wells and the plate was incubated 
in the dark on an orbital shaker. The absorbance in the wells at 405nm after 25 min was 
measured using a plate reader. The GSH and GSSG content were determined from the 
GSH standard curves by using the following formula: 
 
GSH   =    (Absorbance at 405nM) ─ (Y-intercept)     X    sample dilution  
        Slope                                      
GSSG =    (Absorbance at 405nM) ─ (Y-intercept)     X    (sample dilution)/2 
        Slope 
The dilution factor for GSSG content was corrected for the conversion of GSH to GSSG 
as GR reduces the GSSG formed into 2GSH. Protein concentration of each cell extract 
was quantified using BioRad DC Protein Assay (see section 2.9.1). The total glutathione 
(GSH+GSSG, µM/mg) and GSH/GSSG ratio data in each sample were analyzed. A 
two-way ANOVA was performed to identify specific differences between selected 
groups using GraphPad Prism 5.0. In all cases, P<0.05 was required for significance to 
identify specific differences. Figure 2.2 shows the GSH standard curve ranging in 
concentration from 0.2-8.0 µM. Data presented are means ± S.D. of duplicates. 
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GSH calibration curve was prepared from serial dilution of GSH ranging 
from 0.2-8.0 µM plotted versus their absorbance values. Data presented are 
means ± S.D. of duplicates. The change in absorbance at 405 nm is a linear 
function of the GSH concentration with r
2
 > 0.99. 
 
Figure 2.5 GSH calibration curve as absorbance values versus 
glutathione concentrations 
GSH calibration curve 
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2.10 DNA fragmentation assay 
 
DNA fragmentation was assessed by Apoptotic DNA Ladder Extraction Kit (Biovision). 
Briefly, approximately 1X10
7
 cells were harvested, washed with PBS, and pelleted by 
centrifugation for 5 min at 500 × g. The supernatant was removed and the cell pellet 
was resuspended in 50 μl DNA Ladder Extraction Buffer. The mixture was then mixed 
by gentle pipetting for 10 seconds and centrifuged for 5 min at 1600 × g. The 
supernatant was transferred to a new 1.5 ml microfuge tube and the cell pellet was 
extracted again with 50 μl DNA Ladder Extraction Buffer. The supernatants were 
combined and 5 μl Enzyme A solution was added into the supernatant. The solution was 
mixed by gentle vortexing and incubated at 37°C for 10 min. Enzyme B solution (5 μl) 
were then added into the mixture and further incubated overnight at 50°C. The 
following day, 5 μl of ammonium acetate solution was added to the sample and mixed 
well. Isopropanol (100 μl) was then added and the solution was mixed well and kept at 
−20 °C for 20 min. DNA pellet was obtained by centrifugation at 13,000 × g for 10 min 
followed by washing twice with 75% ethanol. The pellet was air-dried for 5 min and 
resuspended in 30 μl DNA Suspension Buffer. Samples were loaded on to a 1.2% 
agarose gel and subjected to electrophoresis at 50 V for 1 h in 1 X TBE buffer. Gels 
were then stained with ethidium bromide and observed under UV light and 
photographed. For each experiment, a negative control was prepared by incubating the 
cells with medium only (no drug treatment). A positive control for apoptosis was also 
included each time when the assay was performed by treating the cells with 5 µM 
camptothecin. Figure 2.3 reveals a characteristic ladder pattern of low molecular weight 
DNA fragments from apoptotic cells induced by camptothecin for 24 h.  
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M     1      2     3      4      5    
 
Lane M :  DNA molecular mass marker (100-bp ladder) 
Lane 1 :  No treatment (control) 
Lane 2 :  1 µM camptothecin 
Lane 3 :  2.5 µM camptothecin 
Lane 4 :  5 µM camptothecin 
Lane 5 :  10 µM camptothecin 
Figure 2.6 Camptothecin induces apoptotic DNA fragmentation in 
HepG2 cells  
 
The apoptotic DNA laddering patterns was observed in HepG2 cells 
treated with 5 and 10 µM camptothecin for 24 h. No DNA fragmentation 
was detected in cells treated with 0-2.5 µM camptothecin.   
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2.11 Caspase-3 activity assay 
 
Caspase-3 activity in cell extracts was measured using Sigma Caspase-3 Fluorometric 
Assay Kit. The detection of caspase activity is based on the hydrolysis of the peptide 
substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) by 
caspase-3, resulting in the release of the fluorescent 7-amino-4-methylcoumarin (AMC) 
moiety. Cells were seeded in T75 flasks at a density of 1X10
7
 cells/ml and exposed to 
inducing agent for designated period of time, pelleted and washed twice with PBS. A 
negative control was prepared by incubating the cells in the absence of inducing agent. 
Cells were then lysed by adding 100 µl of lysis buffer (50 mM HEPES pH7.4, 5 mM 3-
[(3-cholamidopropyl) dimethylammonio]-propanesulfonate (CHAPS), and 5 mM 
dithiothreitol (DTT)) and incubated on ice for 30 min. The lysed cells were centrifuged 
at 4500 rpm for 10 min at 4°C. Five micro litres of cell lysates or caspase 3 positive 
controls were transferred into a black 96-well view plates. These are black plates 
designed for optimal measurement of fluorescence. Assays were performed in the 
presence and absence of 2 µl of caspase 3 inhibitor, Acetyl-Asp-Glu-Val-Asp-al (Ac-
DEVD-CHO) to exclude nonspecific background in the enzymatic reaction. A blank 
control containing assay buffer (20 mM HEPES pH 7.4, 0.1% CHAPS, 5 mM DTT and 
2 mM EDTA) was included to determine the background fluorescence of the substrate. 
The reaction was carried out by adding 200 µl of Ac-DEVD-AMC containing reaction 
mixture into each sample and plates were further incubated for 2 h in the dark. The 
reaction scheme was summarized in Table 2.5. The fluorescence intensity (relative 
fluorescence units, ∆FU) was then measured at excitation 360nm and emission 460nm 
in the Spectramax M5e plate reader (Molecular Devices). Protein concentration of each 
cell extract was quantified using BioRad DC Protein Assay (see section 2.6.1). A 
standard curve was prepared by 10 mM AMC with assay buffer to yield AMC solutions 
ranging in concentration from 200-4000 pmol (Figure 2.4). Data presented are means ± 
S.D. of triplicates. The enzyme specific activity for each sample was calculated using 
the formula below. 
 
 X = pmol AMC liberated per h in the absence of inhibitor 
 Y = pmol AMC liberated per h in the presence of inhibitor 
  
 Caspase activity =       (X-Y)        pmol AMC liberated/ h/ mg 
                                                        protein (mg) 
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Figure 2.7 AMC reference standard calibration curve 
 
A 7-amino-4-methylcoumarin (AMC) fluorescent reference standard 
was plotted as FIV (fluorescence intensity value) versus AMC 
concentration in the range of 200-4000 pmol. Data presented are 
means ± S.D. of triplicates.  
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                                                                             Table 2.5 Reaction scheme for caspase 3 assay 
 
 1 x Assay 
Buffer 
Caspase 3 
(0.5µg/ml) 
Cell lysate Caspase 3 inhibitor                 
Ac-DEVD-CHO (200 µM) 
Reaction 
Mixture 
Reagent Blank 5 µl − − − 200 µl 
Caspase 3 positive control − 5 µl − − 200 µl 
Caspase 3 positive control +   inhibitor − 5 µl − 2 µl 200 µl 
Non-induced cells − − 5 µl − 200 µl 
Non-induced cells  + inhibitor − − 5 µl 2 µl 200 µl 
Induced cells − − 5 µl − 200 µl 
Induced cells + inhibitor − − 5 µl 2 µl 200 µl 
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Chapter 3. Genetic Polymorphisms of Anti-tuberculosis 
Drugs Metabolizing Enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
75 
3 Genetic polymorphisms of anti-tuberculosis drugs 
metabolizing enzymes 
3.1 Introduction 
 
As described in section 1.7, there have been a number of previous studies relating 
genotype to susceptibility to DILI due to anti-TB drugs (ATD), though the overall 
findings are still unclear. NAT2 remains the best studied genotype, especially since there 
is a clear rationale for an association since it has been demonstrated the levels of NAT2 
will affect isoniazid metabolite levels and patterns of metabolites (Lauterburg et al., 
1985; Timbrell et al., 1980). Polymorphisms in CYP2E1, GSTM1, GSTT1 and SOD2 
have also been investigated previously though the contribution of the gene products to 
anti-TB drug metabolism is less direct. The main aim of the work presented in this 
chapter was to investigate the association between NAT2 genotype and ATD-DILI. It 
was also decided to study CYP2E1, GSTM1, GSTT1 and SOD2 polymorphisms in view 
of the previous contradictory data linking these polymorphisms to ATD-DILI. In 
addition, it was decided to study selected polymorphisms in GSTA1, GSTA4, NAT1 and 
PXR as more novel candidates. GSTA1 and GSTA4 were chosen because of their role in 
the detoxification of products of oxidative stress (section 1.5.3.3) including 4-
hydroxynonenal (Gardner et al., 2003; Hartley and Petersen, 1997). NAT1 was studied 
because of unpublished data that became available from a collaborating laboratory 
pointing to a novel association with ATD-DILI (Shen Y and Daly AK, unpublished). 
PXR is of general relevance to both drug metabolism and metabolism of endogenous 
compounds relevant to liver injury such as bile acids, with rifampicin being a potent 
agonist (section 1.6.3.2).  
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3.2 Materials and Methods 
3.2.1 Patient recruitment 
 
The DILIGEN study seeks to identify susceptibility genes for DILI by collecting DNA 
samples from patients diagnosed with DILI either in the past or at the time of sample 
collection from hospitals throughout the UK (Daly et al., 2009). In particular, patients 
who have suffered DILI linked to anti-TB drugs, co-amoxiclav and flucloxacillin are 
being studied. When the study was initiated in 2004, the aim was to collect samples 
from 300 cases of DILI linked to anti-TB drugs. However, up to September 2009, only 
28 cases linked to anti-TB drugs had been enrolled which is poor compared with 
approximately 150 cases linked to flucloxacillin, co-amoxiclav and, more recently, 
other prescribed drugs. Among these 28 cases, a number of different ethnicities were 
represented, including 14 white European, 3 Chinese, 2 African and 9 from the Indian 
subcontinent. The patients were taking a number of different drug combinations for 
their TB, but for all except for one patient of European origin, this included INH. An 
additional 4 cases of Bangladeshi origin were recruited by Dr Abul Hasnat, University 
of Dhaka, Bangladesh. All had been exposed to isoniazid. All cases met one of the 
following biochemical criteria for enrolment into this study: (a) alanine 
aminotransferase (ALT) > 5 x the upper limit of normal (ULN), (b) alkaline 
phosphatase (ALP) > 2 x ULN and bilirubin > ULN, or (c) clinical jaundice or bilirubin 
> 40µmol/l. For the DILIGEN cases, causality assessment was based on the 
biochemical markers and Roussel Uclaf Causality Assessment Method (RUCAM) 
(Danan and Benichou, 1993). The causality assessment was performed using the 
international consensus criteria (ICC) with ICC scoring graded as unlikely, possible, 
probable and highly probable (see section 3.3.1). Only cases assessed as highly 
probable, probable or possible were enrolled in the study. For the Dhaka samples, 
causality assessment was not possible but other causes of liver damage such as hepatitis 
A or B infection were excluded. Ethical approval for the DILIGEN study was provided 
by the Leeds East Research Ethics committee with ethical approval in Bangladesh 
provided by the University of Dhaka. 
It was decided to study the 13 white European cases exposed to isoniazid, the 9 
DILIGEN cases from the Indian subcontinent and the 4 Bangladeshi cases in a case-
control study on NAT2 and other genotypes. As controls, 50 controls of European 
ancestry were supplied by Dr Pete Donaldson (Velaga et al., 2004) together with 81 
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ATD-tolerant controls and 40 controls without TB from the Indian subcontinent. Table 
3.1 summarises clinical information on the cases from the Indian subcontinent and of 
European ethnic origin. The African and Chinese cases were not studied in the case 
control study but sequencing studies were performed on one African patient who 
underwent a liver transplant.    
 
 
 Table 3.1 Clinical and biochemical parameters of DILI patients exposed to INH 
 
 
European cohort South Asian cohort 
DILIGEN  
(n=13) 
DILIGEN  
(n=9) 
BANGLADESH  
(n=4) 
Sex (F/M) 8/5 7/2 1/3 
Age of onset (years) 58.8 ± 12.5 39.3 ± 14.3 46 ± 4.5 
Time to onset (days) 32.4 ± 37.4  52.75 ± 61.8 * Data not available 
Total days on drug 38.8 ± 35.9  60.25 ± 74.0 * Data not available 
Histology patterns  
   
       Cholestatic 3 (23.08%) 6 Data not available 
       Hepatocellular 10 (76.92%) 2 
ICC scoring 
   
       3-5 (possible) 5  (38.46)   
 
Data not available        6-8 (probable) 5  (38.46)  
       >8 (highly probable) 3  (23.08)  
Peak Bilirubin (µmol/l) 130 ± 110.0 179 ± 252.7 * 83.4 ± 19.5 
Peak ALT (U/l) 937 ± 1001.0 793 ± 488.8 * Data not available 
Peak ALP (U/l) 219 ± 98.0 225 ± 146.0 * Data not available 
Liver transplant 
 
2 (15.38%) 3 (33.33%) 0 
 
* Average of the values from 8 samples as the clinical data of 1 patient was not available for   
this study 
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3.2.2 PCR-restriction fragment length polymorphism (PCR-RFLP) 
 
PCR reactions were carried out according to section 2.4.4. RFLP analyses were 
developed for a range of polymorphisms by using specific restriction endonuclease 
enzymes (New England Biolabs) and the restriction fragments were separated by 
electophoresis on either 2% agarose gels or 10% polyacrylamide gels as described in 
section 2.4.5.  
 
3.2.3 Genotyping of NAT2  
 
The amplification of NAT2 fragment in the region of exon 2 was performed by PCR 
with 2 previously reported primers (Kocabas et al., 2004). The sequences of the primers 
were 5'-GACATTGAAGCATATTTTGAAAG-3' and 5'-GATGAAAGTATTTGATGT 
TTAGG-3'. The PCR program consisted of initial denaturation at 94ºC  for 5 min and  
35 cycles of denaturation at 94ºC for 1 min, annealing at 50ºC for 1.5 min, extension at 
72ºC for 2 min, and a final extension at 72ºC for 7 min.  The 999bp PCR product was 
digested with KpnI, TaqI, and BamHI for the detection of mutations 481C>T 
(rs1799929), 590G>A (rs1799930), and 857G>A (rs1799931) respectively (Figure 3.1-
3.3). The wild-type NAT2*4 allele is designated when none of the mutant alleles are 
present. NAT2*5, NAT*6 and NAT*7 variant alleles were identified by KpnI, TaqI and 
BamHI digestions respectively. The presence of any 2 variant alleles defines the slow-
acetylator phenotype, whereas rapid acetylators have 1 or 2 wild-type NAT2*4 alleles. 
In addition, a genetic variant in the promoter region of NAT2 (-9796T>A; rs4646244) 
which has shown a significant lower luciferase activity in reporter gene assays was 
included in the current study (Kim et al., 2009). Amplification of the -9796T>A 
promoter region was performed using the primers 5’-
AATCCCAGTAGACAACACCAG-3’ and 5’AATAGGTTTTGAGGGCCATG-3’. 
PCR was subjected to initial denaturation at 94ºC  for 5 min and  35 cycles of 
denaturation at 94ºC for 1 min, annealing at 54ºC for 1 min, extension at 72ºC for 1 min, 
and a final extension at 72ºC for 7 min. The 469bp PCR product was then digested with 
restriction enzyme MboI resulting in fragments of 277bp and 192bp (A allele; cut) or 
467bp (T allele; uncut). Figure 3.4 shows the detection of the MboI restriction 
fragments of NAT2 -9796T>A on a 2% agarose gel. For selected samples, the NAT2 
coding region was sequenced. The same PCR reaction used for genotyping was 
performed with sequencing carried out as described in section 2.4.5. 
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Restriction analysis for NAT2*5 (481C>T) gene fragment after digestion with 
KpnI on a 2% agarose gel; lane 1 and 2 [without (─) and with (+) KpnI 
digestion] display homozygous CC; lane 3 and 4 [without (─) and with (+) 
KpnI digestion] are homozygous TT; lane 5 and 6 [without (─) and with (+) 
KpnI digestion] are heterozygous CT 
 
Figure 3.1 PCR-RFLP analysis of NAT2*5 (481C>T) polymorphism 
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Restriction analysis for NAT2*6 (590G>A) gene fragment after digestion 
with TaqI on a 10% Polyacrylamide gel; lane 1, 2 and 6 display 
homozygous AA; lane 3 and 4 are homozygous GG; lane 5 are 
heterozygous GA 
 
Figure 3.2 PCR-RFLP analysis of NAT2*6 (590G>A) polymorphism 
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Restriction analysis for NAT2*7(857G>A) gene fragment after digestion 
with BamHI on a 2% agarose gel; lane 1 and 2 [without (─) and with 
(+) BamHI digestion] display homozygous GG; lane 3 and 4 [without 
(─) and with (+) BamHI digestion] are heterozygous GA 
 
 
 
Figure 3.3 PCR-RFLP analysis of NAT2*7(857G>A) polymorphism 
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Figure 3.4 PCR-RFLP analysis of NAT2 (rs4646244) 
Restriction analysis for NAT2 (rs4646244) gene fragment after digestion 
with MboI on a 2% agarose gel; lane 1 and 2 [without (─) and with (+) 
MboI digestion] display homozygous TT; lane 3 and 4 [without (─) and 
with (+) MboI digestion] are homozygous AA; lane 5 and 6 [without (─) 
and with (+) MboI digestion] are heterozygous TA 
 
 
 
 
  
 
83 
3.2.4 Genotyping of CYP2E1 
 
For CYP2E1 genotyping, 3 SNPs from the promoter region -1293G>C (CYP2E1*5B), -
1053C>T (CYP2E1*5B) and -71G>T (CYP2E1*7B), and 1 SNP from the intron 7 
9896C>G (CYP2E1*1B) were genotyped using the PCR-RFLP method (see section 
3.2.3). Figure 3.5 and Table 3.2 show the position of the 4 SNPs on the positive strand 
of the gene and also their respective PCR-RFLP conditions. For -1293G>C 
(CYP2E1*5B) genotyping, PCR product was digested with PstI resulting in fragments 
of 413bp (G allele; uncut) or 295bp and 118bp (C allele; cut) (Figure 3.6). For -
1053C>T (CYP2E1*5B) analysis, PCR product was digested with RsaI to differentiate 
the C→T polymorphism. The wild type C allele produced two fragments of 352bp and 
61bp, whilst T alleles yielded one single fragment of 413bp (Figure 3.7). Analysis of -
71G>T (CYP2E1*7B) polymorphism was performed by digesting the PCR product 
with DdeI. Fragments of 212bp and 163bp (G allele; cut) or 375bp (T allele; uncut) 
were identified following gel electrophoresis analysis (Figure 3.8). For 9896C>G 
(CYP2E1*1B) analysis, a 444bp PCR product was amplified and digested with TaqI. 
The common C allele was identified from its two fragments on 273bp and 171bp, whilst 
G allele remains uncut (Figure 3.9). 
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                                                    Table 3.2 Description of CYP2E1 alleles and their PCR-RFLP conditions 
 
 
Alleles Location Nucleotide 
change 
Rs 
identifier 
Primer sequences Expected 
size 
Annealing 
Temperature 
Restriction 
enzyme 
CYP2E1*5B Promoter -1293G>C rs3813867   5’ CCAGTCGAGTCTACATTGTCA 3’ 
  5’ TTCATTCTGTCTTCTAACTGG 3’ 
413 bp 51 °C PstI 
CYP2E1*5B Promoter -1053C>T rs2031920 
 
  5’ CCAGTCGAGTCTACATTGTCA 3’ 
  5’ TTCATTCTGTCTTCTAACTGG 3’ 
413 bp 51 °C RsaI 
CYP2E1*7B Promoter -71G>T rs6413420 
 
  5’ CACAGTCCAACTCCATCCTC 3’ 
  5’ GAAGAGGTTCCCGATGATGG 3’ 
375 bp 57 °C DdeI 
CYP2E1*1B Intron 7 9896C>G rs2070676 
 
  5' AAGAGCCTCAGCAGATAGTG 3’ 
  5’ TGATCTTTCTCACCTGTGGA 3’ 
444 bp 51 ºC TaqI 
Figure 3.5 The position of four studied SNPs in CYP2E1 
 
rs2031920; -1053C>T
rs6413420; -71G>T
rs2070676; 9896C>G
rs3813867; -1293G>C
 
  
 
85 
Restriction analysis for CYP2E1 -1293G>C (rs3813867) gene fragment 
after digestion with PstI on a 10% Polyacrylamide gel; lane 2, 3 and 5 
display homozygous GG; lane 1 and 4 are heterozygous GC 
 
 
 
Figure 3.6 PCR-RFLP analysis of CYP2E1 -1293G>C (rs3813867)  
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Figure 3.7 PCR-RFLP analysis of CYP2E1 (rs2031920) 
Restriction analysis for CYP2E1 (rs2031920) gene fragment after 
digestion with RsaI on a 2% agarose gel; lane 1 and 2 [without (─) and 
with (+) RsaI digestion] display homozygous CC; lane 3 and 4 [without 
(─) and with (+) RsaI digestion] are heterozygous CT 
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Restriction analysis for CYP2E1 (rs6413420) gene fragment after digestion 
with DdeI on a 2% agarose gel; lane 1 and 2 [without (─) and with (+) DdeI 
digestion] display homozygous GG; lane 3 and 4 [without (─) and with (+) 
DdeI digestion] are heterozygous GT; lane 5 and 6 [without (─) and with (+) 
DdeI digestion] are homozygous TT 
 
 
 
 
Figure 3.8 PCR-RFLP analysis of CYP2E1 (rs6413420) 
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Figure 3.9 PCR-RFLP analysis of CYP2E1 (rs2070676) 
 
Restriction analysis for Cyp2E1 (rs2070676) gene fragment after digestion 
with TaqI on a 10% Polyacrylamide gel; lane 1 and 2 [without (─) and 
with (+) TaqI digestion] display homozygous CC; lane 3 and 4 [without 
(─) and with (+) TaqI digestion] are heterozygous CG; lane 5 and 6 
[without (─) and with (+) TaqI digestion] are homozygous GG 
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3.2.5 PXR -25385 SNP genotyping 
 
Analysis of PXR -25385C>T polymorphism (rs3814055) was performed by the 
approach of primer-engineered RFLP detection described in Andrews et al. (Andrews et 
al.). The sequences of the forward and the reverse primers used  for PCR amplification 
were 5’-TTTTTTGGCAATCCCAGGAT-3’ and   5’-CGAATGTGGTGGATACCAG-
3’. An MboI restriction site was engineered by a nucleotide substitution (T→A) in the 
forward primer to allow RFLP analysis. PCR was subjected to initial denaturation at 
94ºC for 5 min and 35 cycles of denaturation at 94ºC for 1 min, annealing at 51ºC for 1 
min, extension at 72ºC for 1 min, and a final extension at 72ºC for 7 min. PCR product 
was digested with MboI resulting in fragments of 220bp (T allele; uncut) or 200bp and 
16bp (C allele; cut). Figure 3.10 shows the 10% polyacrylamide gel electrophoresis of 
the MboI digestion products. 
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Figure 3.10 PCR-RFLP analysis of PXR-25385 C/T (rs3814055) 
 
Restriction analysis for PXR-25385 C/T (rs3814055) gene fragment after 
digestion with MboI on a 10% Polyacrylamide gel; lane 1 and 2 [without 
(─) and with (+) MboI digestion] display homozygous TT; lane 3 and 4 
[without (─) and with (+) MboI digestion] are homozygous CC; lane 5 and 
6 [without (─) and with (+) MboI digestion] are heterozygous CT 
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3.2.6 Genotyping of anti-oxidative stress-related genes 
3.2.6.1 GSTA1 
 
PCR-RFLP of GSTA1 -69C.>T (rs3957357) in the promoter region was carried out as 
described by Coles et al. (Coles et al., 2001). PCR was performed using the gene-
specific forward and reverse primers, 5’-AATTGTTGATTGTTTGCCTGAAATT-3’ 
and   5’-GTTAAACGCTGTCACCGTCCT-3’ respectively. PCR was subjected to 
initial denaturation at 94ºC for 5 min and 35 cycles of denaturation at 94ºC for 1 min, 
annealing at 61ºC for 1 min, extension at 72ºC for 1 min, and a final extension at 72ºC 
for 7 min. PCR product was then digested with EarI. The wild type C allele yielded one 
single fragment of 480bp, whilst T allele produced two fragments of 380bp and 100bp. 
Figure 3.11 shows the PCR-RFLP analysis of GSTA1 -69C>T polymorphism  on  
agarose gel. 
 
Figure 3.11 PCR-RFLP analysis of GSTA1 -69C>T (rs3957357) 
Restriction analysis for GSTA1 -69C>T (rs3957357) gene fragment after 
digestion with EarI on a 2% agarose gel; lane 1 and 2 [without (─) and 
with (+) EarI digestion] display homozygous CC; lane 3 and 4 [without 
(─) and with (+) EarI digestion] are heterozygous CT; lane 5 and 6 
[without (─) and with (+) EarI digestion] are homozygous TT 
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3.2.6.2 GSTA4 
 
Tag SNPs in the GSTA4 gene region were chosen using the Hapmap database 
(http://www.hapmap.org) and Haploview (http://www.broad.mit.edu/mpg/haploview). 
Haploview was used to generate the linkage dissequilibrium (LD) plot patterns as 
shown in Figure 3.12, and the tag SNPs were selected using Tagger with a pairwise 
tagging algorithm with a minor allele frequency (MAF) ≥ 0.08 and an r2 ≥ 0.8. Five tag 
SNPs, rs316141, rs4147618, rs316128, rs3756980 and rs13207376, which cover most 
of the genetic variation in the GSTA4 were selected and genotyped using the PCR-
RFLP method (see section 3.2.3). The position of the SNPs and their PCR-RFLP assay 
conditions are summarised in Table 3.3. For rs316141 genotyping, a 329bp PCR 
product was digested with restriction enzyme Msp1 resulting in fragments of 164bp and 
165bp (C allele; cut), or 329bp (T allele; uncut) (Figure 3.13). RFLP analysis of a 
T→A polymorphism in rs4147618 was performed by digesting the PCR product with 
HinfI. Fragments of 216bp and 74bp (T allele; cut) or 290bp (A allele; uncut) were 
identified following gel electrophoresis analysis (Figure 3.14). For   rs316128 
genotyping, PCR product was digested with Bpu10I. The wild type A allele yielded one 
single fragment of 268bp, whilst C allele produced two fragments of 177bp and 91bp 
(Figure 3.15). Genotyping of rs3756980 was done by digesting the 218bp PCR product 
with HpyCH4III resulting in fragments of 218bp (A allele; uncut) or 183bp and 35bp (G 
allele; cut). Figure 3.16 shows the restriction enzyme digestion products on 10% 
Polyacrylamide gel. Analysis of rs13207376 was performed by digesting the PCR 
product with HpyCH4IV. Fragments of 122bp and 119bp (G allele; cut) or 241bp (A 
allele; uncut) were identified following agarose gel electrophoresis analysis (Figure 
3.17).   
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Figure 3.12 LD plot of GSTA4 tag SNPs and their position in the gene 
GSTA4 tag SNPs are displayed according to their position on the positive strand 
of the gene. The r
2
 pairwise LD plot and its values were generated using 
Haploview 4.2 software with its standard R-squared colour scheme. The 
intensity of the colour is proportional to the strength of the LD. Five tag SNPs 
(r2 ≥ 0.8; MAF ≥ 0.08) out of a total of 25 reference SNPs, rs316141, 
rs4147618, rs316128, rs3756980, and rs13207376, which cover most of the 
genetic variation in the GSTA4 were selected for analysis.  
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Table 3.3 PCR-RFLP primer sequences and conditions of GSTA4 tag SNPs 
 
 
Rs 
identifier 
 
Location 
 
Chromosome
position Alleles Primer sequences 
 
Expected 
size 
 
Annealing 
Temperature 
 
Restriction 
enzyme 
rs316141 Intron 1 52846158 C/T 
 
5’-CATTGGTACAAAGCCATGC-3’ 
5’-TGTACTTATTGAACTGGTGG-3’ 
 
329 bp 56 °C MspI 
rs4147618 Intron 1 52846742 T/A 
 
5’- AAGTTAGGAAATTCTAAGCC-3’ 
5’-AAACTCAAGCATCCACTGCC-3’ 
 
292 bp 51 °C HinfI 
rs316128 Intron 2 52849146 A/C 
 
5’-GGAAGTGGTTAACATGGCCC-3’ 
5’-CTGAATCATGTGGTCCTAGC-3’ 
 
269 bp 57 °C Bpu10I 
rs3756980 Intron 4 52851979 A/G 
 
5'- GTTGAAATTGCCAGGAAATCAC-3’ 
5’-CCAGGATGCCTCAGATAGTG-3’ 
 
218 bp 55 ºC HpyCH4III 
rs13207376 Intron 6 52859230 A/G 
 
5'-GTCTTCAACCCAGTGCTCA-3’ 
5’-ATTTGTGAAATCCCGTACTG-3’ 
 
241 bp 56 ºC HpyCH4IV 
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Figure 3.13 PCR-RFLP analysis of GSTA4 (rs316141) 
Restriction analysis for GSTA4 (rs316141) gene fragment after digestion 
with MspI on a 10% Polyacrylamide gel; lane 1 and 2 [without (─) and 
with (+) MspI digestion] display homozygous TT; lane 3 and 4 [without 
(─) and with (+) MspI digestion] are heterozygous CT; lane 5 and 6 
[without (─) and with (+) MspI digestion] are homozygous CC 
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Figure 3.14 PCR-RFLP analysis of GSTA4 (rs4147618) 
Restriction analysis for GSTA4 (rs4147618) gene fragment after 
digestion with HinfI on a 10% Polyacrylamide gel; lane 1 and 2 [without 
(─) and with (+) HinfI digestion] display homozygous AA; lane 3 and 4 
[without (─) and with (+) HinfI digestion] are heterozygous TA; lane 5 
and 6 [without (─) and with (+) HinfI digestion] are homozygous TT 
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Figure 3.15 PCR-RFLP analysis of GSTA4 (rs316128) 
 
 
Restriction analysis for GSTA4 (rs316128) gene fragment after digestion 
with Bpu10I on a 10% Polyacrylamide gel; lane 1 and 2 [without (─) and 
with (+) Bpu10I digestion] display homozygous AA; lane 3 and 4 [without 
(─) and with (+) Bpu10I digestion] are heterozygous AC; lane 5 and 6 
[without (─) and with (+) Bpu10I digestion] are homozygous CC. 
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Figure 3.16 PCR-RFLP analysis of GSTA4 (rs3756980) 
Restriction analysis for GSTA4 (rs3756980) gene fragment after digestion 
with HpyCH4III on a 10% Polyacrylamide gel; lane 1 and 2 [without (─) 
and with (+) HpyCH4III digestion] display homozygous AA; lane 3 and 4 
[without (─) and with (+) HpyCH4III digestion] are homozygous GG; 
lane 5 and 6 [without (─) and with (+) HpyCH4III digestion] are 
heterozygous AG. 
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Figure 3.17 PCR-RFLP analysis of GSTA4 (rs13207376) 
 
 
 
 
Restriction analysis for GSTA4 (rs13207376) gene fragment after digestion 
with HpyCH4IV on a 2% agarose gel; lane 1 and 2 [without (─) and with 
(+) HpyCH4IV digestion] display homozygous GG; lane 3 and 4 [without 
(─) and with (+) HpyCH4IV digestion] are heterozygous AG; lane 5 and 6 
[without (─) and with (+) HpyCH4IV digestion] are homozygous AA 
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3.2.6.3 GSTT1 
 
Analysis of GSTT1 gene polymorphism was performed by PCR described in Abdel-
Rahman et al. using primers 5’-TTCCTTACTGGTCCTCACATCTC-3’ and   5’-
TCACCGGATCATGGCCAGCA-3’ (Abdel-Rahman et al., 1998). The promoter region 
of gene encoding tumour necrosis factor-alpha (TNF-α) was co-amplified and used as 
an internal control with the primers 5’-ATCTGGAGGAAGCGGTAGTG-3’ and 
5’AATAGGTT TTGAGGGCCATG-3’. PCR was subjected to initial denaturation at 
94ºC  for 5 min and  35 cycles of denaturation at 94ºC for 1 min, annealing at 50ºC for 1 
min, extension at 72ºC for 1 min, and a final extension at 72ºC for 7 min.  GSTT1 null 
genotypes were detected by the absence of 430bp DNA fragment, while the internal 
positive control (TNF-α) yielded a band of 222bp (Figure 3.18). 
 
 
Figure 3.18 PCR analysis of GSTT1 genotype 
The presence of GSTT1 gene was detected by the presence of a 430bp PCR 
fragment (lane 2, 4, 5, 6, and 7). Lane 1, 3 and 8 show the GSTT1 null 
genotype (the absence of the 430bp fragment). Fragments of 222bp 
indicate the internal controls for TNF-α. 
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3.2.6.4 GSTM1 
 
Analysis of GSTM1 gene polymorphism was performed by PCR described in Zhong et 
al. using primers 5’-CGCCATCTTGTGCTACATTGCCCG-3’ and   5’-
TTCTGGATTGTAGCAGATCA-3’ (Zhong et al., 1993). For an internal control, 
GSTM4 gene fragment was co-amplified using the primers 5’-
CGCCATCTTGTGCTACATTGCCCG-3’ and 5’-ATCTTCTCCTCTTCTGTCTC-3’. 
PCR was subjected to initial denaturation at 94ºC  for 5 min and  35 cycles of 
denaturation at 94ºC for 1 min, annealing at 53ºC for 1 min, extension at 72ºC for 1 min, 
and a final extension at 72ºC for 7 min.  GSTM1 null genotypes were detected by the 
absence of 230bp DNA fragment, while the internal positive control (GSTM1) yielded a 
band of 157bp (Figure 3.19). 
 
 
Figure 3.19 PCR analysis of GSTM1 genotype 
The presence of GSTM1 gene was detected by the presence of a 
230bp PCR fragment (lane 3and 4). Lane 1 and 2 show the GSTM1 
null genotype (the absence of the 230bp fragment). Fragments of 
157bp indicate the internal controls for GSTM1. 
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3.2.6.5 SOD2 
 
Tag SNPs in SOD2 (r
2
 ≥ 0.8; MAF ≥ 0.08) were selected from HapMap CEU 
population and the Linkage disequilibrium (LD) calculation was performed by the 
Haploview software (Figure 3.20). Two tag SNPs, rs4880 and rs5746136 which 
encompass the majority of the genetic variation in SOD2 were identified and 
genotyped using the PCR-RFLP method. PCR for rs4880 was performed using the 
primers 5’-CAGCCCAGCCTGCGTAGACGG-3’ and 5’-
GCGTTGATGTGAGGTTCCAG-3’. A 172bp PCR product was then digested with 
restriction enzyme BsaW1 to identify the common T→C polymorphism resulting in an 
amino acid substitution (Valine to Alanine). The T allele (Val) resulted in fragments of 
89bp and 83bp, whilst the C allele (Ala) remain uncut, which is 172bp (Figure 3.21). 
For rs5746136, a 534bp PCR product was amplified using the primers 5’-
AGTAAGCTGCTCTATTGTAGC-3’ and 5’-TTTGCTGTTGAAGTTTGCCT-3’, 
followed by restriction digestion with TaqI resulting in fragments of 534bp (A allele; 
uncut) or 364bp and 170bp (G allele; cut). Figure 3.22 shows the agarose gel 
electrophoresis of the restriction enzyme digestion products.  
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Figure 3.20 LD plot of SOD2 tag SNPs and their position in the gene 
 
SOD2 tag SNPs are displayed according to their position on the positive 
strand of the gene. The r
2
 pairwise LD plot and its values were generated 
using Haploview 4.2 software with its standard R-squared colour scheme. Two 
SNPs out of a total of 6 reference SNPs, rs4880 and rs5746136, which 
encompass the majority of the genetic variation in the SOD2 were selected for 
analysis.  
 
  
 
104 
Figure 3.21 PCR-RFLP analysis of SOD2 V16A (rs4880) 
 
Restriction analysis for SOD2 V16A (rs4880) gene fragment after 
digestion with BsaW1 on a 10% Polyacrylamide gel; lane 1 and 2 [without 
(─) and with (+) BsaW1 digestion] display homozygous Ala/Ala (CC); 
lane 3 and 4 [without (─) and with (+) BsaW1 digestion] are homozygous 
Val/Val (TT); lane 5 and 6 [without (─) and with (+) BsaW1 digestion] 
are heterozygous Val/Ala (TC) 
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Figure 3.22 PCR-RFLP analysis of SOD2 (rs5746136) 
 
Restriction analysis for SOD2 (rs5746136) gene fragment after digestion 
with TaqI on a 2% agarose gel; lane 1 and 2 [without (─) and with (+) 
TaqI digestion] display homozygous AA; lane 3 and 4 [without (─) and 
with (+) TaqI digestion] are homozygous GG; lane 5 and 6 [without (─) 
and with (+) TaqI digestion] are heterozygous GA 
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 3.2.7 Taqman SNP genotyping assay for NAT1 (rs2739685) 
 
Genotyping for a C/T polymorphism in rs2739685 was carried out using the validated 
Taqman SNP genotyping assay method (assay ID: C__15930238_10, PE Applied 
Biosystems). The assay contains two probes, one for each allele in a two-allele system. 
Each probe consists of oligonucleotides for amplifying the specific sequence with a 5’- 
end fluorescence reporter dye. Specifically, the VIC fluorescence reporter dye is linked 
to the allele 1 probe for the detection of allele C. FAM, another fluorescence reporter 
dye, is linked to the allele 2 probe for the detection of allele T. The reactions were 
prepared in duplicate by using 2x Taqman Universal Master Mix, 40x SNP Genotyping 
Assay Mix, DNase-free water, and 10ng genomic DNA in a final volume of 20µl per 
reaction. Positive controls and a no template control were included in each assay as a 
quality control measure. The positive controls consist of three different genotypes were 
validated by sequencing (Figure 3.23). The PCR amplification was done using the ABI 
Prism 7000 Sequence Detection System machine under the following thermocycler 
conditions: 10 min at 95ºC to activate the AmpliTaq Gold polymerase followed by 40 
cycles of denaturation at 95 ºC for 15s and annealing/extension at 60 ºC for 1 min. The 
allelic discrimination results were determined using the SDS 2.2 software after the 
amplification by performing an end-point read.  
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Sequencing trace for SNP rs2739685 TT homozygote, TC heterozygote and CC 
homozygote positive controls are shown in A, B, C respectively in both forward 
and reverse sequence orientations. 
 
 
GGCCC
A
B HetHet
AATT
Forward sequencing Reverse sequencing
 
Figure 3.23 Sequence electropherogram of the forward and reverse sequence 
traces from a C/T polymorphism in SNP rs2739685 in NAT1 
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3.2.8  Statistical analysis 
3.2.8.1 Power Calculations 
 
Using an online statistical power calculator (http://statpages.org/proppowr.html), a 
power calculation was performed for the NAT2 polymorphism based on the number of 
samples available before the genotyping studies were initiated. The use of 26 cases and 
90 controls provided a statistical power of 80% to detect a change in the proportion of 
slow acetylators from 50% to 80% (Odds ratio 3.33 approx) at a significance level of 
p=0.05.  
 
3.2.8.2 Hardy-Weinberg Equilibrium 
 
In the early twentieth century, through mathematical modelling, both G.H. Hardy and 
W. Weinberg separately concluded that allelic frequencies in a gene pool are inherently 
stable, however evolution should be expected in all populations at all times (Weinberg, 
1963; Hardy, 1908). The model has become known as the Hardy-Weinberg equilibrium 
(HWE) based on the principle for a hypothetical situation in which there is no change of 
the frequencies of alleles in the gene pool and therefore no mechanisms of evolution are 
acting on a population. In order for equilibrium to remain in effect from generation to 
generation, a few basic assumptions need to be met; first, the population has to be 
infinitely large with no random shifts in the frequency of the individual alleles in the 
gene pool. Spontaneous mutations are negligible and there is no migration into or 
emigration out of the population. Individuals are mating randomly and natural selection 
is not occurring in the population. In addition, all individuals in the population are able 
to breed and produce the same number of offspring. When all these assumptions are 
valid and being met, both allele and genotype frequencies in a population will remain 
constant over generations, and the population is said to be in HWE. However, evolution 
is a common occurrence in nature due to natural selection and hence it is virtually 
impossible to meet all these assumptions in the HWE model. Hence, Hardy-Weinberg 
model plays an important role in the field of population genetics and provides a 
theoretical basis for the measurement of evolutionary change. It enables the comparison 
of the predicted or “expected” genotype frequencies with the actual or “observed” 
frequencies in a population and allows scientists to determine whether the population is 
in HWE. If the genotype frequencies deviate from values expected from HWE, it can be 
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assumed that evolution occurs where one or more of the model’s assumptions are being 
violated.  
 
The Hardy-Weinberg model consists of two equations that allow the calculation of 
allele and genotype frequencies respectively. Both equations will sum up to one since 
frequency is involved. In the simplest case of a single locus with two alleles of a diploid 
organism, the dominant allele is denoted A and the recessive allele is denoted a. If p 
represents the frequency of A, f (A)=p and q represents the frequency of a, f(a)=q, the 
equation for allele frequency is p+q=1. Three possible genotypes, AA, Aa and aa can be 
derived from these two allelic forms using a Punnett square (Table 3.4). The Punnett 
square depicts the probabilities of generating all possible genotypes at a diallelic locus 
in a population that conforms to Hardy-Weinberg assumptions. The final three expected 
genotypic frequencies in the offspring become f(AA)= p
2
, f(Aa)= 2pq and f(aa)= q
2
 and 
the equation for genotype frequencies is (p
2
) + (2pq) + (q
2
) = 1. The genotypic 
frequency distribution will not change from generation to generation once a population 
is in HWE. Nevertheless, populations in their natural environment are unable to meet all 
the assumptions required to achieve HWE. Genetic drift or allelic drift happens when 
the allele frequencies in a population change across generations. To test whether 
observed genotypes of a population conform to Hardy-Weinberg expectations, a simple 
chi-square goodness-of-fitness test can be performed. Under the null hypothesis of 
HWE, the observed genotype frequencies are not significantly different from those 
predicted for a population in equilibrium. A probability value, or P value is used to 
evaluate the significance of a chi-square by setting a cutoff point of 0.05 (5%) for 
significance. For example, a P value of less than or equal to 0.05 indicates a significant 
difference between the observed and expected genotype frequencies, the null hypothesis 
is rejected and the population is therefore in HWE. For large-scale genomic studies 
especially those involve the evaluation of thousands of loci segregating for multiple 
alleles, a more robust and powerful exact test is needed for HWE testing to reduce the 
risk of a type I error (Wigginton et al., 2005).  
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          Table 3.4 Punnett square for Hardy-Weinberg equilibrium 
 
 
Females 
A (p) a (q) 
Males 
A (p) AA (p
2
) Aa (pq) 
a (q) Aa (pq) Aa (q
2
) 
 
 
Deviation from Hardy-Weinberg expectations denotes the evolution of a population due 
to the violation of the assumptions of HWE model. Factors that cause violation include 
non-random mating, mutations, selection, limited population size, random genetic drift, 
gene flow and meiotic drive. In a small population, inbreeding or mating between close 
relatives is more likely to occur rather than random mating. Inbreeding changes 
genotype proportions by decreasing the frequency of heterozygotes and increasing the 
frequency of homozygotes. This effect of inbreeding resulting from the inheritance of a 
copy of the same recessive allele from both parents may increase the homozygous 
recessive diseases susceptibility in an individual or a population. Assortative mating is 
another cause of deviation from the HWE. Assortative mating occurs when individuals 
select mates non-randomly from within their population which causes an increase in 
homozygosity for the genes involved in the trait. Small population size may lead to a 
random change in allele frequency. This is due to a sampling effect, also known as 
genetic drift which causes greater chance of deviation of a population from Hardy-
Weinberg expectations during random mating. These sampling effects may result from 
the processes of genetic drift, founder events and population bottlenecks in natural 
populations. All these sampling errors can cause a rapid loss of genetic variation 
through the loss of rare alleles, leading to decreased heterozygosity and an increased 
degree of inbreeding and adaptation impairment (Shama et al., 2011; Nei, 1975).   
Mutation and natural selection can cause the change in allele frequencies. Natural 
selection leads to differential rates of survival and reproduction where individuals with 
some favouring traits are able to adapt to their environment better than individuals with 
other traits. While directional selection leads to decrease over time in the frequency of 
an unfavoured allele, balancing selection, in the contrast to the directional selection, 
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maintains genetic polymorphism in populations (Andrews, 2010). Balancing selection 
leads to equilibrium population with Hardy-Weinberg proportions even though it 
violates the assumption in Hardy-Weinberg principles.  
 
Deviations of the observed genotype frequencies with those expected by Hardy-
Weinberg may suggest violation of HWE assumptions, but may also indicate 
genotyping errors due to selection bias in sample enrolment or laboratory error. These 
genotyping errors could lead to false conclusions and decrease the power of certain 
statistical test for linkage and/or association studies. Thus, the used of HWE testing for 
data quality control is important to limit and detect genotyping error within population-
based data sets. Checking for HWE deviation is a standard practice when performing 
genome wide association studies with markers which fail at test of HWE generally 
discarded. However, deviation can also be due to disease association when this is 
present in a disease group though the controls should still be in HWE. It is also 
suggested that copy number variation (CNV), an event in which a large DNA fragment 
(range from 1,000 base pairs to 5 megabases) is duplicated or deleted could play an 
important factor of HWE violation (Lee et al., 2008). Therefore the study of these SNP 
markers that lies within CNV regions may show an apparent deviation from HWE.    
 
3.2.8.3 Genotype analysis 
 
Statistical analysis was performed using GraphPad Prism 3.0 (California, USA). 
Genotype frequencies between groups were compared using Fisher’s exact test, where 
p-values <0.05 were considered to be statistically significant. Odd ratios (OR) and 95% 
confidence intervals (CI) were also calculated to estimate the risk of ATD-DILI 
associated with each polymorphism. 
 
3.2.8.4 Haplotype analysis 
 
Haplotypes were constructed from genotype data and assigned to each of the case-
control subjects. Haplotype frequencies of the case and control groups for GSTA4 were 
analysed using PHASE v2.1.1. Odd ratios and 95% confidence intervals were calculated 
using the GraphPad Prism 3.0 software. The p-value was determined by fisher’s exact 
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test to assess the significance of differences in haplotype frequencies between the case-
control groups.  
 
3.2.8.5 Multiple testing 
 
The null hypothesis H0is a hypothesis which a researcher seeks to disprove, reject or 
nullify. The acceptance or rejection of the null hypothesis is based an appropriate 
statistical test (Wackerly D., 2008). Type I errors happen when the null hypothesis H0 is 
rejected although the hypothesis is in fact true. On the other hand, Type II error occurs 
when the null hypothesis H0 is accepted although the hypothesis is false. The probability 
of making a Type I error is denoted by α (alpha), and the probability of making a Type 
II error is denoted by β (beta).  A cut-off point of the α level is commonly set at 0.05, 
which means one in twenty statistical tests will incorrectly reject the null hypothesis H0  
and give rise to a false positive finding (Table 3.5). The chance of Type I error could be 
reduced by using a more stringent cut-off value such as 1% (1 in 100) or 0.1% (1 in 
1000) to increase specificity. However, as shown in Table 3.1, when there is a decrease 
in the probability of a Type I error, there is an increase in the probability of a Type II 
error occurring (false negative rate). Therefore, it is important to estimate and optimise 
the balance between Type I and Type II errors. 
 
Table 3.5 Contingency table showing Type I and Type II errors (Rao D. C., 2008) 
 
     Null is true      Alternative is true 
Reject null False positive (Type I error) True positive 
Accept null True negative False negative (Type II error) 
 
With recent advances in single nucleotide polymorphism (SNP) genotyping 
technologies, candidate gene approaches and also genome-wide associations studies 
(GWAS) have gained much popularity in identifying gene with common variants that 
influence susceptibility to complex diseases. The simultaneous testing of hundreds of 
thousands or even millions of SNP markers was made possible, however, this has also 
led to challenges in multiple comparison testing. Failure to adjust for multiple 
comparisons appropriately will yield the rate of Type I errors and decrease the power to 
detect association between genetic markers and a disease phenotype. When a large 
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number of SNPs are tested, the Type I error rate is more inflated as the magnitude of 
increase in type I error rate depends on the sample size (Marquard et al., 2009; 
Moskvina et al., 2006). Generally, the nominal significance level which is also the 
probability of making type I error (α) is adjusted downwards to reduce the likelihood of 
false positive results. Several methods have been proposed to overcome this problem. 
The effects of multiple testing could be minimised through the adjustment of the 
number of tests by limiting the number of association tests performed (Lunetta, 2008). 
For instance, when the associations of a single phenotype and numerous SNPs are 
examined, one could limit the number of tests by performing a single test per SNP by 
selecting the most closely associated SNP with the phenotype. Another option to limit 
the number of tests includes the use of haplotype or multilocus genotypes, rather than 
single SNPs alone to strengthen the power to detect associations. A multivariate test is 
useful for large scale association studies involving different phenotypes and numerous 
SNPs. Associations between individual genetic markers (SNPs) and each phenotype 
will be tested to find out which phenotype or subset of phenotypes is associated with the 
marker (Lunetta, 2008).  
 
Bonferroni correction is a simple and widely used method to correct for multiple 
testing. The adjustment of Bonferroni correction is made by multiplying the nominal P 
values by the total number of tests performed. The adjustment controls the family-wise 
error rate (FWER), which is the probability of making one or more Type I errors. For 
example, if one sets the experiment-wide error rate at 0.05 over 50 independent tests, 
then the Bonferroni-adjusted P values must be <0.001 to be considered significant, and 
the probability of observing at least 1 such result in the entire experiment is ≤0.001. By 
assuming analyses involve independent markers and phenotypes, Bonferroni correction 
is considered as the most stringent and highly conservative method for multiple 
comparisons. Several less conservative multiple test corrections have been proposed, 
such as the step-down correction of Holm (Holm, 1979), the Westfall and Young 
permutation method (Westfall and Young, 1993), and the Benjamini and Hochberg false 
discovery rate (Benjamini and Hochberg, 1995). 
 
The step-down correction of Holm is reasonably similar to the Bonferroni, but slightly 
less conservative. By using a stepwise procedure to assess the ordered set of null 
hypotheses, the test with the lowest probability is tested first with a Bonferroni 
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correction involving all tests. The second test is tested with a Bonferroni correction 
involving one less test and so on for the remaining tests until it fails to reject a null 
hypothesis. This sequential Bonferroni correction procedure of Holm is thus less 
conservative and generally more powerful than the corresponding single-step procedure 
while still maintaining the FWER. 
 
The Westfall and Young permutation method is an alternative way to correct for large 
numbers of tests in typical association studies (Westfall and Young, 1993). It integrates 
the correlation between phenotypes and genotypes and is far less stringent than that 
used in a standard Bonferroni adjustment. To rearrange the apparent relationship 
between phenotypes and genotypes, observed phenotypes are permuted with their 
respective genotypes while the correlation among phenotypes is preserved, and the 
relationship between genotypes (linkage disequilibrium patterns between SNPs) is 
retained within an individual. The entire process is performed by random rearrangement 
and repeated many times until all possible permutations are generated. The association 
between test statistics and corresponding P values of each permuted data set is 
computed similarly to the non-permuted data set. The new minimum P values from the 
permuted data sets are compared to the original P value of the non-permuted data set. 
The adjusted P value is defined when the permuted-based minimum P values is less 
than the original P values. Although permutation testing is complex and 
computationally expensive, it is considered the gold standard for multiple testing 
correction in GWAS by providing unbiased type I error control and high power (Pahl 
and Schafer, 2010).  
 
The false discovery rate (FDR), first proposed by Benjamini and Hochberg, is the least 
stringent form of adjustment compared to other multiple comparison procedures 
described earlier on. The FDR aims at controlling the expected proportion of falsely 
rejected hypotheses (type I errors), unlike other multiple comparisons procedures that 
control the FWER. When all the null hypotheses are true, the FWER and FDR are 
equivalent; otherwise, the FDR is less than the FWER. The FDR approach tolerates 
more false positives while allowing considerably fewer type II errors, and therefore 
provides a sensible alternative with good balance between discovery of statistically 
significant genes and limitation of type I errors. FDR plays an important role in the 
analysis of high-throughput data, such as the discovery of differential expression in 
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microarray and SNP biomarker selection by offering a less conservative with greater 
ability or power to find truly significant results. Nevertheless, careful selection of 
multiple testing comparison procedure is important in limiting type I errors and also to 
prevent erroneous study conclusions. In this chapter, because the total number of 
genotyping tests performed was relatively small, it was decided to correct for multiple 
testing using the Bonferroni correction method above. The primary hypothesis that 
overall NAT2 genotype predicts susceptibility was first investigated without correction.  
 
 
3.3 Results 
3.3.1 NAT2 
3.3.1.1 Investigation of a possible association between NAT2 
genotype and susceptibility to ATD-DILI 
 
To investigate our primary hypothesis that NAT2 slow acetylators were more 
susceptible to ATD-DILI, a total of 26 DILI cases and 90 community controls together 
with 81 controls from the Indian subcontinent who were treated with similar anti-TB 
drugs without developing DILI were genotyped for three SNPs in the NAT2 exons 
(481C>T, 590G>A and 857G>A). Since a SNP in the promoter region of NAT2-
9796T>A (rs4646244) has recently been suggested to be associated with an increased 
risk of DILI (Kim et al., 2009), samples were also genotyped for this SNP. The NAT2 
genotyping results for the combined dataset and for the European and Asian cohorts 
separately are shown in Table 3.6, Table 3.7 and Table 3.8 respectively. All 
polymorphisms were in Hardy-Weinberg equilibrium. The odds ratios and p-value for 
the overall genotypes for the entire cohort as well as for the Europeans and South 
Asians considered separately shown. We observed no significant association between 
the case and control groups either in the combined dataset or in the Asian cohorts alone 
(p>0.05). However, in the European cohort alone, the AA genotype of 590G>A 
polymorphism was found to be associated with ATD-DILI with a p-value of 0.028 
(OR=6.96; 95% CI=1.33-36.57). For -9796T>A, the combined European-South Asian 
cohort showed no evidence for an association of this variant with the risk of ATD-DILI 
(p=0.35) and there was also no significance in the Asian subjects. In the European 
cohort alone, the frequency of the homozygous AA genotype was significantly higher in 
cases compared to control subjects (OR=6.96; 95% CI=1.33-36.57) with a p-value of 
0.028.   
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Table 3.6 Association of NAT2 genotypes and the risk of ATD-DILI in combined 
European and South Asian cohorts 
 
NAT2 
SNP  Genotype 
 
Cases       
(n=26) 
 
 
Community 
controls (n=90) 
 
         Cases vs Controls  
P-value OR (95% CI) 
481C>T  
(rs1799929) 
 
 
590G>A 
(rs1799930) 
 
 
857G>A 
(rs1799931) 
 
-9796T>A 
(rs4646244) 
  CC 
  CT 
  TT 
   
  GG 
  GA 
  AA 
   
  GG 
  GA 
   
  TT 
  TA 
  AA 
  10 (0.38) 
  10 (0.38) 
    6 (0.24) 
     
    8 (0.31) 
  13 (0.50) 
    5 (0.19) 
   
  23 (0.88) 
    3 (0.12) 
   
  11 (0.42) 
  10 (0.39) 
        5 (0.19) 
 41 (0.46) 
 36 (0.40) 
 13 (0.14) 
  
 39 (0.43) 
 41 (0.46) 
 10 (0.11) 
  
 79 (0.88) 
 11 (0.12) 
  
 38 (0.42) 
 44 (0.49) 
   8 (0.09) 
 
 
       0.37 
 
 
 
       0.27 
 
 
     1.00 
 
 
   
     0.16 
 
 
1.78 (0.6-5.26) 
 
 
 
1.72 (0.68-4.37) 
 
 
1.07 (0.27-4.15) 
 
 
 
2.44 (0.72-8.23) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
 
 
  Table 3.7 Association of NAT2 genotypes and the risk of ATD-DILI in European    
cohort 
 
NAT2 
SNP  Genotype 
 
Cases       
(n=13) 
 
 
Community 
controls (n=50) 
 
         Cases vs Controls  
P-value OR (95% CI) 
481C>T  
(rs1799929) 
 
 
590G>A 
(rs1799930) 
 
 
857G>A 
(rs1799931) 
 
-9796T>A 
(rs4646244) 
  CC 
  CT 
  TT 
   
  GG 
  GA 
  AA 
   
  GG 
  GA 
   
  TT 
  TA 
  AA 
       6 (0.46) 
       2 (0.15) 
       5 (0.39) 
 
       6 (0.46) 
       3 (0.23) 
       4 (0.31) 
 
     13 (1.00) 
       0 (0.00) 
 
       7 (0.54) 
       2 (0.15) 
       4 (0.31) 
        18 (0.36) 
        23 (0.46) 
          9 (0.18) 
 
        26 (0.52) 
        21 (0.42) 
          3 (0.06) 
 
        48 (0.96) 
          2 (0.04) 
         
        25 (0.50) 
        22 (0.44) 
          3 (0.06)  
      
 
      0.14 
 
 
 
      0.028 
 
 
      1.00 
 
 
 
      0.028 
 
 
2.85 (0.75-10.77) 
 
 
 
6.96 (1.33-36.57) 
 
 
1.39 (0.06-30.78) 
 
 
 
6.96 (1.33-36.57)  
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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Table 3.8 Association of NAT2 genotypes and the risk of ATD-DILI in South Asian 
subjects 
 
NAT2 
481C>T (rs1799929)             CC      CT      TT  P-value  OR (95% CI) 
 Cases (n=13) 
 ATD-tolerant controls (n=81) 
 Community controls (n=40) 
 
 
  4 (0.31)       
47 (0.58) 
23 (0.57) 
8 (0.61) 
30 (0.37)  
13 (0.33) 
  1 (0.08) 
  4 (0.05)  
  4 (0.10) 
 
0.08 
0.12 
 
3.11 (0.88-10.94) 
3.04 (0.80-11.56) 
 590G>A (rs1799930)     GG      GA      AA  P-value  OR (95% CI) 
 Cases (n=13) 
 ATD-tolerant controls (n=81) 
 Community controls (n=40) 
 
  2 (0.15)       
34 (0.42) 
13 (0.33)  
10 (0.77) 
37 (0.46)  
20 (0.50)  
  1 (0.08) 
10 (0.12)  
  7 (0.17) 
 
0.12 
0.31 
 
3.98 (0.83-19.13) 
2.65 (0.51-13.73) 
 857G>A (rs1799931)     GG     GA      AA  P-value  OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
10 (0.77)       
64 (0.79) 
31 (0.78) 
3 (0.23) 
17 (0.21)  
  9 (0.22)  
  0 (0.00) 
  0 (0.00)  
  0 (0.00) 
 
1.00 
1.00 
 
1.13 (0.28-4.57) 
1.03 (0.23-4.58) 
-9796T>A (rs4646244)      TT     TA      AA  P-value  OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81)       
Community controls (n=40) 
 
  4 (0.31)       
34 (0.42) 
13 (0.33) 
8 (0.62) 
37 (0.46)  
22 (0.55)  
  1 (0.08) 
10 (0.12)  
  5 (0.12) 
 
0.55 
1.00 
 
1.63 (0.46-5.73) 
1.71 (0.18-16.19) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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The three SNPs in the exons were further assigned into alleles NAT2*5 (481C>T), 
NAT2*6 (590G>A), NAT2*7 (857G>A) and NAT2*4 (apparent wild-type). The 
presence of any two mutant alleles defines the slow acetylator phenotype (genotypes 
NAT2*5*5, NAT2*5*6, NAT*5*7, NAT2*6*6, NAT2*6*7 and NAT2*7*7), whereas 
rapid acetylators had no more than one mutant allele (genotypes NAT2*4*4, 
NAT2*4*5, NAT2*4*6 and NAT2*4*7). The overall genotype results obtained are 
summarised in Table 3.9. The odds ratios and p-value for the overall phenotypes for the 
entire cohort as well as for the Europeans and South Asians considered separately 
shown in Table 3.10. In the combined European-South Asian cohort, the slow 
acetylator phenotype was found to be associated with the risk of ATD-DILI (OR=4.60; 
95% CI=1.47-14.44) (p-value=0.006) when compared with the community controls 
with 80% of cases being slow acetylators. In the European cohort alone, an apparent 
increased frequency of the slow acetylator phenotype was observed in the cases but this 
was not statistically significantly different (OR=3.33; 95% CI=0.82-13.58; p=0.12). 
However, for the South-Asian cohort, slow acetylator status was found to be associated 
with an increased susceptibility to ATD-DILI with the p-value of 0.002 (OR=13.58; 
95% CI=1.69-109.4) when compared to the ATD-tolerant controls. A borderline 
significant difference was also observed in these cases when compared to the 
community controls with a p-value of 0.041 (OR=8.00; 95% CI=0.94-67.67).  
 
The relationship between -9796T>A and the other NAT2 polymorphisms studied was 
also investigated. As summarised in Table 3.11, many subjects positive for -9796T>A 
were also positive for NAT2*6. In particular, among the community controls, all 8 
individuals with a AA genotype for the -9796 SNP had a NAT2*6*6 genotype while for 
the cases this was true for 5 of the 6 individuals. Analysis by Fisher’s exact test 
comparing *6 genotypes in those carrying one or more A-9796 alleles (Table 3.12) 
showed a highly significant association for both cases (p=0.0008) and controls 
(p<0.0001) suggesting that the 590G>A and -9796T>A SNPs were in strong linkage 
disequilibrium. 
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            Table 3.9 Association of NAT2 genotypes and the risk of ATD-DILI 
 
   NAT2 
Combined European-South Asian cohort 
 
 NAT2 Allele 
Cases                                     
(n=26) 
Community controls     
(n=90) 
Rapid acetylator 
NAT2*4*4 
NAT2*4*5 
NAT2*4*6 
NAT2*4*7 
Slow acetylator 
NAT2*5*5 
NAT2*5*6 
NAT2*5*7 
NAT2*6*6  
NAT2*6*7 
 
 
 
 2 (0.08) 
 0 (0.00) 
 2 (0.08) 
 0 (0.00) 
 
 6 (0.23) 
 8 (0.31) 
 1 (0.04) 
 5 (0.19) 
 2 (0.08) 
 
 
     6 (0.07) 
   14 (0.16) 
   16 (0.18) 
     5 (0.06) 
 
   13 (0.14) 
   20 (0.22) 
     2 (0.02) 
   10 (0.11) 
     4 (0.04) 
European cohort 
  
NAT2 Allele 
Cases                                     
(n=13) 
Community controls     
(n=50) 
  
Rapid acetylator 
NAT2*4*4 
NAT2*4*5 
NAT2*4*6 
NAT2*4*7 
Slow acetylator 
NAT2*5*5 
NAT2*5*6 
NAT2*5*7 
NAT2*6*6  
         NAT2*6*7 
 
 
2 (0.15) 
0 (0.00) 
1 (0.08) 
0 (0.00) 
 
5 (0.38) 
1 (0.08) 
0 (0.00) 
4 (0.31) 
0 (0.00) 
 
 
     4 (0.08) 
   12 (0.24) 
     9 (0.18) 
     0 (0.00) 
 
     9 (0.18) 
   11 (0.22) 
     1 (0.02) 
     3 (0.06) 
     1 (0.02) 
        
South Asian cohort 
 
        NAT2 Allele 
Cases                                     
(n=13) 
ATD-Tolerant 
controls (n=81) 
Community    
controls (n=40) 
 
Rapid acetylator 
NAT2*4*4 
NAT2*4*5 
NAT2*4*6 
NAT2*4*7 
Slow acetylator 
NAT2*5*5 
NAT2*5*6 
NAT2*5*7 
NAT2*6*6  
         NAT2*6*7 
 
 
0 (0.00) 
0 (0.00) 
1 (0.08) 
0 (0.00) 
 
1 (0.08) 
7 (0.54) 
1 (0.08) 
1 (0.08) 
2 (0.15) 
 
     
  7 (0.09) 
10 (0.12) 
17 (0.21) 
  9 (0.11) 
 
  4 (0.05) 
16 (0.20) 
  4 (0.05)  
10 (0.12) 
  4 (0.05) 
 
 
   2 (0.05) 
   2 (0.05) 
   7 (0.18) 
   5 (0.13) 
 
   4 (0.10) 
   9 (0.23) 
   1 (0.03) 
   7 (0.18) 
 3 (0.08)   
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          Table 3.10 Predicted NAT2 acetylator phenotype and the risk of ATD-DILI 
 
  NAT2  
  
Acetylator Phenotype 
P-value OR (95% CI) 
Rapid Slow 
 
Combined European and 
South Asian cohort 
Cases (n=26) 
Community controls (n=90) 
 
 
 
 
  4 (0.15) 
41 (0.46) 
 
 
 
 
22 (0.85) 
49 (0.54) 
 
 
 
 
 
0.006 
 
 
 
 
 
4.60 (1.47-14.44) 
 
 
European cohort 
Cases (n=13) 
Community controls (n=50) 
 
 
 
  3 (0.23) 
25 (0.50) 
 
 
 
10 (0.77) 
25 (0.50) 
 
 
 
 
0.120 
 
 
 
 
3.33 (0.82-13.58) 
 
South Asian cohort 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
 
  1 (0.08) 
43 (0.53) 
16 (0.40) 
 
12 (0.92) 
38 (0.47) 
24 (0.60) 
 
 
0.002 
0.041 
 
 
13.58 (1.69-109.40) 
8.00 (0.94-67.67) 
 
P-value for comparison of acetylator phenotype frequencies between cases vs controls using 
Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
  
 
 
Table 3.11 The relationship between 9796T>A and the other NAT2 polymorphisms  
 
Combined European-South Asian cohort 
 
NAT2 Allele 
Genotype -9796T>A (rs4646244) 
Cases (n=26)  Community controls (n=90) 
TT TA AA   TT TA AA 
Rapid acetylator 
NAT2*4*4 
NAT2*4*5 
NAT2*4*6 
NAT2*4*7 
Slow acetylator 
NAT2*5*5 
NAT2*5*6 
NAT2*5*7 
         NAT2*6*6  
     NAT2*6*7 
 
 
   2 (0.08) 
        - 
   1 (0.04) 
        - 
 
   5 (0.19) 
   1 (0.04) 
   1 (0.07) 
        - 
   1 (0.07) 
 
  
        - 
        - 
   1 (0.04) 
      - 
 
 1 (0.04) 
 7 (0.27) 
      - 
   1 (0.04) 
        - 
 
        - 
        - 
        - 
        - 
 
        - 
        - 
        - 
   5 (0.19) 
        - 
 
    4 (0.04) 
  12 (0.13) 
    1 (0.01) 
    3 (0.03)  
 
   13 (0.14)            
     3 (0.03) 
     2 (0.02) 
         - 
         - 
  
   2 (0.02) 
   2 (0.02) 
 15 (0.17) 
   2 (0.02) 
    
- 
 17 (0.19) 
        - 
   2 (0.02) 
   4 (0.04)    
 
        - 
        - 
        - 
        - 
 
        - 
        - 
        - 
    8 (0.09) 
        - 
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Table 3.12 Statistical analysis of the association between -9796T>A and other    
NAT2 alleles 
  
  
Genotype -9796T>A (rs4646244) 
P-value OR (95% CI) 
         TT TA/AA 
 
Cases 
NAT2*6 positive  
NAT2*6 negative  
 
 
3 (0.12) 
8 (0.31) 
 
 
 
       14 (0.54) 
 1 (0.04) 
 
 
 
 
0.008 
 
 
 
 
37.33 (3.3-421.8) 
 
Controls 
NAT2*6 positive 
NAT2*6 negative 
 
 
 
4 (0.04 
34 (0.38) 
 
 
 
46 (0.51) 
  6 (0.07) 
 
 
 
 
<0.0001 
 
 
 
 
65.2 (17.1-249.1) 
 
 
P-value for comparison of NAT2-9796T>A genotypes frequencies between NAT2*6 positive vs 
NAT2*6 negative using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
A total of 6 patients who underwent liver transplant following liver failure due to ATD-
DILI were studied in detail. Five of these were cases in the main study but a sixth case 
was of African ethnic origin and was not included in the main study. As shown in Table 
3.13, genotyping for NAT2*5, *6 and *7 suggested that 50% of these cases were fast 
acetylators including two, of European ethnic origin and African ethnic origin 
respectively, who were homozygous for NAT2*4 and therefore predicted to be very 
rapid acetylators. To investigate the possibility that some of these cases of severe DILI 
might be positive for additional NAT2 mutations, the complete coding sequence in all 6 
cases was determined. For the African case, the sequencing showed that this individual 
was heterozygous for NAT2*14A because a G>A base change at position 191 (Arg to 
Glu) was detected (Figure 3.24). This individual was still classed as a rapid acetylator 
as the final genotype was NAT2*4*14A. 
 
Table 3.13 NAT2 genotypes (for *5, *6 and *7) and predicted phenotypes in 6       
liver-transplanted patients  
 
 
* Later found by sequencing to have the genotype NAT2*4*14A 
Patient Ethnic origin NAT2 Genotypes NAT2 Phenotype 
1 African* NAT2*4*4 Rapid acetylator 
2 Bangladeshi NAT2*4*6 Rapid acetylator 
3 European NAT2*4*4 Rapid acetylator 
4 European NAT2*5*5 Slow acetylator 
5 Pakistani NAT2*5*6 Slow acetylator 
6 Indian NAT2*5*6 Slow acetylator 
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Figure 3.24 Detection of the NAT2 191G>A nucleotide change in a liver 
transplant patient from African origin 
 
Sequencing traces showed that this individual possessed the GA genotype 
and therefore was heterozygous for NAT2*14A.   
 
 
          
Heterozygous GA genotype      
(position 191)
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3.3.1.2 Sensitivity analysis on NAT2 genotype as a predictor of anti -
TB DILI 
 
Using the data shown in Table 3.8 for the combined European and South Asian cohort, 
analysis of the value of NAT2 genotype for predicting DILI due to anti-TB drugs was 
determined. Sensitivity, specificity, negative predictive value and positive predictive 
value were each calaulated using standard methods (www.hpa-
midas.org.uk/sensitivity_calculator.asp). The incidence of DILI due to anti-TB drugs 
was assumed to be 2% for the predictive value calculations. The results obtained are 
shown in Table 3.14.  
 
                     Table 3.14 Sensitivity analysis for NAT2 genotyping  
 
 
 
 
 
 
 
 
 
 
 
   
 
     * Predictive values are expressed as a proportion or probability, with a range of 0 to1  
 
 
3.3.2 Genotyping for additional candidate genes for ATD-DILI 
3.3.2.1 Genes chosen for study 
 
To assess the possible contribution of other genes relevant to either ATD metabolism or 
to protection against oxidative stress, it was decided to study the candidate genes and 
SNPs listed in Table 3.15. In the case of PXR, GSTA1, GSTT1 and GSTA1, it was 
decided to study specific polymorphisms which had previously been demonstrated to 
show functional significance. For CYP2E1, the SNPs chosen for study were based on 
previous studies on disease association but for GSTA4 because of the absence of 
previous data, we selected SNPs that tagged the most common haplotypes based on 
information from the Hapmap. For SOD2, we chose to study one SNP previously 
suggested to be functionally significant and relevant to DILI but also selected a second 
SNP so that the common haplotypes were tagged. A total of 14 different polymorphisms 
were chosen for study. All SNPs studied were successfully genotyped and we found no 
deviation from the Hardy-Weinberg equilibrium in all controls except for -1053C>T in 
 
Sensitivity Specificity 
Predictive value* 
Positive Negative 
NAT2 
genotyping 
84.6% 45.6% 0.03 0.99 
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CYP2E1. The minor allele frequency of -1053C>T in CYP2E1 is closed to zero which 
results in a deficiency of heterozygotes relative to Hardy-Weinberg expectations. For 
GSTT1 and GSTM1, the Hardy-Weinberg equilibrium analysis was excluded for these 
genes as the data presented (presence versus the absence of the GSTT1/GSTM1 
polymorphism) cannot be used to assess Hardy-Weinberg equilibrium. Considering that 
a total of 15 genotyping assays were evaluated in our study, the adjusted significant P 
value is 0.0033 after Bonferroni correction for multiple testing. 
 
                          Table 3.15 Additional candidate genes chosen for study 
 
   Gene Position       SNP Reference SNP ID 
CYP2E1 Promoter   -1053C>T   rs2031920 
 Promoter   -71G>T   rs6413420 
 Intron 7   9896C>G   rs2070676 
PXR Promoter   -25385C>T   rs3814055 
GSTA1 Promoter   -69C>T   rs3957357 
GSTA4 Intron 1         –   rs316141 
 Intron 1         –   rs4147618 
 Intron 2         –   rs316128 
 Intron 4         –   rs3756980 
 Intron 6         –   rs13207376 
GSTT1                             Null allele 
GSTM1                      Null allele 
SOD2 Exon 2         –   rs4880 
 3’UTR         –   rs5746136 
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3.3.2.2 CYP2E1 
 
Four SNPs in CYP2E1 (-1293G>C, -1053C>T, -71G>T and 9896C>G) were selected 
and genotyped. The -1293G>C and -1053C>T genotypes were in complete linkage 
disequilibrium and therefore the genotype data for the -1293G>C was excluded in this 
study. The genotyping results for -1053C>T, -71G>T and 9896C>G polymorphisms for 
the combined European-South Asian cohorts are shown in Table 3.16. As shown in 
Table 3.16, an apparent increased frequency of the -1053CT genotype was observed in 
ATD-DILI cases compared to the community controls, however, the difference was not 
significant (OR=7.42; 95% CI=0.65-85.35; p=0.13). We also observed no significant 
differences between the groups in the analysis of -71G>T and 9896C>G 
polymorphisms. In the European cohorts, an increased frequency of the -1053CT 
genotype was found in ATD-DILI cases compared to the community controls 
(OR=21.96; 95% CI=0.99-489.3) with a p-value of 0.04. The result is however not 
reliable as the genotype frequencies in the community controls for the SNP -1053C>T 
did not fit with the Hardy-Weinberg equation (Table 3.17). If Bonferroni correction for 
multiple testing is performed to reflect the fact that genotyping for 15 different 
polymorphisms has been performed and the level of significance is set at 0.0033, the p-
values here are not significant. Genotyping for -71G>T and 9896C>G polymorphisms 
in the cases and controls also showed no significant difference in frequency between the 
groups (p=0.69-0.30). As shown in Table 3.17, there was an increased frequency of 
wild-type CC (9896C>G) in cases compared to ATD-tolerant controls (OR=3.68; 95% 
CI=0.45-23.48) and community controls (OR=4.55; 95% CI=0.53-39.29); however it 
showed no statistical difference in the South Asian cohorts. For the -1053C>T and -
71G>T polymorphisms, there were no differences between the cases and ATD-tolerant 
controls, nor in the community controls (p=1.00).   
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Table 3.16 Association of CYP2E1 genotypes and the risk of ATD-DILI in 
combined European-South Asian cohorts 
 
   CYP2E1 
 
Genotypes 
Cases           
(n=26) 
 
Controls 
(n=90) 
Cases vs Controls 
P-value  OR (95% CI) 
 
-1053C>T  
(rs2031920) 
 
CC 
CT 
TT 
CC vs CT+TT 
 
24 (0.92) 
  2 (0.08) 
0 (0.00) 
 
 
 89 (0.99) 
   1 (0.01) 
   0 (0.00) 
 
 
 
 
 
0.13 
 
 
 
 
 7.42 (0.65-85.35) 
 
-71G>T 
(rs6413420) 
 
 
GG 
GT 
TT 
GG vs GT+TT 
 
22 (0.85) 
  4 (0.15) 
0 (0.00) 
 
 
 79 (0.88) 
 11 (0.12) 
   0 (0.00) 
 
 
 
 
 
0.74 
 
 
 
 
 1.31 (0.38-4.51) 
 
9896C>G 
(rs2070676)  
 
 
CC 
CG 
GG 
CC vs CG+GG  
 
 
21 (0.81) 
  5 (0.19) 
  0 (0.00) 
 
 68 (0.76) 
 11 (0.12) 
   1 (0.01) 
 
 
 
 
 
0.76 
 
 
 
 
 1.35 (0.43-4.27) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
 
Table 3.17 Association of CYP2E1 genotypes and the risk of ATD-DILI in 
European cohorts 
 
   CYP2E1 
 
Genotypes 
Cases           
(n=13) 
 
Controls 
(n=50) 
Cases vs Controls 
P-value  OR (95% CI) 
 
-1053C>T  
(rs2031920) 
 
CC 
CT 
TT 
CC vs CT+TT 
 
11 (0.85) 
  2 (0.15) 
0 (0.00) 
 
 
 50 (1.00) 
   0 (0.00) 
   0 (0.00) 
 
 
 
 
 
0.04 
 
 
 
 
 21.96 (0.99-489.3) 
 
-71G>T 
(rs6413420) 
 
 
GG 
GT 
TT 
GG vs GT+TT 
 
10 (0.77) 
  3 (0.23) 
0 (0.00) 
 
 
 43 (0.86) 
   7 (0.14) 
   0 (0.00) 
 
 
 
 
 
0.42 
 
 
 
 
 1.84 (0.40-8.41) 
 
9896C>G 
(rs2070676)  
 
 
CC 
CG 
GG 
CC vs CG+GG  
 
 
  9 (0.69) 
  4 (0.31) 
  0 (0.00) 
 
 39 (0.78) 
 11 (0.22) 
   0 (0.00) 
 
 
 
 
 
0.49 
 
 
 
 
 1.58 (0.41-6.11) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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 Table 3.18 Association of CYP2E1 genotypes and the risk of ATD-DILI in South 
Asian subjects 
 
  CYP2E1 
 -1053C>T (rs2031920) 
 
CC 
 
CT 
 
TT 
 
P-value 
 
 OR (95% CI) 
 Cases (n=13) 
 ATD-tolerant controls (n=81) 
 Community controls (n=40) 
 
13 (1.00) 
76 (0.94) 
39 (0.97) 
  0 (0.00) 
  5 (0.06) 
  1 (0.03)   
  0 (0.00) 
  0 (0.00) 
  0 (0.00) 
 
1.00 
1.00 
 
1.94 (0.10-37.20) 
1.03 (0.04-26.72) 
 -71G>T (rs6413420) 
 
GG 
 
GT 
 
TT 
 
P-value 
 
 OR (95% CI) 
 Cases (n=13) 
 ATD-tolerant controls (n=81) 
 Community controls (n=40) 
 
12 (0.92) 
74 (0.91) 
36 (0.90) 
  1 (0.08) 
  6 (0.08) 
  4 (0.10)   
  0 (0.00) 
  1 (0.01) 
  0 (0.00) 
 
1.00 
1.00 
 
1.14 (0.13-10.07) 
1.33 (0.14-13.13) 
 9896C>G (rs2070676) 
 
CC 
 
CG 
 
GG 
 
P-value 
 
 OR (95% CI) 
 Cases (n=13) 
 ATD-tolerant controls (n=81) 
 Community controls (n=40) 
 
12 (0.92) 
62 (0.77) 
29 (0.73) 
  1 (0.08) 
18 (0.22) 
10 (0.25)   
  0 (0.00) 
  1 (0.01) 
  1 (0.02) 
 
0.29 
0.25 
 
3.68 (0.45-23.48) 
4.55 (0.53-39.29) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
 
 
3.3.2.3 PXR 
 
The genotyping results for PXR -25385C>T polymorphism in the European and South 
Asian cohorts are shown in Table 3.19. In the combined European-South Asian cohorts, 
an increased frequency for the carriage of a wild-type C allele was observed in the cases 
compared with the community controls, yet the difference was not significant 
(OR=3.00; 95% CI=0.65-13.89; p=0.24). In the European cohort, no association was 
observed between the cases and the community controls (p=0.54). However, in the 
South Asian cohort, a slight increase for the carriage of a wild-type C allele was found 
in the cases compared with the community controls, however the difference was not 
significant (OR=6.05; 95% CI=0.32-113.50; p =0.17). There was also no association 
found between the ATD-tolerant controls with ATD-DILI cases (p=1.00). 
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             Table 3.19 Association of PXR genotypes and the risk of ATD-DILI  
 
PXR 
 -25385C>T (rs3814055) 
 
TT 
 
CT 
 
CC 
 
P-value 
 
 OR (95% CI) 
 
Combined European-
South Asian cohorts 
Cases (n=26) 
Community controls (n=90) 
 
 
 
 
  2 (0.08) 
18 (0.20) 
 
 
 
 
15 (0.58) 
33 (0.37) 
 
 
 
 
  9 (0.35) 
39 (0.43) 
 
 
 
 
 
0.24 
 
 
 
 
 
3.00 (0.65-13.89) 
 
 
 
European cohorts 
Cases (n=13) 
Community controls (n=50) 
 
 
 
   2 (0.15) 
 11 (0.22) 
 
 
 
   8 (0.62) 
 21 (0.42) 
 
 
 
   3 (0.23) 
 18 (0.36) 
 
 
 
 
0.72 
 
 
 
 
 1.55 (0.30-8.07) 
 
 
South Asian cohorts 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
 
 
   0 (0.00) 
   4 (0.05) 
   7 (0.18) 
 
 
   7 (0.54) 
 42 (0.52) 
 12 (0.30) 
 
 
   6 (0.46) 
 35 (0.43) 
 21 (0.53) 
 
 
 
1.00 
0.17 
 
 
 
 1.57 (0.08-30.84) 
 6.05 (0.32-113.5) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
 
3.3.2.4 GSTA1 
 
The genotyping results of -69C>T in the European and South Asian cohorts are shown 
in Table 3.20. We found no association of GSTA1 genotypes and the risk of ATD-DILI 
in Europeans, South Asians and both cohorts combined. The relative frequency of the 
TT genotype among the community control groups varied from 21% in Europeans to 
5% in South Asians. An increased frequency of TT genotype was observed in the cases 
compared to the community controls in the South Asian cohort, however it showed no 
statistical difference in each group (OR=3.46; 95% CI=0.44-27.44; p=0.25). 
 
 
 
 
 
 
 
 
  
 
129 
          Table 3.20 Association of GSTA1 genotypes and the risk of ATD-DILI  
 
GSTA1 
 -69C>T (rs3957357) 
 
TT 
 
CT 
 
CC 
 
P-value 
 
 OR (95% CI) 
 
Combined European-
South Asian cohorts 
Cases (n=26) 
Community controls (n=90) 
 
 
 
  6 (0.23) 
14 (0.16) 
 
 
 
  9 (0.35) 
41 (0.46) 
 
 
 
11 (0.42) 
35 (0.39) 
 
 
 
 
0.38 
 
 
 
  
  1.63 (0.56-4.78) 
 
 
European cohorts 
Cases (n=13) 
Community controls (n=50) 
 
 
 
  4 (0.31) 
12 (0.24) 
 
 
 
  5 (0.38) 
23 (0.46) 
 
 
 
  4 (0.31) 
15 (0.30) 
 
 
 
 
0.72 
 
 
 
 
  0.71 (0.19-2.73) 
 
 
South Asian cohorts 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
 
 
  2 (0.15) 
  7 (0.09) 
  2 (0.05) 
 
 
  4 (0.31) 
33 (0.41) 
18 (0.45) 
 
 
  7 (0.54) 
41 (0.51) 
20 (0.50) 
 
 
 
0.61 
0.25 
 
 
 
  1.92 (0.35-10.47) 
  3.46 (0.44-27.44) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
 
3.3.2.5 GSTA4 
 
The association of five SNPs in GSTA4 and the risk of ATD-DILI in the combined 
dataset and for the European and South Asian cohorts separately are shown in Table 
3.21, Table 3.22 and Table 3.23 respectively. In the combined European-South Asian 
cohorts, we observed an apparently significant association (p<0.05) in rs316128 and 
rs3756980 with the risk of ATD-DILI (Table 3.21). For rs316128, the proportion of A 
allele carriers was significantly higher in the cases compared to the controls (OR=7.14; 
95% CI=0.91-56.05) with a p-value of 0.041. Patients with AA genotype (rs3756980) 
were associated with a higher risk of developing hepatotoxicity due to anti-TB drugs 
(OR=3.67; 95% CI=1.02-13.24) with a p-value of 0.046. However, the p-values here are 
not significant after correction for multiple testing (p>0.0033). In the South Asian 
cohorts, lack of association was observed between GSTA4 polymorphisms and the risk 
of ATD-DILI (p=0.45-1.00). In the European cohort, carriage of a wild-type A allele in 
rs316128 was found to be associated with increased susceptibility to ATD-induced DILI 
with a p-value of 0.027 (OR=11.79; 95% CI=0.7-211.2). An apparent differences of the 
homozygous AA genotype in rs3756980 was also found in the cases compared to the 
controls but this was not significant (OR=8.00; 95% CI=1.0-66.5; p-value=0.045). For 
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rs316141, the frequency of the homozygous CC genotype was higher in the cases than 
the controls; again the difference was not significantly different (OR=3.00; 95% 
CI=0.86-10.51; p=0.103).  
 
Further analysis was performed by reconstructing haplotypes and estimating their 
frequencies using PHASE v2.1.1. The results are summarised in Table 3.24 and Table 
3.25. In the combined European-South Asian dataset, no association was found between 
the ATD-DILI susceptibility with a particular haplotypes. However, in the European 
cohort, a greater frequency of the CTAAA haplotype in the case group (69%) compared 
to the controls (44%) was detected. This gave an odds ratio of 2.86 (95% CI=1.14-7.2) 
with a p-value of 0.028 (Table 3.24).  
 
Table 3.21 Association of GSTA4 genotypes and the risk of ATD-DILI in combined 
European-South Asian cohorts 
 
GSTA4 
 
Genotypes 
 
Cases           
(n=26) 
 
 
Controls 
(n=90) 
 
Cases vs Controls 
P-value  OR (95% CI) 
 
 rs316141 
 
TT 
CT 
CC 
CC+CT vs TT 
 
  2 (0.08) 
12 (0.46) 
12 (0.46) 
 
 
 17 (0.19) 
 40 (0.44) 
 33 (0.37) 
 
 
 
 
 
0.240 
 
 
 
 
 2.80 (0.6-12.99) 
 
 rs4147618 
 
TT 
TA 
TT vs TA 
 
23 (0.88) 
  3 (0.12) 
 
 
 75 (0.83) 
 15 (0.17) 
 
 
 
 
0.760 
 
 
 
 1.53 )(0.41-5.77) 
 
 rs316128 
 
AA 
AC 
CC 
AA+AC vs CC 
 
  9 (0.34) 
16 (0.62) 
  1 (0.04) 
 
 30 (0.33) 
 40 (0.45) 
 20 (0.22) 
 
 
 
 
 
0.041 
 
 
 
 
7.14 (0.91-56.05) 
 
 rs3756980 
 
AA 
AG 
GG 
AA vs AG+GG 
 
22 (0.85) 
  3 (0.12) 
  0 (0.00) 
 
 60 (0.67) 
 27 (0.30) 
   3 (0.03) 
 
 
 
 
 
0.046 
 
 
 
 
 3.67 (1.02-13.24) 
 
 rs13207376 
 
AA 
AG 
GG 
AA vs AG+GG 
 
 
23 (0.88) 
  2 (0.08) 
  1 (0.04) 
 
 84 (0.93) 
   2 (0.02) 
   4 (0.05) 
 
 
 
 
 
0.420 
 
 
 
 
 1.83 (0.42-7.87) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
  
  
 
131 
 
Table 3.22 Association of GSTA4 genotypes and the risk of ATD-DILI in 
European cohorts 
 
  GSTA4 
 
Genotypes 
 
Cases           
(n=13) 
 
 
Controls 
(n=50) 
 
Cases vs Controls 
P-value  OR (95% CI) 
 
 rs316141 
 
CC 
CT 
TT 
CC vs CT+TT 
 
   7 (0.54) 
   6 (0.46) 
   0 (0.00) 
 
 
 14 (0.28) 
 24 (0.48) 
 12 (0.24) 
 
 
 
 
 
0.103 
 
 
 
 
 3.00 (0.86-10.51) 
 
 rs4147618 
 
TT 
TA 
TT vs TA 
 
 12 (0.92) 
   1 (0.08) 
 
 
 40 (0.80) 
 10 (0.20) 
 
 
 
 
0.433 
 
 
 
 3.00 (0.4-25.9) 
 
 rs316128 
 
CC 
CA 
AA 
AA+CA vs CC  
 
   0 (0.00) 
   8 (0.62) 
   5 (0.38) 
 
 15 (0.30) 
 22 (0.44) 
 13 (0.26) 
 
 
 
 
 
0.027 
 
 
 
 
11.79 (0.7-211.2) 
 
 rs3756980 
 
AA 
AG 
GG 
AA vs AG+GG 
 
 12 (0.92) 
   1 (0.08) 
   0 (0.00) 
 
 30 (0.60) 
 18 (0.36) 
   2 (0.04) 
 
 
 
 
 
0.045 
 
 
 
 
 8.00 (1.0-66.5) 
 
 rs13207376 
 
AA 
AG 
GG 
AA vs AG+GG 
 
 
 11 (0.85) 
   2 (0.15) 
   0 (0.00) 
 
 47 (0.94) 
   2 (0.04) 
   1 (0.02) 
 
 
 
 
 
0.273 
 
 
 
 
 0.35 (0.1-2.4) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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Table 3.23 Association of GSTA4 genotypes and the risk of ATD-DILI in South 
Asian subjects 
 
GSTA4 
rs316141 
 
TT 
 
CT 
 
CC 
 
P-value 
 
 OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
  2 (0.15) 
11 (0.14) 
  5 (0.13) 
   6 (0.46) 
 36 (0.44) 
 16 (0.40)   
   5 (0.39) 
 34 (0.42) 
 19 (0.47) 
 
1.00 
0.75 
 
1.16 (0.35-3.85) 
1.45 (0.40-5.20) 
rs4147618 
 
TT 
 
TA 
 
AA 
 
P-value 
 
 OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
11 (0.85) 
73 (0.90) 
35 (0.88) 
   2 (0.15) 
   7 (0.09) 
   5 (0.12)   
   0 (0.00) 
   1 (0.01) 
   0 (0.00) 
 
0.63 
1.00 
 
0.60 (0.11-3.22) 
0.79 (0.13-4.64) 
rs316128 
 
AA 
 
AC 
 
CC 
 
P-value 
 
 OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
  4 (0.31) 
31 (0.38) 
17 (0.42) 
   8 (0.61) 
 39 (0.48) 
 18 (0.45)   
   1 (0.08) 
 11 (0.14) 
   5 (0.13) 
 
0.76 
0.53 
 
1.40 (0.40-4.92) 
1.66 (0.44-6.32) 
rs3756980 
 
AA 
 
AG 
 
GG 
 
P-value 
 
 OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
10 (0.77) 
59 (0.73) 
30 (0.75) 
   2 (0.15) 
 21 (0.26) 
   9 (0.22)   
   1 (0.08) 
   1 (0.01) 
   1 (0.03) 
 
1.00 
1.00 
 
1.24 (0.31-4.94) 
1.11 (0.25-4.86) 
rs13207376 
 
AA 
 
AG 
 
GG 
 
P-value 
 
 OR (95% CI) 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
12 (0.92) 
78 (0.96) 
37 (0.92) 
   0 (0.00) 
   0 (0.00) 
   0 (0.00)   
   1 (0.08) 
   3 (0.04) 
   3 (0.08) 
 
0.45 
1.00 
 
0.46 (0.04-4.81) 
0.97 (0.09-10.26) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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Table 3.24 Association of the most common GSTA4 haplotypes and the risk of 
ATD-DILI in combined European-South Asian cohorts 
 
GSTA4 
Haplotype 
Haplotype frequency Frequency of other haplotype  
Cases 
n=52 
Controls 
n=180 
Cases    
n=52 
 Controls    
n=180 
P-value OR (95% CI) 
 
 
CTAAA 
TTCAA 
TTCGA 
 
 
28 (0.54) 
10 (0.19) 
1 (0.02) 
 
 
 95 (0.53) 
 33 (0.18) 
 18 (0.10) 
 
 
 24 (0.31) 
 42 (0.88) 
 51 (0.96) 
 
 
  85 (0.47) 
147 (0.82) 
162 (0.90) 
 
 
1.00 
0.84 
0.08 
 
 
 1.04 (0.56-1.94) 
 1.06 (0.48-2.33) 
 5.67 (0.74-43.52) 
 
 
P-value for comparison of genotypes frequencies between groups using Fisher’s exact 2 tailed test; 
OR, odds ratios; CI, confidence interval 
 
 
 
 
Table 3.25 Association of the most common GSTA4 haplotypes and the risk of 
ATD-DILI in European cohorts 
 
GSTA4 
Haplotype 
Haplotype frequency Frequency of other haplotype  
Cases 
n=26 
Controls 
n=100 
Cases    
n=26 
 Controls    
n=100 
P-value OR (95% CI) 
 
 
CTAAA 
TTCAA 
TTCGA 
 
 
 
18 (0.69) 
  3 (0.12) 
1 (0.04) 
 
 
44 (0.44) 
20 (0.20) 
12 (0.12) 
 
 
   8 (0.31) 
 23 (0.88) 
 25 (0.96) 
 
 
  56 (0.51) 
  80 (0.88) 
  88 (0.88) 
 
 
0.028 
0.404 
0.300 
 
 
 2.86 (1.14-7.2) 
 1.92 (0.52-7.03) 
 3.41 (0.42-27.5)  
 
P-value for comparison of genotypes frequencies between groups using Fisher’s exact 2 tailed test; 
OR, odds ratios; CI, confidence intervals 
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3.3.2.6 GSTT1 
 
The relative frequency of the GSTT1 null genotype among community control groups 
varies from 27% in the Europeans and 10% in the South Asians (Table 3.26). No 
GSTT1 null mutation was detected in the South Asian cases and only 2 cases (15%) 
with GSTT1 null mutation was observed in the European cohorts. We observed no 
association between GSTT1 null genotype and ATD-DILI in combined dataset and also 
the European and South Asian cohorts separately, thus suggesting that GSTT1 null 
mutation is unlikely to be associated with the risk of ATD-DILI in our studied cohorts.   
 
 
 
 Table 3.26 Statistical analysis of GSTT1 ‘null’ polymorphism and the risk of 
ATD-DILI  
 
   GSTT1  
  
‘Null’ mutation 
P-value  OR (95% CI) 
Present Absent 
 
Combined European and 
South Asian cohorts 
Cases (n=26) 
Community controls (n=90) 
 
 
 
 
  2 (0.08) 
18 (0.20) 
 
 
 
 
24 (0.92) 
72 (0.80) 
 
 
 
 
 
0.24 
 
 
 
 
 
3.00 (0.65-13.89) 
 
 
European cohorts 
Cases (n=13) 
Community controls (n=50) 
 
 
  2 (0.15) 
14 (0.28) 
 
 
11 (0.85) 
36 (0.72) 
 
 
 
0.49 
 
 
 
 2.14 (0.42-10.90) 
 
South Asian cohorts 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
 
  0 (0.00) 
15 (0.19) 
  4 (0.10) 
 
13 (1.00) 
66 (0.81) 
36 (0.90) 
 
 
0.12 
0.56 
 
 
6.29 (0.35-111.8) 
0.30 (0.02-5.97) 
 
P-value for comparison of genotypes frequencies between cases vs controls using Fisher’s 
exact 2 tailed test; OR, odds ratios; CI, confidence intervals 
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3.3.2.7 GSTM1 
 
The association of GSTM1 null polymorphism and the risk of ATD-DILI in Europeans, 
South Asians and both cohorts combined are shown in Table 3.27. All samples, except 
one from the South Asian cases, were successfully genotyped. In the European cohort, 
frequency of the GSTM1 null genotype was higher in the cases than the controls but this 
was not statistically significant (OR=2.44; 95% CI=0.66-8.98; p=0.221). In the South 
Asian cohorts, an apparent increased frequency of  the GSTM1 null genotype was 
observed in the cases, however it was not statistically significant when compared to the 
ATD-tolerant controls (OR=3.40; 95% CI=0.94-12.26; p=0.064) and the community 
controls (OR=3.71; 95% CI=0.95-14.54; p=0.094). In the combined dataset, we 
observed an apparently significant increase in the GSTM1 null mutation in the cases 
(68%) compared to the controls (42%) with a p-value of 0.026 (OR=2.91; 95% 
CI=1.14-7.43). The p-value here however is not significant after correction for multiple 
testing (p>0.0033). The association of the combined effect of NAT2 and GSTM1 
polymorphisms with the risk of ATD-DILI was further examined (Table 3.28). In the 
combined European-South Asian cohorts, the NAT2 slow acetylator phenotype and 
GSTM1 null genotype together showed highest distribution in the cases (56%) 
compared to the controls (26%) with a p-value of 0.007 (OR=3.71; 95% CI=1.48-9.31). 
In contrast, the NAT2 rapid acetylator and GSTM1 null genotype combination was 
higher in the controls with a p-value of 0.008 (OR=9.75; 95% CI=1.25-75.87). This 
suggests that NAT2 slow acetylator and GSTM1 null genotype combination correlated 
significantly with susceptibility to ATD-DILI. 
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Table 3.27 Statistical analysis of GSTM1 ‘null’ polymorphism and the risk of 
ATD-DILI  
 
   GSTM1  
  
‘Null’ mutation 
 P-value  OR (95% CI) 
Present Absent 
 
Combined European-
South Asian cohorts 
Cases (n=25) 
Community controls (n=90) 
 
 
 
 
  17 (0.68) 
  38 (0.42) 
 
 
 
 
    8 (0.32) 
  52 (0.58) 
 
 
 
 
 
0.026 
 
 
 
 
 
2.91 (1.14-7.43) 
 
 
European cohorts 
Cases (n=13) 
Community controls (n=50) 
 
 
    9 (0.69) 
  24 (0.48) 
 
 
    4 (0.31) 
  26 (0.52) 
 
 
 
0.221 
 
 
 
2.44 (0.66-8.96) 
 
South Asian cohorts 
Cases (n=12) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
 
 
    8 (0.67) 
  30 (0.37) 
  14 (0.35) 
 
    4 (0.33) 
  51 (0.63) 
  26 (0.65) 
 
 
0.064 
0.094 
 
 
3.40 (0.94-12.26) 
3.71 (0.95-14.54) 
 
P-value for comparison of genotypes frequencies between cases vs controls using Fisher’s 
exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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Table 3.28 Statistical analysis of combined effect of NAT2 acetylator status and 
GSTM1 ‘null’ polymorphism in ATD-DILI  
 
    
Combined European-South Asian    
cohorts 
Case 
(n=25) 
Control 
(n=90) 
 P-value  OR (95% CI) 
 Slow acetylator + GSTM1 null 
 Slow acetylator + GSTM1 present 
 Rapid acetylator + GSTM1 null 
 Rapid acetylator + GSTM1 present 
 
   
  14 (0.56) 
    7 (0.28) 
    3 (0.12) 
    1 (0.04) 
     
  23 (0.26) 
  26 (0.29) 
  15 (0.17) 
  26 (0.29) 
 
0.007 
1.000 
0.760 
0.008 
 
3.71 (1.48-9.31) 
1.04 (0.39-2.80) 
1.47 (0.39-5.53) 
9.75 (1.25-75.87) 
 European cohorts  Case 
(n=13) 
Control 
(n=50) 
 P-value  OR (95% CI) 
 Slow acetylator + GSTM1 null 
 Slow acetylator + GSTM1 present 
 Rapid acetylator + GSTM1 null 
 Rapid acetylator + GSTM1 present 
 
   
    7 (0.54) 
    3 (0.23) 
    2 (0.15) 
    1 (0.08) 
     
  13 (0.26) 
  12 (0.24) 
  11 (0.22) 
  14 (0.28) 
 
0.092 
1.000 
0.729 
0.162 
 
3.32 (0.94-11.71) 
1.05 (0.25-4.46) 
1.55 (0.30-8.07) 
4.67 (0.55-39.32) 
 South Asian cohorts  Case 
(n=12) 
Control 
(n=40) 
 P-value  OR (95% CI) 
 Slow acetylator + GSTM1 null 
 Slow acetylator + GSTM1 present 
 Rapid acetylator + GSTM1 null 
 Rapid acetylator + GSTM1 present 
 
   
    7 (0.58) 
    4 (0.33) 
    1 (0.08) 
    0 (0.00) 
     
  10 (0.25) 
  14 (0.35) 
    4 (0.10) 
  12 (0.30) 
 
0.042 
1.000 
1.000 
0.047 
 
4.20 (1.09-16.24) 
1.08 (0.28-4.22) 
1.22 (0.12-12.11) 
5.14 (0.60-44.12) 
 
 South Asian cohorts  
Case 
(n=12) 
ATD-tolerant 
control (n=81) 
 P-value  OR (95% CI) 
 Slow acetylator + GSTM1 null 
 Slow acetylator + GSTM1 present 
 Rapid acetylator + GSTM1 null 
 Rapid acetylator + GSTM1 present 
 
   
    7 (0.58) 
    4 (0.33) 
    1 (0.08) 
    0 (0.00) 
     
      17 (0.21) 
      21 (0.26) 
      13 (0.16) 
      30 (0.37) 
 
0.147 
0.728 
0.685 
0.054 
 
2.69 (0.76-9.54) 
1.43 (0.39-5.24) 
2.10 (0.25-17.72) 
7.06 (0.87-57.03) 
 
 
P-value for comparison of genotypes frequencies between cases vs controls using Fisher’s 
exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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3.3.2.8 SOD2 
 
The association of SOD2 polymorphisms and their risk with ATD-DILI in the combined 
dataset and the European and South Asian cohorts separately are shown in Table 3.29, 
Table 3.30 and Table 3.31 respectively. Two SNPs in SOD2 (rs4880 and rs5746136) 
were selected and genotyped. No significant association was found between the case 
and control groups either in the combined dataset or in the European and South Asian 
cohorts separately (p>0.05). 
 
 
Table 3.29 Association of SOD2 genotypes and the risk of ATD-DILI in combined 
European-South Asian cohorts 
 
   SOD2 
 
Genotypes 
 
Cases           
(n=26) 
 
 
Controls 
(n=90) 
 
Cases vs Controls 
P-value  OR (95% CI) 
 
 rs4880 
 
TT 
TC 
CC 
CC+TC vs TT 
 
  7 (0.27) 
12 (0.46) 
  7 (0.27) 
 
 
 20 (0.22) 
 45 (0.50) 
 25 (0.28) 
 
 
 
 
 
0.61 
 
 
 
 
 1.29 (0.47-3.50) 
 
 rs5746136 
 
GG 
GA 
AA 
GA+AA vs GG  
 
 
  8 (0.31) 
16 (0.61) 
  2 (0.08) 
 
 42 (0.47) 
 39 (0.43) 
   9 (0.10) 
 
 
 
 
 
0.18 
 
 
 
 
 1.97 (0.78-4.99) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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Table 3.30 Association of SOD2 genotypes and the risk of ATD-DILI in European 
cohorts 
 
   SOD2 
 
Genotypes 
 
Cases           
(n=13) 
 
 
Controls 
(n=50) 
 
Cases vs Controls 
P-value  OR (95% CI) 
 
 rs4880 
 
TT 
TC 
CC 
CC+TC vs TT 
 
  3 (0.23) 
  7 (0.54) 
3 (0.23) 
 
 
 11 (0.22) 
 23 (0.46) 
 16 (0.32) 
 
 
 
 
 
0.74 
 
 
 
 
 1.57 (0.38-6.50) 
 
 rs5746136 
 
GG 
GA 
AA 
GA+AA vs GG  
 
 
  4 (0.31) 
  9 (0.69) 
 
 
 25 (0.50) 
 21 (0.42) 
   4 (0.08) 
 
 
 
 
 
0.35 
 
 
 
 
 2.25 (0.61-8.27) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
 
 
 
Table 3.31 Association of SOD2 genotypes and the risk of ATD-DILI in South 
Asian subjects 
 
SOD2 
   rs4880 
 
TT 
 
TC 
 
CC 
 
P-value 
 
 OR (95% CI) 
  Cases (n=13) 
  ATD-tolerant controls (n=81) 
  Community controls (n=40) 
 
  4 (0.31) 
11 (0.14) 
  9 (0.23) 
   5 (0.38) 
 36 (0.44) 
 22 (0.55)   
   4 (0.31) 
 34 (0.42) 
   9 (0.23) 
 
0.21 
0.71 
 
2.83 (0.74-10.79) 
1.53 (0.38-6.16) 
   rs5746136 
 
GG 
 
GA 
 
AA 
 
P-value 
 
 OR (95% CI) 
  Cases (n=13) 
  ATD-tolerant controls (n=81) 
  Community controls (n=40) 
 
  4 (0.31) 
40 (0.49) 
17 (0.42) 
   7 (0.54) 
 34 (0.42) 
 18 (0.45)   
   2 (0.15) 
   7 (0.09) 
   5 (0.13) 
 
0.25 
0.53 
 
2.20 (0.63-7.71) 
1.67 (0.44-6.32) 
 
P-value for comparison of genotypes frequencies possession of one or two variant alleles between 
cases vs controls using Fisher’s exact 2 tailed test; OR, odds ratios; CI, confidence interval 
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3.3.3 NAT1 
 
As preliminary evidence from a genome-wide association study on the European ATD-
DILI cases suggested that rs2739685 showed borderline significance for a genome-wide 
association using a different control group (Daly and Shen, unpublished), it was decided 
to genotype all the ATD-DILI cases and the controls for this SNP. A Taqman SNP 
genotyping assay used in this study produced a satisfactory allelic discrimination for 
rs2739685 SNP in all the DNA samples. Figure 3.25 shows three distinct genotype 
clusters from the intensity plot of an allelic discrimination assay using VIC and FAM 
dyes. The generation of the fluorescent signals from VIC and FAM probes only occur in 
the presence of the complementary target sequence to indicate the specific allele. The 
allelic distribution was in Hardy Weinberg equilibrium in both European (p=0.335) and 
South Asian cohorts (p=0.997). As shown in Table 3.32, the frequency of allele C was 
significantly higher in the European cases than controls (OR=7.13; 95% CI=1.86-27.34). 
Fisher’s exact test revealed a significant association between the variant allele (C) and 
the risk of ATD-DILI (p=0.006), suggesting its role of conferring increased risk of the 
development of ATD-DILI. If correction for multiple testing is performed which for a 
total of 15 genotyping assays results in the level of significance set at 0.0033, the 
association observed here is not statistically significant. In the South Asian cohorts, an 
increased frequency of the carriage of T allele was found in the cases but it was not 
statistically significant when compared to the ATD-tolerant controls (OR=2.68; 95% 
CI=0.76-9.40; p=0.14) and community controls (OR=3.75; 95% CI=0.98-14.33; 
p=0.06). In the combined dataset, no significant association was detected between NAT1 
genotypes and ATD-DILI. The lack of association in the combined dataset could be due 
to the allelic heterogeneity between the two populations. The minor allele frequencies 
(MAF) and its 95% confidence interval (CI) values of our present community control 
data sets were analysed and compared against genotypes data from population based 
controls. Using the publicly available data from the British 1985 Birth Cohort 
(http://www.b58cgene.squl.ac.uk/), the MAF from 1398 population controls was 15% 
(95%CI=13-16%). In our present European community controls data set, the MAF was 
12% (95%CI=7-17%), similar to that in the population control group. On the other hand, 
genome data of Gujarati Indians in Houston (n=88) obtained from Ensembl genome 
viewer (http://www.ensembl.org/index.html) was used as the ethnically matched control 
to compared with our South Asian cohort. The published MAF of Gujarati Indians was 
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34% (95%CI=29-39%) which is similar to our South Asian cohort (MAF=32% 
(95%CI=24-39%).  
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Figure 3.25 Allelic discrimination plot of the DNA samples 
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Vertical axis represents relative fluororesence for FAM label (marker of T-major 
allele); horizontal axis represents relative fluorescence for VIC label (marker of 
C- minor allele). Cluster colored blue is homozygous TT genotype. Green 
colored cluster is heterozygous TC genotype while red cluster is homozygous CC 
genotype.Grey colored cluster denotes the no template control (containing 
distilled water).  
Allelic Discrimination Plot  
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        Table 3.32 Association of NAT1 genotypes and the risk of ATD-DILI  
 
NAT1 
 rs2739685 
 
TT 
 
TC 
 
CC 
 
P-value 
 
 OR (95% CI) 
 
Combined European-
South Asian cohorts 
Cases (n=26) 
Community controls (n=90) 
 
 
 
 
13 (0.50) 
53 (0.59) 
 
 
 
 
10 (0.38) 
31 (0.34) 
 
 
 
 
  3 (0.12) 
  6 (0.07) 
 
 
 
 
 
0.50 
 
 
 
 
 
1.43 (0.60-3.44) 
 
 
 
European cohorts 
Cases (n=13) 
Community controls (n=50) 
MAF=12% (95% CI=7-17%) 
 
 
 
 
  4 (0.31) 
38 (0.76) 
 
 
 
 
  6 (0.46) 
12 (0.24) 
 
 
 
  3 (0.23) 
  0 (0.00) 
 
 
 
 
0.006 
 
 
 
 
 7.13 (1.86-27.34) 
 
 
South Asian cohorts 
Cases (n=13) 
ATD-tolerant controls (n=81) 
Community controls (n=40) 
MAF=32% (95%CI=24-39%) 
 
 
 
  9 (0.69) 
37 (0.46) 
15 (0.38) 
 
 
 
  4 (0.31) 
33 (0.41) 
19 (0.48) 
 
 
  0 (0.00) 
11 (0.14) 
  6 (0.15) 
 
 
 
0.14 
0.06 
 
 
 
 2.68 (0.76-9.40) 
 3.75 (0.98-14.33) 
 
P-value for comparison of genotypes frequencies between cases vs controls using Fisher’s exact 2 
tailed test; OR, odds ratios; CI, confidence interval; MAF, minor allele frequency 
 
 
 
3.4 Discussion 
 
The NAT2 polymorphism has been shown as a major susceptibility risk factor for ATD-
DILI; variants associated with slow acetylation showed an increased risk of ATD-DILI 
and this clear association has been confirmed in several studies (Bose et al., 2011; Lee 
et al., 2010; Kim et al., 2009; Bozok Cetintas et al., 2008; Possuelo et al., 2008; Cho et 
al., 2007; Huang et al., 2002; Ohno et al., 2000) including our present findings. The 
frequency of the slow acetylator genotypes in the present study is significantly higher in 
cases (85%) compared to the community controls (54%) with a p-value of 0.006 
(OR=4.60; 95% CI=1.47-14.44) in the combined European-South Asian cohorts. When 
the data from this combined analysis was used for sensitivity analysis, it was found that 
though sensitivity and negative predictive values were high at 85% and 0.99 
respectively, specificity was relatively low at 46% and the positive predictive value was 
only 0.03. This means that if genotyping for NAT2 was performed before prescribing 
isoniazid and slow acetylators were not given this drug, only 3 cases of anti-TB DILI 
would be prevented for every 100 cases tested with many patients being deprived of 
  
 
143 
beneficial isoniazid treatment unnecessarily and possibly prescribed more toxic drugs 
instead. 
 
When the cohorts were studied separately, slow acetylator status in the South Asian 
cohort was found to be associated with an increased susceptibility to ATD-DILI with 
the p-value of 0.002 (OR=13.58; 95% CI=1.69-109.4) when compared to the ATD-
tolerant controls. Similar observations was found in India which showed a statistically 
significant increased frequency of the slow acetylator genotypes in cases (71%) 
compared to the ATD-tolerant controls (45%) with a p-value of 0.005 (OR=2.99; 95% 
CI=1.4-6.2) (Bose et al., 2011). However the differences of the slow acetylator 
frequencies were not significant between cases and controls in the European cohort (p-
value=0.12) which may be a consequence of having insufficient statistical power due to 
small sample sizes (n=13). When the variants of NAT2 in the exon region (481C>T, 
590G>A and 857G>A) were examined separately, 590G>A polymorphism or NAT2*6 
allele was the only SNPs found to be associated to ATD-DILI in the European cohort 
alone with a p-value of 0.028 (OR=6.96; 95% CI=1.33-36.57). The lack of significant 
association of  NAT2*6 allele with ATD-DILI susceptibility observed in cases of the 
South Asian cohorts could be due to their high frequency of NAT2*6 allele (42%) in the 
controls compared to the European controls (27%). The prevalence of NAT2*6 allele is 
low in East Asians with approximately 20% reported in Korean and Taiwan (Lee et al., 
2010; Kim et al., 2009; Huang et al., 2002). Nevertheless, Kim and colleagues have 
reported that NAT2*6 allele was significantly associated with ATD-DILI susceptibility 
(p-value=0.0016) in the Korean population (Kim et al., 2009). Similar observations 
were found by Huang and colleagues where a higher frequency of NAT2*6 allele was 
detected in DILI cases compared to the ATD-tolerant controls (P<0.05) among the 
Taiwanese (Huang et al., 2002). It is however another study based in Taiwan which 
reported neither NAT2*6 nor NAT2*5 (481C>T) alleles were associated with the risk of 
ATD-DILI. Instead, a significant association between NAT2*7 (857G>A) allele and the 
risk of ATD-DILI was found (Lee et al., 2010). In our current study, NAT2*5 allele was 
highly prevalent (42%) among the South Asians which is in agreement with a previous 
study based in India (Bose et al., 2011) indicating that this allele is very common in the 
Indian/South Asian population. NAT2*5 allele was rare among the East Asians with a 
low frequency of 7%, whereas the NAT2*6 and NAT2*7 alleles were predominant (47% 
and 25% respectively) in Taiwanese population (Lee et al., 2010; Huang et al., 2002). 
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NAT2*7 allele was rare among the Europeans (2%) compared to that in South Asians 
(11%) as shown in our current study. When the three alleles were further assigned into 
slow and rapid acetylator phenotypes, both European and South Asian cohorts showed a 
similar frequency of slow acetylator distribution (50-60%), higher than those reported in 
East Asian cohorts (10%). A meta-analysis showed a stronger significant association of 
slow acetylator status with ATD-DILI when the analysis was limited to Asian 
populations (OR=2.52; 95%CI=1.49-4.26) compared to the results from a combination 
of various ethnicity (OR= 1.93; 95%CI 0.81-4.62) (Sun et al., 2008), indicating 
heterogeneity between and within populations could account for the lack of association 
of NAT2 slow acetylator status with ATD-DILI susceptibility. This ethnic heterogeneity 
for the NAT2 effect was observed in two studies based in Europe and Canada with 
mixed ethnicity where no association of risk with acetylator status was found (Yamada 
et al., 2009; Vuilleumier et al., 2006). A polymorphism (-9796T>A) in the NAT2 
promoter region was found to be associated with decreased expression of NAT2 and 
individuals carrying the variant -9796 A allele and NAT2*6 allele were predisposed to 
ATD-DILI (p=0.0004) (Kim et al., 2009). In the present study, a strong linkage 
disequilibrium between -9796 A allele and NAT2*6 allele was observed in both cases 
(p=0.0008) and controls (p<0.0001). Both alleles were also found to be associated to 
ATD-DILI in the European cohort with a p-value of 0.028 (OR=6.96; 95% CI=1.33-
36.57), indicating that these variants in the promoter and exons of NAT2 increase the 
risk of ATD-DILI by decreasing the expression of NAT2 thus confer slow acetylator 
status. As well as numbers of cases being small and of more than one ethnic origin, an 
additional limitation of the present study is that the majority of the patients studied had 
been treated with additional ATD to INH. Though generally causality had been 
demonstrated between exposure to ATD and onset of DILI, it is not possible to 
determine which drug caused DILI and the numbers studied are too small to look at 
separate drug groups. It remains possible that some of the observed DILI was caused by 
pyrazinamide exposure, but DILI due to this drug is unlikely to relate to NAT2 
genotype.  
 
Besides NAT2, association between CYP2E1 and ATD-DILI have been reported. Huang 
and colleagues have reported that the CYP2E1 c1/c1 genotype which is associated with 
the CYP2E1*5B allele shows higher CYP2E1 activity and therefore may lead to a 
greater production of hepatotoxic intermediates by the increased oxidation of 
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acetylhydrazine (Huang et al., 2003). Another two independent studies based in China 
(Wang et al., 2010) and Taiwan (Lee et al., 2010) have also reported a significant 
association between ATD-DILI and CYP2E1 c1/c1 genotype. The CYP2E1*5B (c2 
allele) occurs in approximately 24% of the East Asian population (Lee et al., 2010; 
Wang et al., 2010; Huang et al., 2003), but was rarely found in our present study cohorts 
(<2%). The lack of significant association observed in our present study cohorts might 
be explained by the substantially lower statistical power caused by the lower prevalence 
of CYP2E1 c2 allele. However the high frequency of the c1 allele (>98%) may indicate 
a high prevalence of ATD-DILI susceptibility in the South Asian and European cohorts. 
Controversial results have been reported in some studies with no association found 
between CYP2E1*5B and susceptibility to ATD-DILI in Korean (Kim et al., 2009; Cho 
et al., 2007) and British Columbian population of Canada (Yamada et al., 2009). This 
may indicate that the role of CYP2E1 in determining ATD-DILI may be less important 
compared to NAT2. However the combined risk for ATD-DILI associated with CYP2E1 
genotype and acetylator status may be essential to predict the risk of ATD-DILI. Huang 
and colleagues have demonstrated an increased risk of ATD-DILI in patients with 
combined slow acetylator status with CYP2E1 c1/c1 genotype (OR=7.43; 95% CI=2.42-
22.79) compared to patients possess NAT2 rapid status and CYP2E1 c1/c1 genotype 
(OR=3.94; 95%CI=1.45-10.67) (Huang et al., 2003). Bose and colleagues have also 
shown that slow acetylators carrying the CYP2E1 mutant CD or CC genotype were 
predisposed to develop ATD-DILI (OR=4.76; 95%CI=2.19-10.48) compared to rapid 
acetyators with CYP2E1 mutant CD or CC genotype (Bose et al., 2011).   
 
In present study, some evidence for associations between polymorphisms in the 
glutathione S-transferase genes, particularly GSTM1 and GSTA4 and ATD-DILI was 
found, suggesting a protective role of these enzymes in preventing ATD-DILI. 
However, these associations were not significant after correction for multiple testing. 
GSTA4 plays a major role against liver injury by its detoxifying effects through the 
conjugation of glutathione with harmful electrophiles generated during oxidative stress 
and lipid peroxidation (Zimniak et al., 1994). In particular, GSTA4 has been reported to 
conjugate with 4-hydroxynonenal, a mutagenic compound produced during oxidative 
stress and lipid peroxidation (Esterbauer et al., 1991). Though polymorphisms in 
GSTA4 have not been extensively studied, associations between GSTA4 variants with 
Alzheimer’s disease and Parkinson’s disease have been suggested, which may both be 
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linked to ROS exposure (Coppede et al., 2005). The result produced by this study 
suggests that the GSTA4 haplotype [C-T-A-A-A] carrying A allele at rs316128 and 
rs3756980 (OR=2.86; 95%CI=1.14-7.2) is associated with increased risk of ATD-DILI 
but loses significance after correction for multiple testing. For GSTM1 genotyping 
analysis, we observed an increased incidence of GSTM1 null mutation in the cases 
(68%) compared to the controls (42%) with a p-value of 0.026 (OR=2.91; 95% 
CI=1.14-7.43) in the combined European-South Asian cohorts. This result is consistent 
with two other studies involved Indian (OR=2.13; 95%CI=1.25-3.50) and Taiwanese 
populations (OR= OR=2.23; 95%CI=1.07-4.67) (Huang et al., 2007; Roy et al., 2001). 
However, when our studied cohorts were analysed separately, frequency of the GSTM1 
null genotype was higher in the cases than the controls but this was not statistically 
significant in neither European nor South Asian cohorts (p>0.05). This could be 
possibly due to an inadequate sample size of the European (n=13) and South Asian 
(n=12) to achieve adequate power. A similar observation was made in a Taiwanese 
population where the frequency of GSTM1 null genotype was higher in the cases 
(60.6%) than the controls (48.6%) but this was not statistically significant (OR=1.62; 
95%CI=0.94-2.79). Another two studies involving Indian and Caucasians have however 
reported no difference of GSTM1 null genotype between cases and controls (Chatterjee 
et al., 2010; Leiro et al., 2008). It was reported that the frequency of GSTM1 null 
genotype ranges from 20% to 79% in the Indian population (Naveen et al., 2004). India 
has a heterogeneous population with subjects from the southern part differing 
significant from those of the northern and eastern regions, thus require careful 
consideration for subject recruitment. Our current South-Asian cohort has shown a 
frequency of 35% of GSTM1 null genotype in the community controls which was in 
agreement with a previous report based on South India population (30.4%) (Naveen et 
al., 2004). As for the European cohort, we have observed a frequency of 48% of GSTM1 
null genotype among the controls which is similar to studies based in Taiwan (46%), 
China (48.6%) and Spain (41.7%) (Wang et al., 2010; Leiro et al., 2008; Huang et al., 
2007). of 48% 13.1% to 54.5% in Caucasians, from 41.7% to 55.5% in Asians, 46.7% 
in African-Americans, and 26.9% in Africans (Mo et al., 2009). In our present study, 
the risk of ATD-DILI susceptibility was significantly increased in subjects with 
combined NAT2 slow acetylator phenotype and GSTM1 null genotype (OR=3.71; 95% 
CI=1.48-9.31). In contrast, the NAT2 rapid acetylator and GSTM1 null genotype 
combination was higher in the controls (OR=9.75; 95% CI=1.25-75.87). This finding 
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was in agreement to a study reported by Fukino and colleagues which involved 
Japanese populations (Fukino et al., 2008). In their study, the genotypes of genes coding 
for drug-metabolising enzymes involved in INH metabolism including NAT2, CYP2E1, 
GSTT1 and GSTM1, and their relationship with serum concentrations of INH and its 
metabolites were examined in 129 tuberculosis patients. It was found that serum 
concentration of hydrazine was significantly higher in subjects with NAT2 slow 
acetylator phenotypes, high concentration of serum RMP, and GSTM1 null genotype. 
Hydrazine, a major INH toxic metabolite can be formed both directly by amidase-
catalysed hydrolysis of INH or indirectly by amidase-catalysed hydrolysis of acetyl 
isoniazid. Studies have indicated that hydrazine plays an important role in the 
mechanism of INH-induced hepatotoxicity in animals and human (Sarich et al., 1999; 
Woo et al., 1992). It has also been demonstrated that RMP enhance idiosyncratic 
hepatocellular reactions by inducing formation of hydrazine from isoniazid particularly 
in slow acetylators (Sarma et al., 1986). Thus, GST enzymes could play an important 
role to limit or prevent ATD-DILI by reducing INH toxic metabolites or neutralising 
toxic products of oxidative stress such as 4-hydroxynonenal, particularly in slow 
acetylators.  
 
PXR genotype was studied because RMP treatment may lead to the increased 
expression of certain genes including various CYPs and carboxyesterases that may be 
relevant to INH metabolism. The SNP studied had been shown to be functionally 
significant and a risk factor for flucloxacillin-induced DILI (Andrews et al., 2010) but 
had not been studied previously in ATD-DILI. No association was detected but as with 
the other genes studied, the possibility of a small effect not detectable because of lack of 
statistiual power cannot be ruled out. 
 
A significant association was detected between a NAT1 SNP (rs2739685) and ATD-
DILI in European cohort (OR=7.13; 95% CI=1.86-27.34). This result confirmed the 
preliminary evidence from a genome-wide association study on the European ATD-
DILI cases (Daly and Shen, unpublished). However no association was found in South 
Asian cohort and also currently there is no clear role of this gene in the metabolism of 
anti-tuberculosis medications. Further studies are required to elucidate a possible role 
for NAT1 in ATD-DILI. In our present study, we found no association of ATD-DILI 
susceptibility with GSTA1, GSTT1, SOD2, CYP2E1 and PXR. We could not confirm the 
  
 
148 
previous findings that the risk of ATD-DILI is higher in subjects with GSTT1 null 
genotype (OR=2.60; 95%CI=1.08-6.24) (Leiro et al., 2008), the C variant allele of 
SOD2 (OR=2.47; 95%CI=1.13-5.39) (Huang et al., 2007) or CYP2E1 alleles (Bose et 
al., 2011; Lee et al., 2010; Wang et al., 2010; Vuilleumier et al., 2006; Huang et al., 
2003). In addition, genotyping for an additional SOD2 SNP so that the main haplotypes 
were tagged did not indicate any further SOD2 association. SOD2 is an attractive 
candidate gene for susceptibility to DILI induced by a variety of drugs because of its 
major role in protecting against oxidative stress. An association has been reported with 
SOD2 C homozygotes suggested to be more prone to suffer DILI from drugs that are 
hazardous to mitochondria or produce reactive intermediates (Lucena et al., 2010). 
Though INH is a drug which may be in this category, the studies performed here did not 
confirm this association with C homozygotes. 
 
HLA genotypes are also important genetic risk factors for DILI due to certain drugs 
(Daly, 2010). Though the present study did not consider HLA genotypes in ATD-DILI, 
the absence of HLA-DQA1*0102 (OR=4.0), and the presence of HLA-DQB1*0201 
alleles (OR=1.9) (Sharma et al., 2002) have been suggested to be risk factors 
previously. However, recent GWAS analysis of the European ATD-DILI cases did not 
find any evidence that HLA genotype was a predictor for this form of DILI (Daly and 
Shen, unpublished). Nevertheless, the previously reported HLA class II gene association 
may indicate the possibility of some cases of ATD-DILI involving an adaptive immune 
mechanism. It has been previously shown that INH can induce other immune responses, 
in particular autoimmunity similar to lupus (Salazar-Paramo et al., 1992).  
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Chapter 4. In Vitro Hepatotoxicity and                                        
Interactions between Anti-tuberculosis Drugs 
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4 In vitro hepatotoxicity and interactions between 
anti-tuberculosis drugs 
4.1 Introduction 
 
Rifampicin (RMP) is an effective antibiotic and prescribed along with isoniazid (INH) 
for the treatment of TB. It has been reported that the concurrent use of RMP and INH 
has resulted in increased incidence of hepatotoxicity (2.6%), greater than when these 
drugs were administrated separately (1.6% with INH and 1.1% with RMP alone) (Steele 
et al., 1991). Though RMP combined with pyrazinamide (PZA) has been used 
previously for treating latent TB, a two months regimen of PZA and RMP is no longer 
recommended as severe and fatal cases of hepatotoxicity were observed among patients 
receiving the RMP plus PZA regimen (CDC, 2003; Lee et al., 2002). The additive or 
synergistic adverse effects of RMP with other anti-TB drugs could be due to its potent 
inducing or suppressing effect on drug-metabolising enzymes, which can result in 
clinically relevant drug-drug interactions (Grange et al., 1994). Studies have indicated 
that RMP administration may induce the formation of hepatotoxic hydrazine 
metabolites by stimulating the INH hydrolase activity in the non-acetylating hydrolysis 
metabolic pathway (see section 1.6) particularly in individuals with the slow acetylator 
phenotype (Fukino et al., 2008; Askgaard et al., 1995; Sarma et al., 1986). A previous in 
vivo study in rats suggested that hydrazine induced the cytochrome P4502E1 (CYP2E1) 
and increased the hepatotoxicity of INH (Yue et al., 2004). CYP2E1 is a major 
contributor of reactive oxygen species (ROS) and has been associated with lipid 
peroxidation stimulation which plays an important role in the development of INH-
induced hepatotoxicity (Caro and Cederbaum, 2004). Recently, it has been proposed 
that RMP enhanced INH-induced toxicity via induction of CYP2E1 in primary human 
hepatocytes in vitro (Shen et al., 2008). However, there is controversy about the 
CYP2E1-inducing effect of RMP seeing that the levels of CYP2E1 mRNA and protein 
were not increased by RMP in human hepatocytes in vitro as well as rat liver in vivo 
(Yue et al., 2009; Raucy et al., 2004; Yue et al., 2004; Rae et al., 2001).  On the 
contrary, it appears that RMP suppresses the expression of CYP2E1 in rats and thus 
reduces the risk of INH-induced oxidative stress through hepatic CYP2E1 (Yue et al., 
2009; Yue et al., 2004). Previous studies in mice also demonstrated that RMP protects 
against carbon tetrachloride-induced hepatotoxicity by suppressing CYP2E1 expression 
and therefore reduced the formation of free radicals (Takeda et al., 2000; Huang et al., 
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1995). It has also been suggested that another drug-metabolising enzyme rather than 
CYP2E1 could be involved in the adverse effects of RMP in INH-induced 
hepatotoxicity (Shen et al., 2008).  
 
RMP binds to nuclear pregnane X receptor (PXR) resulting in the activation of target 
genes that involved in xenobiotic detoxification and excretion. It promotes the 
upregulation of phase I CYP450 enzymes such as CYP2B6, CYP2C8, CYP2C9 and 
CYP3A4 (Song et al., 2004; Kliewer et al., 2002). CYP3A4, the most abundant 
CYP450 isoform, comprises approximately 50% and 60% of total P450 expressed in 
human liver and small intestine respectively (Kolars et al., 1994; Shimada et al., 1994). 
CYP3A4 is more efficiently induced than other CYP450 enzymes and catalyses the 
metabolism of 50-60% of clinically prescribed drugs subject to P450 metabolism (Desai 
et al., 2002; Gibson et al., 2002). Variations in its catalytic activity occur in humans 
resulting in individual differences in the oral bioavailability of CYP3A4 substrates 
(Evans and McLeod, 2003; Guengerich, 1999; Shimada et al., 1994). These differences 
may be of clinical significance and affect the disposition of drugs and their metabolites 
which in turn increase drug toxicity due to toxic metabolites accumulation and 
CYP3A4-mediated drug-drug interactions (Martinez-Jimenez et al., 2007). In addition 
to CYP3A4, RMP has been shown to induced the expression of carboxylesterase 2 
(CES2) in cultured human and rat hepatocytes (Yang and Yan, 2007; Zhu et al., 2000). 
CES2, highly expressed in the human small intestine and liver, plays an important role 
in the metabolism and detoxification of drugs/prodrugs by increasing their 
bioavailability and aqueous solubility (Satoh et al., 2002). It is possible that the induced 
expression of CES2 by RMP stimulates the INH hydrolysis pathway and increases the 
formation of toxic metabolite hydrazine. Furthermore, INH-induced toxicity was greatly 
reduced following in vivo administration of carboxylesterase inhibitor, bis-p-
nitrophenyl phosphate (Tafazoli et al., 2008; Mitchell et al., 1975).  
In the present study, we investigated the role of RMP in regulation of CYP2E1, 
CYP3A4 and CES2 expression in LS180 cells and also in human hepatocytes. LS180 is 
a well characterized human intestinal colon carcinoma cell line and appears to be 
responsive to RMP, in contrast to other cell lines such as HepG2, thus making it a 
suitable model for intestinal drug absorption studies. Human hepatocytes cultured in 
vitro are excellent hepatic model system in predicting enzyme induction in vivo and 
valuable for evaluating the effects of xenobiotics on drug-metabolizing enzyme 
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induction, particularly of the CYP450 family. The aim was to examine the expression of 
these genes in the presence or absence of RMP and the response of the cells to INH and 
PZA treatment in the presence or absence of RMP.  
 
4.2  Materials and Methods 
4.2.1 Cell culture of human hepatocytes  
 
Fresh human primary hepatocytes from three donors were purchased from Gibco-
Invitrogen Corporation (UK) in a 24-well plate with a density of 3x10
5 
cells per well. 
Immediately upon arrival, the medium of the hepatocytes were replaced with Williams’ 
medium E (WME) supplemented with 1μg/ml insulin (Sigma), 50µg/ml gentamicin 
(Sigma), 100U/ml Penicillin (PAA), 10mg/ml Streptomycin (PAA) and 2 mM 
Glutamine (PAA). The cells were allowed to settle overnight prior to any treatment.  
 
4.2.2 Cell proliferation effects of RMP combined with INH and PZA 
4.2.2.1 LS180 cells 
 
The effects of RMP combined with INH and PZA on cell proliferation were assessed by 
performing the MTT assay according to section 2.8. The intestinal human colon 
adenocarcinoma cell line LS180 (passage number 56-62) was cultured according to 
section 2.3 and seeded overnight in a 6-well plate at 1x10
6
 cells per well. To examine 
the effects of RMP on cell viability, LS180 cells were either pre-treated with 50 µM 
RMP for 72 h before adding INH or pre-treated with 0.5% DMSO for 72 h followed by 
simultaneous treatment of RMP and INH for 48 h. A control without RMP treatment 
was included by pre-treating the cells with 0.5% DMSO for 72 h followed by 0, 40, 50, 
60, 70 and 80 mM INH for 48 h. In addition, the effect of RMP on PZA response was 
examined by exposing the cells with 0, 25, 50 and 75 mM of PZA for 24 h with or 
without 72 h RMP pre-treatment. Assays were performed in duplicate from three 
independent experiments.  
 
4.2.2.2 Human hepatocytes 
 
The cytotoxic effects of RMP on INH in human primary hepatocytes were determined 
by the MTT assay (see section 2.8). To examine the effects of RMP in cell proliferation, 
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hepatocytes were treated with 50 µM RMP or vehicle control (0.5% DMSO) for 72 h 
before proceeding to INH treatment for 48 h. Assays were performed in duplicate from 
three independent experiments, derived from three donors. 
 
4.2.3 Effects of Rifampicin on mRNA expression profile 
4.2.3.1 LS180 cells 
 
LS180 cells were cultured according to section 2.3 and seeded overnight in a 6-well 
plate at 1x10
6
 cells per well. To determine the effect of RMP in the mRNA expressions 
of CES2, CYP2E1 and CYP3A4, LS180 cells were treated with 50 µM RMP or vehicle 
control (0.5% DMSO) for 48 or 72 h. Medium was replaced daily under the same 
condition of drug treatment. Cells were then harvested using a sterile plastic scraper and 
RNA was immediately extracted and reverse-transcribed into cDNA prior to analysis 
(see section 2.6). The Q-RTPCR was performed in triplicate from three independent 
experiments using specific primers listed in Table 2.3. 
 
4.2.3.2 Human hepatocytes 
 
Human hepatocytes derived from three donors were treated with 50 µM RMP or vehicle 
control (0.5% DMSO) for 72 h. Medium was replaced daily under the same condition of 
drug treatment. Cells were then harvested using a sterile plastic scraper and RNA was 
immediately extracted and reverse-transcribed into cDNA. The transcript levels of 
CYP3A4, CYP2E1 and CES2 in these cells were then determined by quantitative RT-
PCR using specific primers listed in Table 2.3.  
 
4.2.4 NAT2 genotyping 
 
To investigate whether NAT2 acetylator genotypes affect the cytotoxic effect of INH, 
NAT2 genotyping was performed on human hepatocytes derived from three donors and 
LS180 cells (see section 3.2.4). Briefly, cells were harvested using a sterile plastic 
scraper and genomic DNA was immediately prepared (see section 2.4). Amplification 
of NAT2 fragment was performed by PCR and RFLP analyses were carried out by 
digesting the PCR product with KpnI, TaqI and BamHI to detect the NAT2*5, NAT*6 
and NAT2*7 mutant alleles respectively. The wild-type NAT2*4 allele is designated 
when none of the mutant alleles are present. The presence of any 2 mutant alleles 
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defines the slow-acetylator phenotype, whereas rapid acetylator have 1 or 2 wild-type 
NAT2*4 alleles.  
 
4.3 Results 
4.3.1 Cell proliferation effects of RMP combined with other anti-TB 
medications 
4.3.1.1 LS180 cells 
 
The effect of 50 µM RMP exposure on INH cytotoxicity was assessed in LS180 cells by 
MTT assay. As shown in Figure 4.1, cells receiving 40 mM INH and RMP 
concurrently are inclined to cell death (P<0.05) compared to RMP pre-treated and no 
pre-treatment control cells. However, a significant INH-induced cell death at 40, 50, 60, 
70 and 80 mM was observed in cells with RMP pre-treatment and concurrent 
administration of RMP and INH compared to the control cells. The EC50 values for cells 
with RMP pre-treatment (49.05 mM) and cells treated with INH and RMP 
simultaneously (48.04 mM) were lower than the control cells (60.33 mM). These 
findings suggest that concurrent or pre-administration of RMP amplifies the effect of 
INH on cell proliferation in LS180 cells. The effect of RMP on PZA response was also 
examined by exposing the cells with 0, 25, 50 and 75 mM of PZA for 24 h with or 
without 72 h RMP pre-treatment. Figure 4.2 reveals that RMP pre-treated cells were 
more susceptible to PZA-induced inhibition of proliferation with a significant difference 
at 60 and 75 mM INH (P<0.001). A lower EC50 (64.86 mM) was also observed in RMP 
pre-treated cells compared to the no pre-treatment cells (78.51 mM), suggesting 
administration of RMP increases the inhibitory effect of PZA on the proliferation of 
LS180 cells.  
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Figure 4.1 The influence of rifampicin co-administration on INH-induced  
decreased cell proliferation in LS180 cells 
 
To examine the effects of RMP on cell proliferation, LS180 cells were either pre-treated 
with 50 µM RMP for 72 h before INH treatment or pre-treated with 0.5% DMSO 
(vehicle control) for 72 h followed by concurrent administration of RMP and INH for 48 
h. The inhibitory effect of INH alone on cell proliferation was also determined by pre-
treating the LS180 cells with 0.5% DMSO for 72 h and followed by 48 h INH treatment 
at 0, 40, 50, 60, 70 and 80 mM. Proliferation was assessed immediately after 96 h of 
INH/RMP treatment using the MTT colorimetric assay.  Treatment with INH causes a 
dose-dependent inhibition of LS180 cell proliferations. The EC50 values of RMP pre-
treated cells (49.05 mM) and concurrent administration of RMP with INH (48.04 mM) 
were lower than the no treatment control cells (60.33 mM). Concurrent or pre-
administration of RMP has significantly inhibited cell proliferation in LS180 when 
treated with 40, 50, 60, 70 and 80 mM INH (P<0.05) which indicates that RMP 
increases the inhibitory effect of INH on the proliferation of LS180 cells. 
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Figure 4.2 The influence of rifampicin co-administration on PZA-induced  
decreased cell proliferation in LS180 cells. 
 
The effect of RMP on PZA response in LS180 cells was examined by exposing the cells 
with 0, 25, 50 and 75 mM of PZA for 24 h with or without 72 h RMP pre-treatment. 
Cells proliferation was assessed immediately after 96 h of PZA/RMP treatment using 
the MTT colorimetric assay. A dose-dependent inhibition on LS180 cell proliferation 
was observed following PZA treatment (0-75 mM). The EC50 value of RMP pre-
treated cells (64.86 mM) was lower than the no treatment control cells (78.51 mM). 
RMP pre-treatment has significantly decreased cell proliferatin compared to the 
control cells when treated with 45, 60 and 75 mM PZA (P<0.001), suggesting that 
RMP increases the inhibitory effect of PZA on the proliferation of LS180 cells. 
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4.3.1.2 Human primary hepatocytes 
 
To evaluate the effect of RMP exposure on cell proliferation, human hepatocytes were 
treated with 50 µM RMP or vehicle control (0.5% DMSO) for 48 h before proceeding 
to INH treatment for 48 h. Figure 4.3 shows the results of MTT assay performed in 
duplicate from three donors.  Hepatocytes from Donor 1 were pre-treated with or 
without RMP followed by INH treatment in the range from 0-10 mM INH. RMP pre-
treatment has reduced cell proliferation compared with cells with no pre-treatment 
(Figure 4.3 (A)). However, no significant differences were found in these cells. It was 
also observed that no inhibitory effect of INH on cell proliferation in this range of 
concentration and therefore a higher concentration of INH (0-50 mM) was applied to 
Donor 2 and 3. As shown in Figure 4.3 (B), reduced cell proliferation caused by RMP 
pre-treatment was observed compare to the control cells. The EC50 value of the RMP 
pre-treated cells was higher (29.89 mM) than the control cells (9.7 mM) with a 
significant increased at 10 mM INH treatment (P<0.05). Conversely, these phenomena 
did not occur in hepatocytes obtained from Donor 3 as RMP pre-treated cells were more 
susceptible to the inhibition of cell proliferation compared to the control cells (Figure 
4.3 (C)).  The EC50 value of the RMP pre-treated cells (16.93 mM) was lower than the 
control cells (38.42 mM) with a significant decrease at 10 mM INH treatment (P<0.05). 
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Figure 4.3 Effect of Rifampicin pre-treatment in hepatocytes derived from (A) 
Donor 1, (B) Donor 2 and (C) Donor 3, evaluated by the MTT assay 
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4.3.2 Effects of Rifampicin on mRNA expression profile 
4.3.2.1 LS180 cells  
 
The effect of RMP exposure on mRNA expression of CYP3A4, CYP2E1 and CES2 
was further evaluated in LS180 cells by quantitative RT-PCR. A typical calculation of 
the relative expression study by using the ∆∆Ct method is shown in Table 4.1. Figure 
4.4 shows the average fold change found in LS180 cells in response to 50 µM RMP 
treatment to corresponding levels in vehicle controls (set as 1), normalized with respect 
to GAPDH mRNA levels. Following exposure to 72 h RMP, CYP3A4 and CES2 
mRNA levels were significantly (p<0.001) increased with 11- and 4-fold induction 
respectively, but the apparent elevation of these mRNA levels seen at 48 h was not 
statistically significant. At 48 h of exposure to RMP, CYP2E1 mRNA level was 
reduced by 30% compared with controls but this was not statistically significant. A 
longer RMP exposure time (72 h) showed no change in CYP2E1 mRNA level in LS180 
cells.  
 
Table 4.1 A sample calculation for the fold change expression of CYP3A4 after 
RMP treatment by using the ∆∆Ct method 
 
Sample 
CYP3A4 
Average Ct 
GAPDH 
Average Ct 
∆Ct 
 
∆∆Ct 
 
2
-∆∆Ct
 
Vehicle control 
(0.5% DMSO) 
 
28.51±0.40 17.34±0.17 11.16 0.00±0.54 1.0±0.35 
50 µM RMP 
treatment (48 h) 
26.47±0.21 16.99±0.12 9.49 –1.68±0.32 3.3±0.66 
 
Data presented are means ± S.D. of triplicates from an independent experiments of the 
fold increase of CYP3A4 mRNA expression levels in LS180 cells to corresponding 
levels in vehicle control (0.5% DMSO), normalized with respect to GAPDH mRNA 
levels. ∆Ct values are calculated (∆Ct = CtCYP3A4 – CtGAPDH), and the effects of RMP on 
the target cDNA was expressed relative to the amount in the vehicle control sample 
(∆∆Ct = ∆Ctcompound - ∆Ctvehicle). Relative fold changes in target gene expression were 
determined by taking 2 to the power of the ∆∆Ct value (2-∆∆Ct). 
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Gene Fold increase in mRNA expression 
 48 h 72 h 
CYP3A4 4.48 ± 2.99 10.59 ± 4.66 
CYP2E1 0.70 ± 0.43 1.07 ± 0.52 
CES2 2.60 ± 0.90 4.05 ± 1.58 
 
Data presented are means ± S.D. of triplicates from three independent 
experiments of the fold increase of CYP3A4, CYP2E1 and CES2 mRNA 
expression levels in LS180 cells to corresponding levels in vehicle control (0.5% 
DMSO), normalized with respect to GAPDH mRNA levels. 
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Figure 4.4 Quantitative RT-PCR analysis of the effect of 50 µM of RMP on 
CYP3A4, CYP2E1 and CES2 mRNA expression level in LS180 cells.  
 
LS180 cells were treated with 50 µM RMP or 0.5% DMSO (control) for 48 or 72 h 
prior to quantitative RT-PCR analysis. (A) Table shown is the average fold change 
found in LS180 cells in response to 50 µM RMP treatment to corresponding levels in 
controls (set as 1), normalized with respect to GAPDH mRNA. A chart (B) was then 
plotted and difference between groups was assessed statistically by two-way ANOVA 
(*P<0.05, **P<0.01, ***P<0.001). 
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4.3.2.2 Human primary hepatocytes 
 
The effect of RMP in the mRNA expression of CYP3A4, CYP2E1 and CES2 in human 
primary hepatocytes was evaluated by quantitative RT-PCR (Figure 4.5). Following 
exposure to 50 µM RMP, approximately a 20-fold (Donor 1 and 2) and 10-fold (Donor 
3) increase in CYP3A4 expression was observed. The CYP2E1 mRNA level in Donor 1 
was not altered by RMP treatment. Conversely, a significant decrease of CYP2E1 level 
was found in Donor 3 (P<0.01) and a marginal significant decrease was observed in 
Donor 2 (P=0.054). The substantial decrease in CYP2E1 expression in Donor 2 and 3 
may be associated with a rapid loss of CYP2E1 expression in these cells. RMP 
treatment caused significant differences in CES2 expression in all donors. Interestingly, 
CES2 expression was elevated in Donor 1 and 2 (P<0.01) but decreased in Donor 3 by 
23% (P<0.05).   
 
4.3.3 Determination of NAT2 genotype 
 
Among the three donors of the human hepatocytes, Donor 1 (NAT2*5/NAT2*4) was a 
rapid acetylator and Donor 2 (NAT2*5/NAT2*7) and Donor 3 (NAT2*6/NAT2*6) were 
found to be slow acetylators. LS180 cells possessed the NAT2*5/NAT2*6 genotype 
and therefore was classified as slow acetylator. 
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 Gene 
Fold increase in mRNA expression 
Donor 1 Donor 2 Donor 3 
 CYP3A4 23.46  ±  4.77 19.70  ±  2.74 11.26  ±  2.01 
 CYP2E1   1.02  ±  0.09   0.69  ±  0.30   0.29  ±  0.16 
 CES2   4.69  ±  2.43   3.12  ±  1.05   0.77  ±  0.31 
   
Data presented are means ± S.D. of triplicates from two independent experiments of 
the fold increase of CYP3A4, CYP2E1 and CES2 mRNA expression levels in human 
hepatocytes from three donors to corresponding levels in vehicle control (set as 1),  
normalized with respect to GAPDH mRNA level. 
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Human hepatocytes from 3 donors were treated with 50 µM RMP or 0.5% DMSO 
(control) for 72 h prior to quantitative RT-PCR analysis. (A) Table shown is the 
average fold change of mRNA expression levels in response to 50 µM RMP 
treatment to corresponding levels in controls (set as 1), normalized with respect to 
GAPDH mRNA. A chart (B) was then plotted and difference between groups was 
assessed statistically by student’s t-test (*P<0.05, **P<0.01, ***P<0.001). 
 
 
 
Figure 4.5 Quantitative RT-PCR of CYP3A4, CYP2E1 and CES2 transcript 
level in human hepatocytes exposed to rifampicin (50 µM) 
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4.4  Discussion 
 
In the present study, the in vitro INH and PZA toxicity in LS180 was increased 
following pre-treatment or concurrent administration of a non-toxic concentration of 
RMP (50 µM) (Figure 4.1 and 4.2). However, in the human hepatocyte samples, 
differential effect of RMP on INH toxicity was demonstrated by the results that RMP 
enhanced INH-induced cytotoxicity in Donor 3 but not in Donor 1 and 2 (Figure 4.3). 
Conversely, RMP pre-treatment was shown to provide some protection against INH-
induced cytotoxicity in Donor 1 and 2. These results suggest the intriguing possibility 
that the altered expression or activity of drug-metabolising enzymes by RMP might 
have a protective role against INH toxicity. The lack of induction of CYP2E1 mRNA by 
RMP in both LS180 and human hepatocytes may indicate that CYP2E1 is unlikely to 
magnify INH toxicity caused by RMP pre-treatment. Furthermore, INH itself is an 
inducer of CYP2E1 (Skakun and Shman'ko, 1985) and therefore free radical generation 
through CYP2E1 induction could be from INH administration. It has been proposed that 
hepatic CYP2E1induction by hydrazine contributes to INH-induced hepatotoxicity in 
rats through free radical generation (Yue et al., 2004). Rats, as well as rabbits appear 
more susceptible to INH-induced hepatotoxicity compared to the human due to a higher 
amidase activity, which catalyses the hydrolysis of INH to hydrazine, enhances 
CYP2E1 and therefore generates more free radicals. In our present study, RMP has 
shown to elevate the CES2 mRNA level in LS180 cells (approximately 2 to 4-fold) 
suggesting that CES2 elevation by RMP may increase the hydrolysis of INH which in 
turn generates more hydrazine. Therefore, it is possible that RMP can elevate CYP2E1 
when RMP is given concomitantly with INH by an indirect mechanism involving CES2 
induction and cause more toxicity to the cells through hydrazine formation. However, 
the moderate induction of CES2 did not demonstrate any obvious toxic effect in our 
current donor 1 and 2 hepatocyte cultures. In addition, a lack of CES2 expression was 
detected in Donor 3, thus suggesting that CES2 may not play a major role in the 
aggravation of INH toxicity by RMP in human hepatocytes. It was recently revealed 
that RMP co-administration significantly reduced INH-induced CYP2E1 activity and 
increased the levels of the glutathione S-transferase mu isoform (GST mu) activity in rat 
liver (Yue et al., 2009). Previous studies in mice also demonstrated that RMP reduced 
the formation of free radicals by suppressing the CYP2E1 expression and may play an 
essential role against carbon tetrachloride-induced hepatotoxicity (Takeda et al., 2000; 
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Huang et al., 1995). Shen et al. presented data showing that RMP exacerbated INH 
toxicity in human hepatocytes possibly through CYP2E1 induction (Shen et al., 2008). 
In that study, hepatocytes from five patients were harvested where Donors 1-3 were 
used to demonstrate the effect of RMP on INH toxicity and CYP2E1 metabolic activity; 
Donors 3-5 were used to evaluate toxicity caused by INH only, and Donor 5 was used 
for CYP2E1 mRNA expression assay. The reliability of the results presented was 
questionable and inconclusive as the hepatocytes from different donors were used for 
separate experiments involving different treatments. According to Yue et al. (Yue and 
Peng, 2009), 4-nitrophenol hydroxylase (4-NPH) activity was the only probe used in the 
paper to demonstrate the increased CYP2E1 activity by RMP but CYP3A was also 
previously found to make a significant contribution to 4-NP activity in human and rat 
hepatocytes. The increase in 4-NPH activity could be due to the induction of CYP3A as 
RMP is a strong inducer of human CYP3A. Semi-quantitative RT-PCR but not 
quantitative RT-PCR was performed on Donor 5 only. The finding of Shen et al. that 
RMP exacerbates INH toxicity in human hepatocytes through increased CYP2E1 
mRNA expression and metabolic activity is therefore questionable and needs 
confirmation by others. In the current study, as expected, RMP has greatly induced 
CYP3A4 and caused a 10 to 20-fold induction of CYP3A4 mRNA expression in LS180 
and human hepatocytes. Previous observations in cultured human hepatocytes and small 
intestinal enterocytes revealed a marked inter-individual difference in CYP3A4 mRNA 
expression caused by RMP induction (Kolars et al., 1992; Watkins et al., 1989). These 
differences affect the oral bioavailability of CYP3A4 substrates and lead to variations in 
drug efficacy and/or toxicity. In the present study, we observed an approximately 10-
fold CYP3A4 induction in LS180 and the hepatocytes from donor 3 after 72 h of RMP 
treatment. Both samples demonstrated a significant increased of INH toxicity caused by 
RMP. On the other hand, we observed a 20-fold CYP3A4 induction in hepatocytes from 
donors 1 and 2 and these observations correlated with an inhibitory effect of RMP in the 
development of INH toxicity. Nevertheless, it was previously reported that CYP3A4 
contributed to INH toxicity in HepG2 cells by increasing the INH toxic metabolites 
(Vignati et al., 2005). Vignati et al. demonstrated that CYP3A4-overexpressing HepG2 
cells exhibit higher INH toxicity and co-incubation with the CYP3A4 inhibitor 
ketoconazole prevented the INH toxicity by reducing the formation of toxic metabolites 
(Vignati et al., 2005). RMP did not increase the INH toxicity in rat and mouse (Yue et 
al., 2009; Takeda et al., 2000; Huang et al., 1995) possibly due to the lack of CYP3A 
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inducibility by RMP in rat and mouse because of differences in the PXR in these 
species  (Martignoni et al., 2006). Hence, another drug-metabolizing enzyme rather than 
CYP3A4 could be involved in the reduced INH toxicity by RMP in hepatocytes from 
donors1 and 2 inour current studies. NAT2 acetylator status of the hepatocyte donors did 
not seem to be the likely factor that leads to RMP-induced INH toxicity as Donor 2 who 
possesses the NAT2 slow acetylator genotype was also shown to have a reduced INH 
cytotoxic effect by RMP.  
 
In addition to CYP3A4, RMP has shown to induce UDP-glucuronosyltransferase 1A 
(UGT1A), some glutathione-S-transferases (GSTs) and multidrug resistance 1 (MDR1) 
(Soars et al., 2004; Rae et al., 2001; Greiner et al., 1999). The upregulation of UGTA1 
by RMP through PXR and CAR promotes UGT glucuronidation of steroids and 
xenobiotics and thus increases the clearance of steroids and potentically toxic 
xenobiotics or their reactive metabolites (Soars et al., 2004; Xie et al., 2003). GSTs play 
an important role in the detoxification by catalysing the conjugation of reactive 
electrophilic alkylating agent of the xenobiotics with reduced glutathione. P-
glycoprotein, a well characterised ATP-binding cassette (ABC) superfamily of transport 
proteins encoded by the ABCB1 gene, is found primarily in the epithelia of drug-
eliminating organs (intestine, liver and kidney) (Fromm, 2003). It is responsible for the 
efflux of toxins and xenobiotics from cells and has also been shown to interplay with 
CYP3A4 in RMP inducing drug-drug interactions (Cummins et al., 2003). RMP did not 
aggravate INH toxicity after 72 h treatment in Donor 1 and 2, which could be due to the 
general upregulation of PXR-mediated detoxification genes (UGT1A, GSTs and p-
glycoprotein) by RMP which enhanced the excretion of both INH and its toxic 
metabolites from hepatocytes. Further work is needed to elucidate the potential role of 
RMP in INH-mediated hepatotoxicity.   
 
The present results using primary human hepatocytes were slightly more sensitive to 
INH toxicity compared to the LS180 cell lines. Primary human hepatocytes appear to 
retain major drug metabolising activities including inducible cytochrome P450 
enzymes, thus making it the most suitable in vitro model for use in drug metabolism and 
toxicity studies. An alternative to our current individual gene expression analysis is 
using the microarray approach which allows a more comprehensive evaluation of the 
effects of drugs by interrogating thousands of genes at once. It is an excellent tool for 
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gene expression studies especially in limited samples such as the primary human 
hepatocytes and provides useful information on the mechanism of drug toxicity. 
However, there are limitations in the use of human primary hepatocytes. One of the 
major limitations is the availability of the healthy human hepatocytes for primary 
culture, which makes it difficult to obtain a reproducible data. The rapid loss of specific 
drug metabolising enzymes especially the P450 enzymes due to dedifferentiation is a 
common problem with primary cultured cells (Elaut et al., 2006). It is notable that the 
human hepatocytes exhibit substantial interindividual variability in response to enzyme 
inducers such as that observed in our study. Recently a hepatoma cell line HepaRG was 
found to retain important hepatic functions for several weeks, including expression of 
the major CYP450 isoforms. It has also been shown to differentiate at levels 
comparable with those found in primary human hepatocytes (Andersson, 2010; Aninat 
et al., 2006). HepaRG cells could therefore provide an alternative to human hepatocytes 
for prediction of drug-induced hepatotoxicity. 
 
In summary, these experiments indicated a modulatory effect by RMP on inhibition of 
cell proliferation by INH though this was rather inconsistent. The ability of RMP to 
induce CES2 expression at the RNA level was confirmed. Hepatocytes showing 
induction of CES2 by RMP treatment showed decreased INH toxicity suggesting that 
the hydrolysis pathway involving hydrazine formation from INH might not be an 
important contributor to overall toxicity. 
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Chapter 5. In Vitro Effects of NAT2 Allelic Variants on 
Isoniazid Toxicity 
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5 In vitro effects of NAT2 allelic variants on isoniazid 
toxicity 
5.1 Introduction 
 
The gene encoding NAT2 is polymorphic, thus resulting in rapid and slow acetylator 
phenotype. As described previously in section 1.6, the predominant pathway of 
isoniazid (INH) is acetylation by the hepatic enzyme NAT2. Early NAT2 phenotyping 
study has shown that the fast acetylator phenotype with detectable NAT2 is associated 
with an increased risk of INH-induced DILI (Mitchell et al., 1975). However, later 
studies have revealed that individuals with the slow acetylator phenotype lacking 
functional NAT2 catalytic activity are more susceptible to developing INH-induced 
DILI due to accumulation of the toxic metabolite acetylhydrazine (Lauterburg et al., 
1985; Dickinson et al., 1981; Timbrell et al., 1980). Approximately 50% of Caucasians 
in Europe are of slow acetylator phenotype and are less efficient than rapid acetylators 
in the metabolism of INH (Blum et al., 1991). The slow acetylator phenotype results 
from nonsynonymous SNPs in the NAT2 coding region. These SNPs have been 
identified and characterized for their functional and structural effects (Table 5.1) 
(Walraven et al., 2008).  
 
Previous studies have investigated the relationship between NAT2 genotype and 
acetylator phenotype through recombinant expression of NAT2 alleles or haplotypes and 
individual SNPs using bacteria (Hein et al., 1995; Hein et al., 1994), yeast (Fretland et 
al., 2001) and mammalian (Zang et al., 2007a; Zang et al., 2004; Blum et al., 1991) cell 
systems. Some of these NAT2 alleles including NAT2*5 (341T>C), NAT2*6 (590G>A) 
and NAT2*7 (857G>A) showed reduced levels of NAT2 protein and also decreased 
NAT2 catalytic activity when compared with NAT2*4 (Zang et al., 2007b; Blum et al., 
1991).  NAT2*5 and NAT2*6  alleles account for more than 90% of slow acetylator 
alleles of the European Caucasians (Blum et al., 1991). Our present study on NAT2 
genotyping has revealed that among the European control subjects, NAT2*5 and 
NAT2*6 alleles account for 60% and 36% of the slow acetylator alleles respectively. A 
strong linkage disequilibrium was reported among the 341T>C, 481C>T and 803A>G 
polymorphisms in European Caucasians as well as North Indian population (Batra et al., 
2006).  
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The aim of this chapter is to examine the functional significance of NAT2 acetylation 
phenotypes using an in vitro overexpression approach to characterise NAT2 acetylation 
phenotypes and their relevance to the development of isoniazid-induced hepatotoxicity. 
Two recombinant plasmids contained the NAT2*4 and NAT2*5 (possessing 341T>C 
and 481C>T variants) alleles were constructed to represent the rapid and slow 
acetylation phenotype respectively.  
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Table 5.1 Non-synonymous SNPs in human NAT2 function and structure*  
 
SNP rs identifier Amino acid 
change 
NAT2 allele/haplotype Functional effect(s) Structural Effect(s) 
190C>T 1805158 R64W NAT2*19 Decreased stability Loss of electrostatic 
interactions 
191G>A 1801279 R64Q NAT2*14 cluster & others Decreased stability Loss of electrostatic 
interactions 
341C>T 1801280 I114T NAT2*5 cluster Increased protein degradation Conformational change 
364G>A 4986996 D112N NAT2*12D Decreased protein Catalytic triad disruption 
411A>T 4986997 L137F NAT2*5I Decreased protein Conformational change 
434A>C - Q145P NAT2*17 Decreased protein Conformational change 
499G>A - E167K NAT2*10 Decreased protein Conformational change 
590G>A 1799930 R197Q NAT2*6 cluster & others Decreased stability Loss of electrostatic 
interactions 
803A>G 1208 K268R NAT2*12 cluster & others No effect None expected 
845A>C 56054745 K282T NAT2*18 Slight decreased stability Loss of electrostatic 
interactions 
857G>A 1799931 G286E NAT2*7 cluster Decreased protein Altered active site size/shape 
 
* Table is adapted from (Walraven et al., 2008)
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5.2 Materials and Methods 
5.2.1 Choice of Cell line 
 
To determine the best choice of cell line for NAT2 overexpression study, HepG2, 
LS180 and Huh 7.5 cell lines were genotyped for common NAT2 alleles using the PCR-
RFLP method (see section 3.4). The cell line with the slow acetylator phenotype was 
used for NAT2 overexpression studies.  
 
5.2.2 Construction of NAT2 recombinant stable cells 
 
Two 879 bp NAT2 open reading frame DNA fragments representing the wild-type 
NAT2*4 and NAT2*5 (possessing 341T>C and 481C>T variants) alleles were 
amplified by PCR from DNA samples of known NAT2 genotype. Comparison of both 
DNA inserts containing the NAT2*4 and NAT2*5 alleles are shown in Figure 5.1. The 
PCR parameters were 35 cycles at 95ºC for 1 min, 55ºC for 1.5 min, and 72ºC for 1.5 
min; forward primer: 5’-GCCACCATGGACATTGAAGCAT-3’and reverse primer: 5’- 
CTAAATAGTAA GGGATCCATCACC -3’. The PCR products were separated on a 
2% agarose gel and purified using QIAGEN Gel Extraction Kit. The amplified product 
was cloned in the mammalian expression vector pTARGET (Promega) to generate a 
rapid acetylator recombinant (RAR) containing the NAT2*4 allele and a slow acetylator 
recombinant (SAR) containing the NAT2*5 allele (see section 2.5). The presence of the 
recombinant construct was confirmed by digesting the plasmid DNA (3 µl) with EcoRI 
restriction enzyme. Figure 5.2 shows the presence of DNA inserts after EcoRI digestion 
of pTARGET plasmids. The sequences of both RAR and SAR plasmids were confirmed 
by sequencing (see section 2.4.6). The plasmids were then stably transfected into 
HepG2 cells and the cells were selected with 500 µg/ml G418 antibiotic for 3-4 weeks 
until the G418-resistant clones were established (see section 2.5.4). The stably 
transfected cells were then maintained in 250 µg/ml G418. 
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Figure 5.1 Comparison of DNA sequences of rapid acetylator recombinant (RAR) 
and slow acetylator recombinant (SAR) plasmids.  
 
The DNA sequences of NAT2 coding region of RAR (NAT2*4 allele) and SAR (NAT2*5) 
plasmids are shown in (A) and (B) respectively. Primers used to amplify the DNA 
fragments of NAT2*4 and NAT2*5 alleles are shown in underline; the start codon (ATG) 
and stop codon (TAG) are shown in blue bold letters; the 341T>C and 418C>T single 
nucleotide polymorphisms (SNPs) are highlighted in red bold letters.  
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Figure 5.2 Ethidium bromide-stained agarose gel pattern showing digested 
pTARGET plasmids 
 
The presence of desired DNA fragments after EcoRI digestion demonstrates the 
successful cloning of insert DNA into the pTARGET plasmids. The upper bands 
(approximately 5,620 bp) of lane 1, 2 and 3 are the linearised pTARGET 
plasmids after EcoRI digestion. The lower bands of lane 1 and 2 are DNA 
fragments of NAT2*4 and NAT2*5A alleles respectively while the lower band of 
lane 3 is the cDNA fragment of GSTA4. 
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5.2.3 Recombinant expression of NAT2 alleles  
 
The NAT2 overexpression efficacy of rapid acetylator recombinant (RAR) and slow 
acetylator recombinant (SAR) were assessed by RT-PCR and immunoblotting. The non-
transfected cells were used as a control. Immunoblotting and RT-PCR were performed 
as described in Section 2.6 and 2.7. For the immunoblot, quantification of the protein 
bands was done by uploading a scanned image of the blot saved as a GIF file into the 
program ImageJ and following the procedure for analysis described for this program 
(http://rsb.info.nih.gov/ij/).  
 
5.2.4 N-acetyltransferase-2 enzyme assay 
 
The NAT2 enzyme activity in RAR, SAR and non-transfected cells were measured by 
the bioluminescent NAT2 enzyme assay (Promega) using a novel luciferin derivative, 
Luciferin-NAT2 as a specific substrate. The Luciferin-NAT2 is prosubstrate for the 
light-generating reaction of firefly luciferase. As shown in Figure 5.3, Luciferin-NAT2 
is substantially converted to a more active luciferin substrate by NAT2 enzyme that is 
detected in a second reaction with luciferin detection reagent (LDR). LDR containing 
firefly luciferase reacts with active luciferin to produce light. The amount of light 
generated is proportional to NAT2 enzyme activity. Briefly, cells were harvested and 
disrupted by sonication in buffer (66 mM NaH2PO4, pH 7.2, 1 mM EDTA, and 2 mM 
DTT). The cell lysates were centrifuged at 12,000g for 10 min at 4˚C and the 
supernatants were immediately assayed. Protein concentration was determined using 
BioRad DC Protein Assay (see section 2.9.1). A stock solution of Luciferin-NAT2 (1 
mM) was prepared in a solution of water and methanol (1:1) containing 2 mM HCl. The 
assay was performed by mixing 25 µl of 80 µM Luciferin-NAT2 solution in assay 
buffer (100 mM HEPES, pH 8) with 23 µl of cell lysate (1:10 dilution with assay 
buffer) and 2 µl of 10 mM acetyl coenzyme A (Acetyl-CoA). The final concentrations 
of Luciferin-NAT2 and Acetyl-CoA were 40 µM and 400 µM respectively. A no-
enzyme background control for each sample was prepared by replacing acetyl-CoA with 
distilled water. The mixture was then incubated for 0-12 h prior to the addition of LDR 
(50 µl). The luminescence was measured 20 min later using a Modulus luminometer 
(Turner Biosystems). NAT2 enzyme activity for each sample was calculated by 
subtracting the background control and expressed in relative luminescent units per mg 
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of sample per h (RLU/mg/h). A positive control consisting of rat liver lysate was 
included each time when the assay was performed. Preparation of rat liver lysate is 
described in section 5.2.5. Figure 5.4 shows the increased NAT2 activity of rat liver 
lysate using various concentration of Luciferin-NAT2 in assay buffer (2.5-80 µM). 
 
 
        
 
NAT2 enzyme
Luciferin Detection Reagent (LDR)
Light
pro-luciferin substrate
active luciferin (substrate)
                                         
Figure 5.3 Detection of NAT2 enzyme activity using Luciferin-NAT2 
The Luciferin-NAT2, a novel luciferin derivative, is a prosubstrate for the light-
generating reaction of firefly luciferase. Acetylation of Luciferin-NAT2 by NAT2 
enzyme produces a more active luciferin substrate for the light-generating 
enzyme in the luciferin detection reagent (LDR). LDR generates light in the 
proportion to the activity of the NAT2.  
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Figure 5.4: NAT2 activity in rat liver lysate using Luciferin-NAT2 
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The Km of Lucifein-NAT2 with rat liver lysate is 22.2 ± 4.0 µM. Rat liver lysate 
were incubated with various concentration of Luciferin-NAT2 in assay buffer for 
1 h before the addition of Luciferin Detection Reagent. Values presented are 
means ± SD, n=3. 
Dose-response curve of rat liver lysates to 
Luciferin-NAT2 
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5.2.5 Rat liver lysate preparation 
 
Rat liver (2 g) was washed repeatedly using homogenisation buffer (0.25 M sucrose in 
10 mM Tris-HCl, pH 7.4 contaning 1 mM EDTA), transferred into a pre-cooled beaker 
and minced into small pieces.  Homogenisation buffer (10 ml) was then added into the 
beaker and the entire contents of the beaker were then transferred into a pre-cooled 
Potter-Elvehjem homogeniser tube. Homogenisation of the liver was done by five 
passess of a Teflon pestle. All steps were carried out at 4°C to reduce proteolysis. The 
homogenate was then transferred into a Beckman centrifuge tube and centrifuged at 
1000 g for 10 min at 4°C. The supernatant was removed into a new centrifuge tube and 
subjected to centrifugation at 12,500 g at 4°C for 15 min. The supernatant was analysed 
on proteins and stored at -80°C. 
 
5.2.6 Functional characterisation of NAT2 acetylation phenotypes  
 
To test whether NAT2 acetylation phenotypes affect isoniazid toxicity, RAR, SAR and 
non-transfected HepG2 cells were subjected to MTT test, GSH assay, DNA 
fragmentation assay and Caspase-3 activity assay (see section 2.8-2.11). A two-way 
ANOVA analysis was performed to identify specific differences between selected 
groups using GraphPad Prism 5.0. In all cases, P<0.05 was required for significance to 
identify specific differences. 
 
 
5.3 Results 
5.3.1 Sequencing  
 
Sequencing traces showing the variation of SNPs (341T>C and 418C>T) in the NAT2 
coding region of RAR and SAR plasmid constructs are presented in Figure 5.5. The 
complete sequencing traces of plasmid inserts for both plasmids are shown in Appendix 
A & B. Sequence analysis showed that no variant (wild type) was detected in the NAT2 
coding region of RAR plasmid while SAR plasmid contained no other variant except for  
341T>C and 481C>T (mutant alleles).  
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TT genotype (position 341)
CC genotype (position 481)
A
 
 
 
CC genotype (position 341)
TT genotype (position 481)
B
 
   Figure 5.5 Sequencing result of the (A) rapid acetylator recombinant (RAR) plasmid 
containing the NAT2*4 wild-type allele and (B) slow acetylator recombinant (SAR) 
plasmid containing the NAT2*5 allele (341T>C and 481C>T) 
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NAT2 genotypes of HepG2, LS180 and Huh 7.5 cell lines were determined using PCR-
RFLP methods. Huh7.5 was found to be a rapid acetylator (NAT2*4/*4) while HepG2 
and LS180 cells possess NAT2*5/*6 slow acetylation genotypes. HepG2 was chosen for 
the expression studies and was stably transfected with RAR and SAR plasmids to study 
the effect of NAT2 overexpression. NAT2 overexpression efficacy of rapid acetylator 
recombinant (RAR) and slow acetylator recombinant (SAR) were assessed by RT-PCR 
and immunoblotting at mRNA and protein levels respectively. Figure 5.6 shows the 
semiquantitative RT-PCR analysis of NAT2 mRNA expressions in non-transfected, 
RAR and SAR cells. B-actin and GAPDH were used as a control. The NAT2 mRNA 
level in RAR and SAR cells are markedly higher by the presence of the more intense 
bands when compared to the non-transfected cells. However, NAT2 mRNA expression 
was similar between RAR and SAR cells. It was then further confirmed by quantitative 
RT-PCR analysis which showed no expression differences between RAR and SAR-
stably transfected cells (Table 5.2). The NAT2 mRNA expression in RAR and SAR 
were increased 364.76 ± 85.13 and 335.04 ± 74.31 fold respectively compared to the 
non-transfected cells. Figure 5.7 shows the expression level of NAT2 at protein level in 
(A) non-transfected, (B) RAR and (C) SAR cells. Relatively high level of NAT2 
expression was found in RAR and SAR cells compared to the non-transfected cells. 
However, NAT2 protein expression in SAR is lower when compared to the RAR cells. 
Quantification of the NAT2 bands in the immunoblot using ImageJ software revealed 
that NAT2 protein expression in SAR was 39% of that for RAR though untransfected 
cells also showed a detectable band of intensity about 10% of the RAR cells (Table 
5.3).  
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Table 5.2 Quantitative RT-PCR of NAT2 transcript level in non-transfected, 
RAR and SAR stably transfected cells 
 
Cell lines Average fold increase in mRNA 
expression 
Non-transfected HepG2 1.00  ±  0.02 
RAR-stably transfected HepG2  364.76  ±  85.13 
SAR-stably transfected HepG2  335.04  ±  74.31 
 
Data presented are means ± S.D. of triplicates from three independent experiments of 
the fold increase of NAT2 mRNA expression levels in RAR and SAR-stably transfected 
cells to corresponding levels in non-transfected cells, normalized with respect to 
GAPDH mRNA levels. 
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NAT2
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GAPDH
SAR
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Figure 5.6 Semiquantitative RT-PCR analysis of NAT2 mRNA expressions 
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Table 5.3 Quantification of recombinant protein expressions of NAT2 alleles in 
HepG2 cells normalized to GAPDH expression using ImageJ software 
 
Cell lines Integrated 
density value* 
 
Fold increase in NAT2 
protein expression 
Non-transfected HepG2 34465   1.0 
RAR-stably transfected HepG2  345894 10.0 
SAR-stably transfected HepG2  135169   3.9 
* Integrated density values of NAT2 was normalized to respective GAPDH level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Western blot of NAT2 protein expressions in non-transfected 
(A), RAR-stably transfected (B) and SAR-stably transfected cells (C) 
 
 
NAT2
GAPDH 36 kDa
34 kDa
A           B          C
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5.3.2 Determination of NAT2 enzyme activity 
 
To determine whether overexpression of NAT2 enzyme results in catalytically active 
enzyme in RAR and SAR cells, the NAT2 enzyme activities were assayed and 
compared to the non-transfected cells (control). NAT2 enzyme activities were readily 
detectable in RAR, SAR and control cells incubated with 40 µM Luciferin-NAT2 for 0-
12 h. Figure 5.8 displays the linearly increased of the relative luminescent units (RLU) 
over the entire time course with r
2
 > 0.9 for all samples.  NAT2 enzyme activity for 
each sample are presented in Table 5.4 and expressed in relative luminescent units per 
mg protein per h (RLU/mg/h). A significantly higher NAT2 activity (p<0.05) was 
detected in the RAR and SAR compared to the control cells, indicating the functional 
overexpression from both RAR and SAR plasmids. As shown in Table 5.4, RAR cells 
demonstrated a 4.3-fold increase in NAT2 activity over constitutive HepG2 activity 
compared with SAR where there was still an increase but this was significantly lower at 
2.2 fold (p<0.05). These data suggest that cell lines showing overexpression of NAT2 
from the RAR and SAR clone have been created, with the RAR clone exhibiting 
significantly higher NAT2 activity than SAR.  
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Table 5.4 NAT2 activities of RAR, SAR and non-transfected cells as 
evaluated by the bioluminescent NAT2 enzyme assay 
 
Cell lines NAT2 activity 
(RLU/mg/h) 
Fold increase 
Non-transfected 367.60  ±  22.76    1 
SAR 825.66  ±  82.16 2.2 
RAR 1590.11  ±  127.76 4.3 
 
Data presented are means ± S.D. of triplicates from two independent experiments 
† 
Net NAT2 activities in RAR and SAR were calculated by subtracting the activity 
measured in the non-transfected cells
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Cell lysates of RAR, SAR and non-transfected cells were incubated with 40 µM 
Luciferin-NAT2 with or without the presence of 400 µM Acetyl-CoA for 0-12 h prior 
to adding LDR. Zero-time values were measured in samples where the acetyl-CoA was 
withheld until after LDR addition. Data presented are means ± S.D. of triplicates from 
two independent experiments. The reactions were linear over the entire time course 
with r2>0.9 for all samples.  
Time course of NAT2 activity with Luciferin-NAT2 
Figure 5.8 Time course of NAT2 activity with Luciferin-NAT2 
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5.3.3 Functional characterisation of NAT2 acetylation phenotypes  
5.3.3.1 Effects of NAT2 overexpression on cell proliferation  
 
The functional consequences of difference NAT2 acetylation phenotypes on INH 
toxicity were evaluated. MTT assays were performed and the EC50 values were 
determined. As shown in Figure 5.9, no apparent differences were observed in RAR 
and SAR cells compared to the control cells.  The EC50 values of the control cells was 
slightly higher (28.43 mM) than the RAR (EC50=24.73 mM) and SAR cells (24.76 
mM). However, these differences were not statistically significant. 
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Values are the means ± S.D of duplicates from four independent experiments. 
Significant difference between groups was assessed statistically by two-way ANOVA 
(*P<0.05). 
 
Figure 5.9 INH-induced decreased cell proliferation at 48 h in RAR, SAR and 
non-transfected cells 
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5.3.3.2 Effects of NAT2 overexpression on cellular GSH and GSSG  
 
RAR, SAR and the non-transfected cells were assessed for cellular content of GSH and 
GSSG after 48 h exposure to INH. The effect of NAT2 overexpression on total 
glutathione (GSH+GSSG) and GSH/GSSG ratio are summarized in Figure 5.10 and 
Figure 5.11 respectively. INH exposure decreases the total glutathione levels in all cell 
types. No significant differences in total glutathione levels were observed in RAR and 
SAR compared to the non-transfected cells. The GSH/GSSG ratio was further 
calculated and a significant decrease was found between RAR and the non-transfected 
cells at 20 mM INH (p<0.05) and 40 mM INH (p<0.001). Compared to the non-
transfected cells, GSH/GSSG levels were lower in SAR and a significant decrease was 
observed at 40 mM INH treatment (p<0.05). GSH/GSSG levels in RAR appeared lower 
than SAR at various concentration of INH treatment but these differences were not 
statistically significant. These data indicate that overexpression of NAT2 may slightly 
decrease the GSH/GSSG ratio, indicating an increased level of intracellular oxidative 
stress. 
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Figure 5.10 The effect of NAT2 overexpression on total glutathione depletion 
in RAR, SAR and non-transfected cells 
Values are the means ± S.D of duplicates from three independent experiments. 
Difference between groups was assessed statistically by two-way ANOVA 
(*P<0.05). 
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Figure 5.11 The effect of NAT2 overexpression on GSH/GSSG ratio in RAR, 
SAR and non-transfected cells 
*  
Values are the means ± S.D of duplicates from three independent experiments. 
Difference between groups was assessed statistically by two-way ANOVA (*P<0.05, 
**P<0.01, ***P<0.001). 
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5.3.3.3 Effects of NAT2 overexpression on INH-induced apoptosis  
 
To investigate the functional role of NAT2 overexpression on INH-induced apoptosis, 
DNA fragmentation assay and caspase-3 activity assay were performed in RAR, SAR 
and non-transfected cells. As shown in Figure 5.12, apoptotic DNA laddering was 
observed in all cell types at the INH concentration of 50 and 60 mM. Nevertheless, an 
early apoptotic ladder pattern was seen in RAR at 40 mM of INH treatment. RAR are 
cells with higher acetylation capacity than SAR and appear to be more susceptible to 
INH-induced apoptotic DNA fragmentation. Caspase-3 activity assay was then 
performed to verify the findings of DNA fragmentation assay. Figure 5.13 shows the 
significant increased of caspase-3 activity in RAR and SAR compared to the non-
transfected cells (p<0.05) when exposed to various concentration of INH. However 
there was no significant difference of caspase-3 activity observed between RAR and 
SAR cells. These findings suggest that RAR cells are marginally more susceptible to 
apoptosis at high INH concentrations. 
 
Non-transfected
0   30   40  50   60    INH (mM)
SAR
0   30   40   50  60    
RAR
0    30  40   50   60    
 
Figure 5.12 Effects of NAT2 overexpression on INH-induced DNA 
fragmentation  
Image shown is the representative from one of two duplicates. DNA 
fragmentation assay was performed as indicators of apoptosis following 48 
h of INH treatment. The apoptotic ladder patterns were seen in all cell 
types at 50 and 60 mM INH. However, RAR were found to be more 
susceptible to apoptosis induced by 40 mM INH compared to SAR and non-
transfected cells as a more intense apoptotic DNA laddering was observed 
in these cells.  
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ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
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Figure 5.13 INH-induced increased caspase-3 activity in RAR, SAR and non-
transfected cells 
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5.4 Discussion 
 
These experiments aimed to look at the effect of stably expressing a wild-type NAT2 
gene on isoniazid toxicity in a cell line that was homozygous for variant NAT2 alleles 
and therefore had a slow acetylator phenotype. As a control, a variant (NAT2*5) gene 
was expressed in a parallel experiment. The first step involved the isolation of HepG2 
cell lines stably expressing the relevant genes. Previous studies have described the 
transient expression of NAT2*4 and a few of the mutant NAT2 alleles or haplotypes 
including a combination of NAT2*5 alleles (341T>C and 481C>T) in monkey kidney 
COS-1 cells (Zang et al., 2007; Zang et al., 2004; Blum et al., 1991) and E.coli (Hein et 
al., 1994). The 341T>C polymorphism results in an amino acid change (Ile-114 to Thr) 
which substitutes a polar (Thr) for a non-polar (Ile) amino acid, whereas 481C>T is a 
synonymous SNP which has no effect on NAT2 mRNA, protein or catalytic activity 
(Zang et al., 2007). Blum and colleagues reported that the M1 allele which contain the 
341T>C and 481C>T variants greatly reduced the expression of NAT2 protein without 
affecting mRNA expression (Blum et al., 1991). They concluded that the combined 
variants of these two SNPs together affected impaired translation of NAT2 protein 
when compared to the expression of NAT2*4 allele using COS-1 cells. However, Hein 
and colleagues did not observe any significant reduction of NAT2 protein in 
recombinant NAT2 containing both 341T>C and 481C>T variants in expression studies 
in E.coli (Hein et al., 1994), indicating the distinction between recombinant NAT2 
protein expression system in prokaryotic and eukaryotic cells. Our present study 
showed that the stable expression of slow acetylator recombinant (SAR) featuring both 
NAT2 variants (341T>C and 481C>T) in HepG2 cells has a significantly reduced NAT2 
protein expression level but a similar mRNA transcription level compared to the rapid 
acetylator recombinant (RAR), agreeing with the earlier finding using COS-1 cells. 
However the level of NAT2 protein in cells overexpressing the NAT2*4 reference allele 
was 6.1-fold higher than in COS-1 cells overexpressing 341T>C variant (Zang et al., 
2004). Zang and colleagues have also demonstrated the 341T>C variant showed eight-
fold lower NAT2 catalytic activity compared to COS-1 cells overexpressing NAT2*4 
allele using sulfamethazine as substrate (Zang et al., 2004). In another transfection study 
using sulfamethazine as NAT2 substrate, Blum and colleagues reported that NAT2 
catalytic activity from the M1 allele (NAT2*5) was about 5-fold lower compared to that 
seen when the NAT2*4 allele was transfected (Blum et al., 1991). It was proposed that 
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the lower NAT2 protein and enzyme activity due to 341T>C polymorphism resulted 
from enhanced protein degradation (Zang et al., 2004). Our current study has 
demonstrated a 2.7-fold statistically significant lower NAT2 activity in SAR stable 
transfected cells compared to RAR stable transfected cells. The observed lower NAT2 
catalytic activity (2.7-fold) agrees well with the lower NAT2 protein expression (3.1-
fold lower than expression from NAT2*4) by western blotting. Nevertheless, the 
observed difference in NAT2 catalytic activity in SAR compared to RAR using 
Luciferin-NAT2 as substrate was smaller than those reported previously. The significant 
overexpression of NAT2 enzymes in both SAR and RAR cells leads to a substantial net 
increase in NAT2 enzyme activity over background (non-transfected HepG2 cells) 
could be the reason why a smaller than expected difference was detected between the 
RAR and SAR cells. Ideally, a pTARGET empty plasmid or a nonsense vector should 
have been stably expressed in parallel to eliminate any non-specific effects which could 
have led to an underestimate of the difference in enzyme activity between RAR and 
SAR cells. A sensitive direct assay for isoniazid acetylation would have been more 
appropriate but this was not available for the current study. A comparison with a 
NAT2*6 construct similar to the NAT2*4 and *5 constructs used here would also be of 
interest.  
 
We studied three different cell lines, the original "slow acetylator genotype" HepG2 
cells, HepG2 cells with increased expression of mutated NAT2 and HepG2 cells with 
expression of wild-type NAT2. Previous studies showed that INH treatment could 
decrease cell proliferation and increase oxidative stress with mitochondrial dysfunction 
accompanied by apoptosis seen in HepG2 cells as well as in other cell lines (Bhadauria 
et al., 2010; Schwab and Tuschl, 2003). Both studies have demonstrated that INH could 
produce apoptosis in HepG2 cells at millimolar concentrations (26 mM) and therefore a 
comparable concentration in the range of 20 to 60 mM was used in our present study. 
The results from MTT assay showed that overexpression of either wild-type or variant 
NAT2 has no effect on cell proliferation as no significant differences of the EC50 values 
were observed in RAR and SAR cells compared to the control cells. However, when the 
cells were assessed for cellular content of GSH and GSSG, the GSH/GSSG ratio in both 
RAR and SAR cells were significantly lower than the controls, indicating that 
overexpression of NAT2 may increase the level of intracellular oxidative stress. 
However, the effect in RAR cells seems greater than for SAR. Overexpression of either 
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NAT2 construct also increased INH-induced apoptosis in HepG2 cells. These results 
suggested that the INH reactive metabolites generated by NAT2 rather than the parent 
drug might be responsible for the development of INH-induced toxicity in HepG2. 
Acetylhydrazine, a toxic metabolite of INH has been suggested to be the cause of INH-
induced hepatotoxicity, especially in slow acetylation phenotype (Lauterburg et al., 
1985; Timbrell et al., 1980; Ellard et al., 1978). Individuals with rapid acetylator 
phenotype were suggested to be less susceptible to INH-induced DILI as they convert 
acetylhydrazine more rapidly into non-toxic diacetylhydrazine and decrease 
acetylhydrazine accumulation. On the other hand, slow acetylators with reduced NAT2 
enzyme convert acetylhydrazine to diacetyhydrazine more slowly and thus increase 
acetylhydrazine accumulation. Acetylhydrazine can be hydrolysed into hydrazine, a 
major INH toxic metabolite and it has been shown that hydrazine is of greater 
quantitative significance in slow than in rapid acetylator (Sarich et al., 1996). Slow 
acetylators with increased acetylhydrazine accumulation will hydrolyse some of the 
acetylisoniazid to hydrazine via this alternate pathway. More recent studies have 
suggested that hydrazine rather than acetylhydrazine could be the cause of INH-induced 
hepatotoxicity (Sarich et al., 1996; Gent et al., 1992; Noda et al., 1983). 
 
 In our present study, there was no statistically significant difference in functional 
consequences of NAT2 acetylation phenotypes on INH toxicity observed between RAR 
and SAR cells though some suggestions that toxicity was greater in RAR were seen. 
The relatively small effects and lack of specificity could be due to the short duration of 
INH treatment (48 hours) in these cells and perhaps a longer duration for the cells 
exposed to INH is needed to allow the possibility for accumulation of more toxic effects 
of hydrazine and acetylhydrazine. Another reason could be due to that the amount of 
hydrazine formed indirectly by this alternate pathway via hydrolysis of acetylisoniazid 
was very little and may not cause serious toxicity to the cells. Conceivably, hydrazine 
formed directly by direct hydrolysis of INH may play an important role in the 
development of hepatotoxicity. It has been demonstrated that RMP enhance 
idiosyncratic hepatocellular reactions in slow acetylators by inducing formation of 
hydrazine from isoniazid (Sarma et al., 1986). A more recent study has also 
demonstrated that serum concentration of hydrazine was significantly higher in subjects 
with NAT2 slow acetylator phenotypes, high concentration of serum RMP, and GSTM1 
null genotype (Fukino et al., 2008). These may suggest that polymorphisms in the 
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NAT2 alone may not fully account for the development of ATD-DILI and there could 
be another ATD metabolising enzymes or additional factors that contribute the 
idiosyncratic nature of liver toxicity caused by anti-tuberculosis medication. Though 
these preliminary findings suggesting overexpression of NAT2 results in increased INH 
toxicity are interesting, there are a number of limitations. In particular, HepG2 cells are 
not a perfect model for liver metabolism because they show relatively low levels of 
P450 and other xenobiotic metabolising enzyme expression (Westerink and Schoonen, 
2007). However, it would not have been possible to perform these stable transfection 
studies in primary hepatocytes and HepG2 was the best alternative available.  
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Chapter 6. The Protective Role of Glutathione S-transferase 
A Class Isoforms against Cytotoxic Effects of Isoniazid 
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6 The protective role of glutathione S-transferase A 
class against cytotoxic effects of isoniazid 
6.1 Introduction 
 
As described in chapter 5, INH-induced hepatotoxicity appears to be associated with 
reactive metabolites produced by NAT2, a major drug-metabolizing enzyme in INH 
metabolism. Exposure to reactive INH metabolites is believed to play a central role in 
accumulation of reactive oxygen species (ROS) within hepatocytes that may promote 
intracellular oxidative stress and lead to hepatocyte death via apoptosis and necrosis. 
Thus several enzyme systems including glutathione S-transferase enzymes (GSTs) and 
superoxide dismutase 2 (SOD2) may play a major role against liver injury by its 
detoxification effects through the conjugation of glutathione with harmful electrophiles 
generated during oxidative stress and lipid peroxidation. The inter-individual 
differences in the ability to detoxify certain drugs and their toxic intermediates could 
increase susceptibility to DILI due to toxic metabolites accumulation. As described in 
section 1.7.3, genetic polymorphisms of GSTM1, GSTT1 and SOD2 have previously 
found to be associated with ATD-DILI. In our present genotyping study (Chapter 3), 
some evidence for associations between polymorphisms in the glutathione S-transferase 
genes, particularly GSTM1 and GSTA4 and ATD-DILI was found, suggesting a 
protective role of these enzymes in preventing ATD-DILI. The aim of this chapter is to 
assess the protective role of glutathione S-transferase (GSTs) and their association with 
INH-induced DILI by using in vitro overexpression and siRNA knockdown approaches. 
In view of the well characterised role of GSTA4  in detoxification of 4-hydroxynonenal 
(Hubatsch et al., 1998), a product of lipid peroxidation, the main aim of the experiments 
described in this chapter was to perform in vitro studies on this isoform in relation to 
INH toxicity.  
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6.2 Materials and Methods 
6.2.1 The overexpression effect of hGSTA4 on INH toxicity 
6.2.1.1 Construction of hGSTA4 recombinant stable cell lines 
 
Total RNA was isolated from human primary hepatocytes and reverse transcription of 
mRNA was performed to synthesize cDNA (see section 2.5). Amplification of hGSTA4 
cDNA was performed by using PCR. The PCR conditions were 35 cycles at 95ºC for 
60s, 51ºC for 90s and 72ºC for 90s; forward primer: 5’-AAGCTATCATGGCAGCAAG 
G-3’ and reverse primer: 5’- GACAATACCATCTCTAGGA -3’. The PCR product 
(729 bp) was analysed in a 2% agarose gel and purified using Qiagen Gel Extraction 
Kit. It was used as the DNA insert for the recombinant plasmid construction (Figure 
6.1) and cloned into the mammalian expression vector pTARGET (Promega). The 
presence of the recombinant construct was confirmed by digesting the plasmid DNA (3 
µl) with EcoRI restriction enzyme (Figure 5.2) and the nucleotide sequence of the 
plasmid containing the DNA inserts were confirmed by sequencing (see section 2.4.6). 
The plasmid was then stably transfected into HepG2 cells using GeneJuice transfection 
reagent and the cells were selected with 500 µg/ml G418 antibiotic for 3-4 weeks until 
the G418-resistant clones were established (see section 2.5.4). The stably transfected 
cells were maintained in 250 µg/ml until further analysis. The overexpression of 
GSTA4 in the stably transfected cells were evaluated using quantitative RT-PCR and 
western blotting. The non-transfected HepG2 cells were used as a control. 
 
6.2.1.2 Functional analysis of GSTA4 overexpression in HepG2 cell 
line against isoniazid hepatotoxicity  
 
To test whether hGSTA4 overexpressing cell lines have a protective role against 
isoniazid hepatotoxicity, hGSTA4-stable transfected cell lines were harvested prior to 
apoptosis markers and cell viability analyses. G-418 selective culture medium were 
removed and replaced with fresh growth medium for 2 days. Cells were then subjected 
to MTT test, DNA fragmentation assay and Caspase-3 fluorometric assay (see section 
2.8, 2.10 and 2.11). 
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1
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274
334
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694
AAGCTATCATGGCAGCAAGGCCCAAGCTCCACT
ATCCCAACGGAAGAGGCCGGATGGAGTCCGTGAGATGGGTTTTAGCTGCCGCCGGAGTCG
AGTTTGATGAAGAATTTCTGGAAACAAAAGAACAGTTGTACAAGTTGCAGGATGGTAACC    
ACCTGCTGTTCCAACAAGTGCCCATGGTTGAAATTGACGGGATGAAGTTGGTACAGACCC
GAAGCATTCTCCACTACATAGCAGACAAGCACAATCTCTTTGGCAAGAACCTCAAGGAGA 
GAACCCTGATTGACATGTACGTGGAGGGGACACTGGATCTGCTGGAACTGCTTATCATGC 
..............-M--Y--V--E--G--T-=L=-D--L--L--E--L--L--I--M--
ATCCTTTCTTAAAACCAGATGATCAGCAAAAGGAAGTGGTTAACATGGCCCAGAAGGCTA   
H--P--F--L--K--P--D--D--Q--Q--K--E--V--V--N--M--A--Q--K--A--
TAATTAGATACTTTCCTGTGTTTGAAAAGATTTTAAGGGGTCACGGACAAAGCTTTCTTG   
I--I--R--Y--F--P--V--F--E--K--I--L--R--G--H--G--Q--S--F--L--
TTGGTAATCAGCTGAGCCTTGCAGATGTGATTTTACTCCAAACCATTTTAGCTCTAGAAG   
V--G--N--Q--L--S--L--A--D--V--I--L--L--Q-=T=-I--L--A--L--E--
AGAAAATTCCTAATATCCTGTCTGCATTTCCTTTCCTCCAGGAATACACAGTGAAACTAA   
E--K--I--P--N--I--L--S--A--F--P--F--L--Q--E--Y--T--V--K--L--
GTAATATCCCTACAATTAAGAGATTCCTTGAACCTGGCAGCAAGAAGAAGCCTCCCCCTG   
S--N--I--P--T--I--K--R--F--L--E--P--G--S--K--K--K--P--P--P--
ATGAAATTTATGTGAGAACCGTCTACAACATCTTTAGGCCATAAAACAACACATCCATGT   
D--E--I--Y--V--R--T--V--Y--N--I--F--R--P--*-................
GTGAGTGACAGTGTGTTCCTAGAGATGGTATTGTC 
...................................
 
Figure 6.1 Nucleotide sequences of plasmid insert possessing GSTA4 coding   
region.  
 
Figure shown is the nucleotide sequences of plasmid insert (729bp) containing 
GSTA4 coding region. Primers used to amplify the DNA fragments are shown in 
underline; the start codon (ATG) and stop codon (TAG) are shown in red bold 
letters; the protein sequences are highlighted in yellow. 
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6.2.2 Effects of GSTA1 inhibition in INH Cytotoxicity 
6.2.2.1 Detection of GSTA1 expression in mammalian cells  
 
To assess the significance of GSTA1 mRNA and protein expression, HepG2, LS180, 
Caco-2, and Huh 7.5 cell lines were evaluated using quantitative RT-PCR and western 
blotting. Cell line with the presence of highly abundant GSTA1 protein was used for 
siRNA studies.  
 
6.2.2.2 Small interfering RNA (siRNA) knockdown of GSTA1 
 
Small interfering RNA (siRNA) GSTA1 knockdown experiment was performed using 
validated Silencer Select predesigned siRNA (Ambion, Applied Biosystems). The 
siRNA sequences consisted of sense: r(AAUAAAGUACUUUACCUAA)dTdT and 
antisense: r(UUAGGUAAAGUACUUUAUU)dGdT, targeting the exon 7 of the 
GSTA1. A reverse transfection technique was performed using RiboJuice siRNA 
transfection reagent (Novagen, Merck Biosciences). Cell lines were passaged every 2-3 
days to ensure rapid growth and doses were optimised to ensure highest transfection 
efficiency. Briefly, cells were detached from the flask to form a suspension of 1,000,000 
cells per well in a 6-well plate format. For each well, 2 µl of RiboJuice were mixed 
thoroughly in 224 µl of serum free medium in a sterile tube and incubated for 5 min at 
room temperature. The optimized concentration of siRNA was then added into the 
mixture and incubated further at room temperature for 10 min. The 
siRNA/RiboJuice/medium complex mixture was then added into the cell suspension in 
1.25 ml of antibiotic-free complete medium. After 4-8 h incubation, the transfection 
mixture were removed and replaced with complete growth medium. The cells were 
incubated for 72 h to allow optimal silencing of the GSTA1 expression and GSTA1 
knockdown was assessed by both RTPCR and immunoblotting.  
 
Pilot experiments included internal controls of untreated cells, mock-transfected cells 
with no siRNA, and a non-silencing siRNA control (Silencer Select Negative Control 
siRNA, Ambion). The Silencer Select Negative Control siRNAs are siRNAs with 
sequences that do not target any gene product to determine siRNA transfection 
efficiency and to control for the effects of siRNA delivery. A positive control using 
Silencer Select GAPDH siRNA (Ambion) was tested to develop and optimizing the 
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transfection condition. Optimisation of gene silencing was performed by quantifying 
GSTA1 mRNA levels by Q-RTPCR and GSTA1 protein levels by immunoblotting. 
 
6.2.2.3 Analysis of the effects of GSTA1 inhibition in INH 
cytotoxicity  
 
The effect of GSTA1 silencing on INH cytotoxicity was tested by performing the 
apoptosis marker and cell viability analyses. Cells were transfected with GSTA1 siRNA 
or non-silencing siRNA control for 72 h and subjected to MTT test, DNA fragmentation 
assay and Caspase3 fluorometric assay (see section 2.8, 2.10, 2.11). 
 
 
6.3 Result 
6.3.1 The effect of hGSTA4 in INH toxicity 
6.3.1.1 Evaluation of GSTA4 expression in stably transfected 
HepG2 cells with GSTA4 plasmid 
 
The GSTA4 overexpression efficacy of stably transfected HepG2 cells with GSTA4 
plasmid at mRNA and protein levels was assessed by RT-PCR and immunoblotting 
respectively. Figure 6.2 shows the semiquantitative RT-PCR analysis of GSTA4 
mRNA expression in (A) non-transfected and (B) hGSTA4-stably transfected HepG2 
cells. B-actin and GAPDH were used as a control. GSTA4 mRNA level in hGSTA4-
stably transfected HepG2 cells are increased by the presence of the more intense bands 
when compared to the non-transfected cells. The semiquantitative RT-PCR findings 
were further quantified by quantitative RT-PCR analysis as shown in Table 6.1. The 
hGSTA4-stably transfected cells have shown an approximately 60 fold increase in 
GSTA4 transcript level when compared with the non-transfected cells. Data presented 
are means ± S.D. of triplicates from three independent experiments of the fold increase 
of GSTA4 mRNA expression levels in hGSTA4-stably transfected cells to 
corresponding levels in non-transfected cells, normalized with respect to GAPDH 
mRNA levels.  
The expression level of GSTA4 at protein level reflected mRNA findings, with a 
relatively high level of GSTA4 expression in hGSTA4-stably transfected cells compared 
to the non-transfected cells (Figure 6.3). 
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Table 6.1 Quantitative RT-PCR of GSTA4 transcript level in non-transfected 
and stably transfected HepG2 with hGSTA4 plasmid 
 
 
Cell lines 
Average fold increase in mRNA 
expression 
Non-transfected HepG2   1.00  ±  0.02 
hGSTA4-stably transfected HepG2 60.29  ±  6.41 
 
Data presented are means ± S.D. of triplicates from three independent experiments of 
the fold increase of GSTA4 mRNA expression levels in hGSTA4-stably transfected 
cells to corresponding levels in non-transfected cells, normalized with respect to 
GAPDH mRNA levels. 
 
 
GSTA4
GAPDH 36 kDa
25 kDa
A            B          
 
Figure 6.3 Immunoblot of GSTA4 protein expressions in 
non-transfected (A) and GSTA4-stably transfected HepG2 
cells (B) 
 
                
GAPDH
Β-actin
GSTA4
Non-
transfected
hGSTA4
158 bp
207 bp
445 bp
 
Figure 6.2 Semiquantitative RT-PCR analysis of GSTA4 mRNA 
expressions in non-transfected (A) and hGSTA4-stably transfected 
HepG2 cells (B) 
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6.3.1.2 Functional role of GSTA4 against INH-decreased cell 
proliferation in HepG2 cells  
 
To evaluate the functional consequences of hGSTA4 overexpression on cell 
proliferation, MTT assays were performed and the EC50 values were determined. The 
hGSTA4-stably transfected cells have significantly reduced cell proliferation inhibition 
caused by INH at 20, 30, 40, 50 and 60 mM, compared with the non-transfected cells 
(P<0.05). The EC50 values of the hGSTA4-stably transfected cells was 38.64 mM 
which was higher than the non-transfected cells (29.16 mM), indicating that GSTA4 has 
a protective role against toxicants generated by INH (Figure 6.4).  
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Figure 6.4 INH-induced decreased cell proliferation at 48 h in hGSTA4-
transfected and non-transfected HepG2 cells 
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Values are the means ± S.D of duplicates from three independent experiments. 
Difference between groups was assessed statistically by two-way ANOVA (*P<0.05, 
**P<0.01, ***P<0.001). 
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6.3.1.3 Inhibitory effect of INH-induced apoptosis in HepG2 
overexpressing GSTA4 
 
DNA fragmentation assay and caspase-3 activities were determined as indicators of 
apoptosis following 48 h of INH treatment in hGSTA4-stably transfected and non-
transfected cells. DNA fragmentation was detected by an ethidium bromide stained gel 
following INH treatment (Figure 6.5). In non-transfected cells, obvious DNA 
fragmentation was observed at the concentration of 50 mM and 60 mM INH. However, 
DNA fragmentation ladder pattern of hGSTA4-stably transfected cells was only evident 
after INH treatment at 60 mM. This result was consistent with the findings in caspase-3 
activity assay as reduced caspase-3 activity was observed in hGSTA4-stably transfected 
cells compared to the non-transfected cells (Figure 6.6). Significantly reduced (P<0.05) 
caspase-3 activity was observed in hGSTA4-stably transfected cells at 50 mM INH 
treatment. This result is concordant with the results of MTT and DNA fragmentation 
assay, suggesting the inhibitory effect of INH-induced cytotoxicity in HepG2 by the 
overexpression of GSTA4. 
 
 
 
 
 
Non-transfected
0    30   40   50   60    INH (mM)
hGSTA4
0     30   40    50   60    
 
Figure 6.5 INH-induced DNA fragmentation in hGSTA4-stably 
transfected cells 
Early detection of apoptotic DNA fragmentation was seen in non-
transfected cells treated with 50 mM INH, whilst 60 mM INH in hGSTA4-
transfected cells. Shown is a representative gel from two experiments. 
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Values are the means ± S.D of duplicates from three independent experiments. 
Difference between groups was assessed statistically by two-way ANOVA 
(*P<0.05). 
 
*  
Figure 6.6 INH-induced increased caspase-3 activity in hGSTA4- and non-
transfected HepG2 cells 
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6.3.2 The effect of isoniazid on GSTA1 expression profile in human cell 
line 
 
To examine whether the toxicity of INH is enhanced in GSTs-knockdown cells, small 
interfering RNA (siRNA) GSTA4 knockdown experiment was initially performed in 
HepG2 and LS180 cells. GSTA4 mRNA and protein expression were evaluated in both 
cell lines. However due to the lack of GSTA4 expression in both cell lines (data not 
shown), GSTA1 was then chosen as the candidate gene to study the toxicity profile of 
INH in GSTA1-knockdown cells.  
  
6.3.2.1 GSTA1 expression in mammalian cell lines 
 
The expression of GSTA1 transcripts in mammalian cell lines was investigated using 
quantitative RT-PCR and GSTA1 protein levels were assessed by immunoblotting. The 
GSTA1 transcript expression level in the HepG2, LS180 and Huh7.5 is relatively low to 
corresponding level in Caco-2 cells (Table 6.2). The Caco-2 cell line has shown to 
express higher GSTA1 transcript expression levels. The expression level of total 
GSTA1 at protein level reflected mRNA findings, with relatively low levels of 
expression in (A) HepG2, (B) LS180 and (D) Huh7.5 and higher levels in (C) Caco-2 
cell lines (Figure 6.7).  
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Table 6.2 Quantitative RT-PCR of GSTA1 transcript level in Caco-2, HepG2, 
Huh7.5, and LS180 cell lines 
 
 
Cell lines 
 
Average fold reduction in mRNA expression 
 
Caco-2 1.000  ±  0.129 
HepG2 0.072  ±  0.063 
Huh7.5 0.019  ±  0.012   
LS180  0.001  ±  0.001 
 
Data presented are means ± S.D. of triplicates from two independent experiments 
of the fold increase of GSTA1 mRNA expression levels in HepG2, Huh7.5 and 
LS180 to corresponding levels in Caco-2 cells, normalized with respect to GAPDH 
mRNA levels. 
 
 
 
GSTA1 26 kDA
42 kDA
A       B       C        D
Β-actin
 
Figure 6.7 Immunoblot of GSTA1 protein level in mammalian 
cell lines 
Immunoblotting was used to determine GSTA1 expression levels in (A) 
HepG2, (B) LS180, (C) Caco-2 and (D) Huh 7.5 cells. No GSTA1 
protein level was detectable in HepG2, LS180 and Huh7.5 except for 
Caco-2 cell lines. 
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6.3.2.2 GSTA1 silencing decreased GSTA1 transcript levels  
  
Caco-2 cell line was chosen as the cell line for GSTA1 silencing work, due to its high 
expression levels of GSTA1. The efficiency of GSTA1 knockdown was analyzed by 
quantitative RT-PCR 72 h after transfection. Cells were transfected with 5 nM, 10 nM 
and 25 nM GSTA1 siRNA for 72 h. Comparison was made between non-silencing 
siRNA controls (NSCs) and the GSTA1 siRNA. Internal controls included no treatment 
and mock-transfected cells with RiboJuice only. The GSTA1 knockdown efficiency at 
the mRNA transcript level was shown in Table 6.3 and Figure 6.8. Neither mock-
transfected nor no treatment cells had significantly reduced GSTA1 transcript levels 
compared to NSCs. Both 10 nM and 25 nM GSTA1 siRNAs significantly reduced the 
expression levels of GSTA1 by 77% and 81% respectively when compared to the 
NSCs. 
 
Table 6.3 Quantitative RT-PCR analysis of the effect of GSTA1 siRNA on 
GSTA1 transcript levels at 72 h  
 
 
Treatment 
Average fold reduction in 
mRNA expression 
 
Non-silencing siRNA controls (NSCs) 1.00  ±  0.12 
Mock-transfection  0.87  ±  0.17 
No treatment 0.97  ±  0.10 
5 nM GSTA1 siRNAs 0.41  ±  0.21 
10 nM GSTA1 siRNAs 0.23  ±  0.12 
25 nM GSTA1 siRNAs 0.19  ±  0.05 
 
Data presented are means ± S.D. of triplicates from two independent experiments.  
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Figure 6.8 Silencing effect of GSTA1 siRNA on GSTA1 transcription levels at 
72 hours by quantitative RT-PCR 
Quantitative RT-PCR analysis of GSTA1 transcription levels  
GSTA1 transcription levels in Caco-2 cells transfected with 5, 10 and 25 nM of GSTA1 
siRNA, comparing with non-silencing siRNA controls (NSCs), mock transfection with 
RiboJuice only and no treatment control. All mRNA levels were normalized to GAPDH 
levels. The mRNA level for NSCs was set at 1 and fold reduction in the respective 
mRNA levels in the presence of corresponding siRNAs were determined. As shown, 25 
nM GSTA1 siRNA efficiently silences the GSTA1 mRNA levels by greater than 80%. 
The GSTA1 transcript levels remained unchanged in all controls.  
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6.3.2.3 GSTA1 silencing decreased GSTA1 total protein levels  
 
Having determined that GSTA1 siRNA successfully reduced GSTA1 at transcript levels, 
the effect on protein expression was assessed by immunoblotting after 72 h. In keeping 
with mRNA finding, GSTA1 protein levels remained unaltered in mock transfected 
NSCs and no treatment controls (Figure 6.9) (Table 6.4). Quantification of the GSTA1 
bands using ImageJ software revealed 5 nM, 10 nM and 25 nM GSTA1 siRNAs reduced 
the protein expression levels of GSTA1 by 32%, 79% and 89% respectively when 
compared to the NSCs. Knockdown efficiency of GSTA1 is increased when cells were 
transfected with higher concentration of GSTA1 siRNA (25 nM). Therefore 25 nM 
siRNA was used for efficient knockdown of GSTA1 functional analyses. 
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Table 6.4 Quantification of protein expression of GSTA1 normalized to β-actin 
level using ImageJ software 
 
Treatment Absolute peak 
area value* 
 
Fold reduction in 
GSTA1 expression  
Non-silencing siRNA controls (NSCs) 22.88 1.00 
Mock-transfection  22.66 0.99 
No treatment 23.20 1.01 
5 nM GSTA1 siRNAs 15.66 0.68 
10 nM GSTA1 siRNAs   4.90 0.21 
25 nM GSTA1 siRNAs   2.52 0.11 
* Absolute peak area value of GSTA1 were normalized to β-actin level 
 
 
 
 
 
GSTA1
Β-actin
26 kDA
42 kDA
A       B       C        D        E       F 
 
Immunoblotting was used to determine GSTA1 expression levels in Caco-2 cells 
transfected with (A) 5, (B) 10 and (C) 25 nM of GSTA1 siRNA, comparing with (D) no 
treatment (control), (E) mock transfection with RiboJuice only and (F) non-silencing 
siRNA controls (NSCs) at 72 h. Knockdown of GSTA1 protein was obvious by the 
GSTA1 siRNA at the concentration of 25 nM, and GSTA1 expression was unaltered in 
all control treatments 
Figure 6.9 Effect of GSTA1 siRNA on GSTA1 protein levels 
 
 .          
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6.3.2.4 GSTA1 silencing abolished protection against INH-induced 
cell proliferation inhibition 
 
MTT assays were performed to determine the functional consequences of GSTA1 
silencing on cell proliferation in Caco-2 cells. Treatment with INH causes a dose-
dependent inhibition of cell proliferation in both NSCs and GSTA1 siRNA knockdown 
cells (GSTA1s). As shown in Figure 6.10, GSTA1 silencing has significantly enhanced 
cell proliferation inhibition in GSTA1s compared to the NSCs when treated with 30, 45, 
60, 75 and 90 mM INH (p<0.001). The EC50 value of the GSTA1s was 48.82 mM 
lower than the NSCs (68.88 mM) which indicates that GSTA1s were more susceptible 
to INH-mediated cell proliferation inhibition compared to NSCs.  
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Figure 6.10 INH-induced decreased cell proliferation in GSTA1 siRNA 
knockdown cells (GSTA1s) 
***  
***  
***  
***  
Values are the means ± S.D of duplicates from three independent experiments. 
Difference between groups was assessed statistically by two-way ANOVA (*P<0.05, 
**P<0.01, ***P<0.001). 
 
  
 
211 
6.3.2.5 GSTA1 silencing promotes INH-induced apoptosis  
 
To investigate the functional role of GSTA1 in INH-induced apoptosis, DNA 
fragmentation assay and caspase-3 activity assay were performed in NSCs and 
GSTA1s. As shown in Figure 6.11, DNA fragmentation ladder pattern of GSTA1s was 
evident after INH treatment at 30, 45 and 60 mM. In NSCs, intense DNA laddering was 
observed at the concentration of 45 and 60 mM INH and a faint ladder pattern was seen 
at 30 mM INH. None of the apoptotic DNA laddering was observed in NSCs and 
GSTA1s cells, neither in caco-2 cells without INH treatment. Caspase-3 activity assay 
was performed to confirm the findings of DNA fragmentation assay. Figure 6.12 shows 
the increased of caspase-3 activity in NSCs and GSTA1s when exposed to 15, 30, 45 
and 60 mM INH. A significant induction of caspase-3 activity was observed in GSTA1s 
at 15, 30 and 45 mM INH (P<0.001) compared to NSCs. These findings confirmed the 
results of MTT and DNA fragmentation assay, suggesting GSTA1 silencing increased 
INH-induced cytotoxicity in Caco-2 cells. 
  
N          NSCs
0    0    30   45   60    INH (mM)
GSTA1s
0    30   45   60    
 
Figure 6.11 DNA fragmentation analyses in Caco-2 cells transfected 
with NSCs and GSTA1s cells 
The apoptotic DNA fragmentation was detected in NSCs and GSTA1s 
treated with 30, 45 and 60 mM INH. However, less apoptotic DNA 
laddering was observed in NSCs compared to GSTA1s when treated with 
30 mM INH, suggesting the protective role of GSTA1 against INH-induced 
apoptosis. No DNA fragmentation was detected in caco-2 cells (N), NSCs 
and GSTA1s in the absence of INH treatment.  
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6.4 Discussion 
 
Though P450 mediated metabolism usually biotransforms drugs into water-soluble 
metabolites which are easier to eliminate, in some cases it causes the activation of a 
drug to a hepatotoxic metabolite and increases drug toxicity. In the case of isoniazid, 
polymorphisms in metabolic enzymes such as NAT2 and CYP2E1 may be associated 
with isoniazid-induced liver injury due to the increased level of toxic metabolites of 
isoniazid. Thus, GST enzymes may play an important role to limit or prevent ATD-
DILI by reducing INH toxic metabolites or neutralising toxic products of oxidative 
stress such as 4-hydroxynonenal, particularly in slow acetylators. The present study 
aimed to examine in detail the possible relevance of GSTA4 to protection against INH-
related toxicity. GSTA4 appears to be the main GST isoform that protects against 4-
hydroxynonenal toxicity (Balogh and Atkins, 2011). Transfection of HepG2 cells with 
 
   
     
0
1000
2000
3000
4000
5000
6000
0 15 30 45 60
NSCs
GSTA1s"
 
INH concentrations (mM) 
INH-induced increased caspase-3 activity 
 
 
 
 
 
 
 
NSCs  
 
 
 
 
 
 
 
GSTA1   
C
a
s
p
a
s
e
 a
c
ti
v
it
y
 
(p
m
o
l 
A
M
C
/h
o
u
r/
m
g
) 
Figure 6.12 INH-induced increased caspase-3 activity in GSTA1 siRNA 
knockdown cells (GSTA1s) 
 
 
***  
***  
***  
Values are the means ± S.D of duplicates from three independent experiments. 
Difference between groups was assessed statistically by two-way ANOVA 
(*P<0.05, **P<0.01, ***P<0.001). 
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GSTA4 has also been shown previously to protect against 4-hydroxynonenal-mediated 
oxidative injury (Gallagher et al., 2007) but the effect of its stable expression on INH-
related toxicity has not been previously investigated. The current study has shown 
clearly that GSTA4 expression in HepG2 cells does result in decreased INH-related 
toxicity. This is of interest in view of the borderline significant associations seen for 
some GSTA4 SNPs for ATD-DILI (Chapter 3). 
 
To confirm the GSTA4 protective effect, we sought to assess INH toxicity after siRNA 
transfection to knockout GSTA4. Unfortunately, it was not possible to do this in any of 
the available cell lines as none were found to express GSTA4 constitutively at 
detectable levels. As an alternative and further investigation on the role of GSTA 
isoforms in protection against INH toxicity, siRNA studies were performed to knockout 
GSTA1. GSTA1 is not able to conjugate 4-hydroxynonenal but has been shown to 
decrease reduction of lipid peroxides due to having GSH peroxidase activity (Balogh 
and Atkins, 2011). This means it may have a role in preventing the formation of 4-
hydroxynonenal. As for GSTA4, GSTA1 was expressed at low levels in several cell 
lines including HepG2. However, levels of expression in the epithelial colorectal 
adenocarcinoma cell line Caco-2 were relatively high and it was therefore decided to do 
the siRNA studies in these cells although a liver cell line would have been a better 
model for INH-related DILI. GSTA1 silencing significantly abolished protection against 
INH-induced cell proliferation inhibition and increased INH-induced apoptosis in Caco-
2 cells.  
 
Therefore, though the GSTA isoforms were not able to prevent completely toxicity 
induced by INH, these results demonstrated that expression of GSTA1 or A4 could 
function to limit the effect of INH on the extent of apoptosis/necrosis. This finding 
suggests that lipid peroxidation could play a role in the mechanism for ATD-DILI.  
In Chapter 3, some evidence that individuals with the GSTM1 null genotype are more 
susceptible to ATD-DILI was also obtained. There is evidence that GSTM1 may also 
contribute to detoxification of 4-hydroxyalkenals from lipid peroxidation as well as 
having GSH peroxidase activity (Berhane et al., 1994) and it would also have been 
interesting to have performed expression and siRNA studies for this isoform. GSTA1, 
GSTA4 and GSTM1 are all expressed in human hepatocytes (Aninat et al., 2006) and 
are therefore very relevant to ATD-DILI.  
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As well as the findings reported in Chapter 3, it has been shown that the homozygous 
null genotype of GSTM1 and GSTT1 is implicated in methotrexate, troglitazone and 
carbamazepine-induced liver injury as well as DILI relating to a range of different drugs 
(Lucena et al., 2008a; Imanishi et al., 2007; Ueda et al., 2007; Watanabe et al., 2003). 
Therefore it is worth undertaking further studies on the possible role of GST in DILI 
using the types of approaches described in this chapter. In this present study, 
overexpression of GSTA4 have significantly reduced cell proliferation inhibition caused 
by INH and decreased INH-induced apoptosis in HepG2 cells. GSTA1 silencing has 
significantly abolished protection against INH-induced cell proliferation inhibition and 
increased INH-induced apoptosis in Caco-2 cells. Though the GSTs were not able to 
revert completely hepatic injury induced by INH, these results enabled to conclude that 
expression of GSTs could function to limit the effect of INH to the extent of 
apoptosis/necrosis. Individuals with GSTs deficiency are suggested to be less capable of 
detoxifying reactive metabolites thus, causing their hepatocytes to be less protective 
against oxidative damage during INH metabolism. In the previous chapter, some 
evidence for associations between polymorphisms in the GSTs, particularly GSTM1 and 
GSTA4 and ATD-DILI were found, suggesting a protective role of these enzymes in 
preventing ATD-DILI. It has been shown that homozygous null mutations of GSTM1 
and GSTT1 implicated in methotrexate, troglitazone and carbamazepine-induced liver 
injury (Imanishi et al., 2007; Ueda et al., 2007; Watanabe et al., 2003). Genetic 
polymorphisms of GSTs have also been associated with many diseases including cancer 
and alcoholic liver disease (Andrade et al., 2009). Therefore it is worth undertaking 
further studies on the possible role of the polymorphisms in anti-oxidative stress genes 
which may influence their expression and consequently predict susceptibility and 
severity of DILI in individuals.  
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Chapter 7. General Discussion 
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7 General Discussion 
 
Drug-induced liver injury (DILI) is one of the most commonly detected adverse drug 
reactions both during drug development and in clinical practice. Idiosyncratic adverse 
drug reactions such as DILI have received much attention because they are 
unpredictable and are often the key reason for useful drug withdrawals from the 
pharmaceutical market. Genetic factors in idiosyncratic DILI remain poorly understood. 
Over the past few decades, the association of genetic polymorphisms in drug 
metabolising enzymes with various ADRs have been extensively studied. Recent 
progress in pharmacogenetics research suggests that patients with specific genetic 
characteristics may be prone to specific ADRs and personalized drug therapy with 
pharmacogenetics can therefore lead to safer, more effective drugs and reduce ADRs. 
The evaluation of predisposing factors of ADRs may not fully prevent the occurrence of 
ADRs, but it can reduce the incidence and severity of ADRs, reduce the overall cost of 
healthcare and improve patient outcomes. 
 
First-line anti-TB drugs used for disease treatment and latent TB infection (LTBI) are 
isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), ethambutol and streptomycin. 
The fact that multiple drugs are used is vital in treating the disease effectively but also 
means that assigning an adverse drug reaction to a particular drug is more difficult. 
DILI due to ATD is more common than most other forms of idiosyncratic DILI with the 
frequency of overt clinical hepatitis caused by INH and RMP coadministration reported 
to be 2.6%, but only 1.1% with rifampicin alone and 1.6% with INH alone (Steele et al., 
1991). The frequency of anti-TB drugs hepatotoxicity increases greatly when they are 
used simultaneously (van Hest et al., 2004). These findings contrast with the reported 
frequencies of DILI due to flucloxacillin as 8.5 in every 100,000 new users (Daly et al., 
2009) and co-amoxiclav as 1 in every 10,000 prescriptions (Donaldson et al., 2010). 
Despite the higher frequency for ATD-DILI, progress in identifying genetic risk factors 
and understanding the underlying mechanism has been slower than for other forms of 
DILI. However, it is important to point out that most of the other strong genetic 
associations described so far are with HLA alleles and any evidence for HLA 
involvement in ATD-DILI is very limited. 
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There has been some progress in identifying genetic risk factors for DILI with reported 
associations with genes such as NAT2, CYP2E1 and GSTM1 now reported and 
replicated, though not all studies have reported positive associations (see Chapter 1). 
The NAT2 and GSTM1 associations have been replicated in the current study but the 
overall effects are not particularly high with odds ratios of 4.6 for NAT2 slow 
acetylators and 2.9 for GSTM1 null detected. The current study has considerable 
limitations with numbers of cases studied small and subject to ethnic heterogeneity. The 
positive associations with NAT2 and GSTM1 seem to be particularly driven by the South 
Asian subjects, with less overall effect in Europeans and this needs further study  in 
larger patient groups, especially since a lack of association between NAT2 slow 
acetylators and European ATD-DILI cases has been reported previously by others 
(Yamada et al., 2009; Vuilleumier et al., 2006).  
 
Using the data from the current study, it was possible to determine negative and positive 
predictive values for NAT2 genotyping to prevent DILI from isoniazid. The negative 
predictive value of 0.99 suggests that genotyping would lead to a decrease in the 
number of cases but the low positive predictive value of 0.03 showed that large numbers 
of patients would be deprived of isoniazid treatment unnecessarily. Despite a much 
higher odds ratio for the association of flucloxacillin-related DILI with HLA B*5701 
than for isoniazid DILI with NAT2 slow acetylation, the positive predictive value for 
B*5701 for DILI is only 0.002(Daly et al., 2009) so is lower than that for NAT2 slow 
acetylator alleles for isoniazid DILI. This difference arises mainly because the risk of 
developing DILI from flucloxacillin is much lower than from isoniazid. Flucloxacillin 
DILI affects only 1 in every 500 individuals who are B*5701-positive whereas 
isoniazid-related DILI affects approximately 4 in every 100 individuals who are slow 
acetylators. There is therefore no clinical value in genotyping for either risk factor 
before the particular drugs are prescribed. NAT2 typing could be included in a range of 
genotyping tests if additional genetic risk factors for DILI due to isoniazid could be 
identified and this increased the overall positive predictive value of a genotyping test. 
 
Metabolic idiosyncrasy is generally postulated as the basis for the development of INH-
induced hepatotoxicity. Our present study using an in vitro overexpression approach has 
suggested that toxic metabolites of INH caused more cytotoxicity than the parent drug 
in HepG2 cells overexpressing NAT2 enzymes. Hydrazine, acetylhydrazine and 
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isonicotinic acid are potentially hepatotoxic metabolites of INH and accumulation of 
these reactive metabolites in patients may cause DILI (Metushi et al., 2011). However, 
it has been suggested recently (Metushi et al., 2011) that in addition to factors 
determining reactive metabolite formation, an immune component to isoniazid DILI is 
also a possibility. These workers suggest that this is partly suggested from features such 
as the delay in development of DILI following exposure to the drug and the appearance 
of liver biopsies from ATD-DILI patients which often have an appearance similar to 
those from patients with autoimmune hepatitis. A previous report of an HLA association 
is also cited as evidence for an immune association (Sharma et al., 2002) but a recent 
genome-wide association study (GWAS) involving some of the cases included in the 
current study has failed to detect any HLA association (Daly and Shen, unpublished). 
Nevertheless, the possibility of some involvement from either the innate or adaptive 
immune system in ATD-DILI as recently suggested (Metushi et al., 2011) deserves 
further study. 
 
Most of the genetic studies up to now on ATD-DILI have focussed on INH, probably 
because this tends to the common drug used in the patients who develop DILI though 
some also receive pyrazinamide which is known to increase the risk of DILI when 
included in a ATD regimen (Stout et al., 2003). Occasionally patients who receive PZA 
but not INH also develop DILI but such cases tend to be rare in the UK because PZA 
without INH will be mainly only used where the mycobacteria are found to be INH-
resistant. It is also sometimes possible to identify cases where the DILI is likely to have 
been due to PZA not INH on the basis of successful reintroduction of ATD following 
DILI. However, this also raises the complication of adaptation where patients may 
suffer ATD-DILI which meets the phenotypic requirements used in studies such as the 
DILIGEN study but then do not suffer recurrence of symptoms when the drugs are 
reintroduced (Watkins, 2005). All these factors make genetic studies on ATD-DILI, 
including the present one, very challenging, though it may be possible to find cases 
where the DILI can be shown to be clearly due to either INH or PZA if sufficient 
numbers of ATD-DILI cases with good clinical information can be collected.  
 
Recent success in identifying strong genetic associations for particular adverse drug 
reactions including DILI, myotoxicity and skin reactions have involved genome-wide 
association studies, not candidate gene association studies. For example associations 
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with HLA-B*5701 have been detected for DILI due to flucloxacillin (Daly et al., 2009), 
with HLA-DRB1*1501 and A*0201 for DILI due to co-amoxiclav (Lucena et al., 2011), 
with SLCO1B1 for simvastatin-induced myopathy (Link et al., 2008) and with HLA-
A*3101 for carbamazepine-induced skin rash (McCormack et al., 2011). A similar study 
to understand genetic factors affecting susceptibility to ATD-DILI seems the best way 
forward. A small GWAS study on the available European ATD-DILI samples in the 
present study has been negative apart from the NAT1 association described in Section 
3.3.3 (Daly and Shen, unpublished) but efforts to increase recruitment and collaborate 
with other international DILI networks including EUDRAGENE (Molokhia and 
McKeigue, 2006) and DILIN (Fontana et al., 2009)  should enable a larger GWAS 
study to be performed and hopefully detect specific genetic associations which can be 
replicated (Daly AK, personal communication). 
 
The in vitro studies described in this thesis (Chapters 4 to 6) have provided some novel 
findings concerning increased INH toxicity when NAT2 is overexpressed but decreased 
toxicity when GSTA4 is expressed. The finding that RMP pretreatment decreases INH 
toxicity while inducing expression of genes such as CES2 in at least some human 
hepatocyte preparations is also interesting. Whether CES2 can catalyse the formation of 
hydrazine from INH is still unclear and this aspect needs further study. A general 
limitation of all the in vitro studies is that millimolar concentrations of INH are needed 
to cause detectable toxic effects in either primary cultures or established cell lines. The 
maximum recommended dosage of INH is 300 mg/day and this will typically result in 
plasma levels of approximately 10 ug/ml which would give a molar concentration of 
approx. 100 uM. Hepatocytes could be exposed to slightly higher concentrations than 
those seen in plasma but they are unlikely to be as high as those needed in vitro to see 
detectable toxicity. It would be helpful to find more sensitive indicators for toxicity.  
Examining changes in mRNA expression by use of expression microarrays as reported 
recently in studies on flucloxacillin DILI (Andrews et al., 2010) or at the protein level 
by proteomics analysis after treating hepatocytes or other cell cultures with lower INH 
concentrations would be interesting. If a change in gene expression at a physiological 
INH concentration was seen, the transfection studies described here could be repeated to 
see if they could either prevent the change or make it larger. 
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In conclusion, the candidate gene studies described in this thesis provide further 
confirmation that NAT2 genotype affects susceptibility to ATD-DILI, though this risk 
factor only accounts for a small proportion of total susceptibility. Approx. 50% of the 
UK population are positive for the slow acetylator NAT2 genotype but only 1 or 2% are 
likely to develop ATD-DILI should they need treatment for TB. Therefore, 
susceptibility must involve a combination of NAT2 slow acetylator genotype and several 
other susceptibility genes along with non-genetic risk factors. Considerable further work 
is needed both to understand the mechanism by which ATD-DILI occurs and to develop 
a genotyping test that would have adequate sensitivity and specificity to detect those at 
risk of ATD-DILI. A test of this type would be helpful since it would be possible to use 
alternatives to INH in TB treatment if it could be shown that this would prevent a 
patient developing DILI.  
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Chapter 8. Appendices 
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Start codon
 
Appendix A (i) Electropherogram for rapid acetylator recombinant (RAR) plasmid  
 
Electropherogram shown is the sequencing traces of RAR plasmid using T7 primer (5’-TAATACGACTCACTATAGGG-3’). 
Appendix A 
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Continue….
 
Appendix B (ii) Electropherogram for rapid acetylator recombinant (RAR) plasmid  
 
Electropherogram shown is the sequencing traces of RAR plasmid using second primer (5’-TAATACGACTCACTATAGGG-3’), located 
251 to 271 bp downstream of the start codon (ATG). 
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Stop codon (TAG)
Continue….
 
Appendix A (iii) Electropherogram for rapid acetylator recombinant (RAR) plasmid  
 
Electropherogram shown is the sequencing traces of RAR plasmid using third primer (5’-TCCTGCCAAAGAAGAAACAC-3’), located 538 to 
558 bp downstream of the start codon (ATG). 
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Start codon
 
Appendix B (i) Electropherogram for slow acetylator recombinant (SAR) plasmid  
 
Electropherogram shown is the sequencing traces of SAR plasmid using T7 primer (5’-TAATACGACTCACTATAGGG-3’). 
Appendix B 
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Appendix B (ii) Electropherogram for slow acetylator recombinant (SAR) plasmid  
 
Electropherogram shown is the sequencing traces of SAR plasmid using second primer (5’-TAATACGACTCACTATAGGG-3’), located 
251 to 271 bp downstream of the start codon (ATG). 
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Appendix B (iii) Electropherogram for slow acetylator recombinant (SAR) plasmid  
 
Electropherogram shown is the sequencing traces of SAR plasmid using third primer (5’-TCCTGCCAAAGAAGAAACAC-3’), located 538 
to 558 bp downstream of the start codon (ATG). 
 
Stop codon (TAG)
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